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 Recombinant Human Lactoferrin Injectable Hydrogel as an Osteogenic Biomaterial 
 
Ashley Ali Amini, PhD 
University of Connecticut, [2014] 
 
The bidirectional signaling of lactoferrin (LF) that suppresses osteoclastogenesis 
and enhances osteoblast proliferation and survival supports the notion that LF is a strong 
candidate for bone tissue engineering.  The proposed studies were aimed to increase our 
understanding of the effect of recombinant human LF (rhLF) in modulating skeletal cells 
and further establish rhLF crosslinked gel as an excellent candidate for a skeletal 
regenerative biomaterial.     
In situ formation of injectable biomaterials has several advantages as cell delivery 
vehicles.  In this study, the biological properties rhLF were utilized as the building block, 
to develop the engineered cell delivery system.   These studies reported the development 
of a novel injectable cell delivery vehicle that can significantly improve cell survival and 
osteogenic functions by serving as a biomaterial ligand to induce receptor mediated cell 
signaling of encapsulated cells.  Furthermore, the bioactive rhLF gel matrix was shown to 
promote cell survival, proliferation and differentiation.  The positive effects of rhLF gel 
on cellular processes supports the notion that rhLF gel is a strong candidate for bone 
tissue engineering.  
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1 Synopsis 
The pursuit for bone tissue engineering has been prompted by clinical demands 
that may occur as a result of congenital anomalies, trauma and skeletal diseases (Geckil 
et al. 2010, Huang et al. 2011).   The current gold standard for skeletal repair is autografts 
(Laurencin et al. 1999).   However, this treatment has limitations, which include donor 
site morbidity and limited availability.   Allografts are commonly used as an alternative 
option to autografts, however, it too is associated with significant limitations – delayed 
vascular penetration, slow bone formation, high incidence of non-union or delayed union 
and possibility of disease transmission (Delloye et al. 2007).  A new avenue, namely 
bone tissue engineering, is currently being explored to overcome the limitations of these 
biological grafts.  Tissue engineering uses cells, scaffolds, and biological factors alone or 
in combination toward the repair, restoration and replacement of bone tissues (Laurencin 
et al. 1999). 
A major modality in tissue engineering is cell-based therapeutics, and its 
efficiency is based on successful delivery of cells to sites of repair or regeneration.  
Recently, various biomaterials have been employed to mediate localized cell delivery.  In 
situ—forming gel scaffolds (i.e., injectable, crosslinked polymeric networks) are of great 
interest since they can be implanted simply by injection to fill irregularly shaped defects.  
These crosslinked networks allow for the accomadation of homogeneous incorporation of 
cells and bioactive molecules in a three-dimensional (3D) microenvironment.  Moreover, 
protein-based gels are especially attractive since their bioactivity may encourage 
encapsulated cells to recognize and bind to specific sites within proteins.  Recently, 
significant interest has grown towards developing biologically active gels that could 
modulate the functions of encapsulated cells for better regenerative outcome. Our lab has 
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previously developed a novel, in situ—forming, lactoferrin (LF) – based gel system that 
may utilize the biological functions of the native protein for the development of a 
bioactive biomaterial in order to modulate encapsulated cell functions.   The rationale for 
developing a LF-based gel is multi-fold.  1) The gel is in situ forming, which allows for 
non-invasive implantation through injection.  2) The injectable gel may also be used as a 
cell delivery vehicle as it provides a mild water rich environment.  3) Due to the potential 
bioactivity of LF, the gel might present a bioactive environment for enhanced cellular 
performance. 
Our preliminary studies discussed here demonstrated the bioactivity of bovine LF 
(bLF) gel.   bLF was used to evaluate the bioactivity of the novel biomaterial since there 
is significant literature on the bioactivity of soluble bLF protein.  The advent of the 
recombinant human protein technology, however, offers a cost-effective alternative and a 
foundation for producing consistent and predictable results for potential clinical 
applications. The goal of the present study aimed to evaluate the bioactivity of rhLF 
towards osteoblast cells, and develop a bioactive injectable cell delivery system based on 
rhLF.   
We hypothesize that injectable rhLF gel can be formulated and this biomaterial 
will possess osteogenic activities.  We further hypothesize that the cell survival activities 
of the rhLF gel are regulated upstream of PI3K/Akt and the osteogenic activities will be 
transduced via a β-catenin—dependent signaling pathway.   
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Figure 1.  Crystal structure of (A) bLF of (B) hLF. 
Each protein binds to two Fe3+ atoms (pink spheres) – one in each lobe of the protein.  
Image taken from (Vogel 2012). 
 
Since there is only 69% species homology between the bLF and human LF (hLF) 
(van Berkel et al. 2002b) (Figure 1), we first confirmed the bioactivity of rhLF protein 
using in vitro cell models.  We also investigated the biological effects of the various iron 
saturation forms of rhLF (apo-, pis- and holo-) on MC3T3 pre-osteoblast cells to 
understand the effect of iron concentration on rhLF bioactivity and identify the suitable 
polymer to develop injectable hydrogels for bone tissue engineering application. We 
performed a global gene analysis using microarrays to examine the effect of LF iron 
saturation on MC3T3 cells.  MC3T3 cell line was selected to evaluate the bioactivities of 
rhLFs since it is a well-characterized murine osteoblast cell line (Sudo et al. 1983) that 
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has been used extensively as a model for osteoblasts in vitro.   Next, we compared the 
effect of holo-rhLF on two in vitro culture systems: clonal MC3T3 cells and primary 
NHOst cell cultures.   These comparative experiments were designed to confirm whether 
MC3T3 could act as a good model cell line to demonstrate the potential future clinical 
efficacy of the system.  Further, the biological effects (cell survival, proliferation and 
osteogenesis) of holo-rhLF were tested using standard cell culture system.  Molecular 
mechanism underlying LF’s anti-apoptotic and osteogenic effects were probed using 
western blot analysis and PCR arrays, and confirmed using pharmacological inhibitor 
studies.  Finally, after establishing the biological effects and molecular mechanisms of 
holo-rhLF protein on MC3T3 cells, our next aim was to characterize the physical 
properties of crosslinked holo-rhLF gel based on gelation time, water uptake, mechanical 
properties and morphology properties to be further employed as a regenerative skeletal 
biomaterial.  In all these studies, enzyme-crosslinked injectable gelatin gel was used as 
the control.  Biological effect of holo-rhLF on MC3T3 pre-osteoblasts was evaluated 
based on its ability to promote cell survival, proliferation and differentiation compared to 
the gelatin gel. 
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2 Literature review 
2.1 Injectable hydrogels for skeletal repair  
The pursuit to engineer bone and cartilage microenvironments are prompted by 
the clinical demand for skeletal tissue repair and replacement, which occur as a result of 
congenital anomalies, trauma and skeletal diseases (Geckil et al. 2010, Huang et al. 
2011).  Autografts, the current gold standard for bone and cartilage repair, presents itself 
with limitations, including donor site morbidity and limited availability.  Although the 
use of allografts can overcome these limitations, they also have substantial limitations, 
which include delayed vascular penetration, slow bone formation, high incidence of non-
union or delayed union and possibility of disease transmission (Burchardt 1987, Wozney 
et al. 1988).  The avenue of tissue engineering explores the use of cells, scaffolds, and 
biological factors alone or in combination toward the repair, restoration and replacement 
of tissues (Laurencin et al. 2001).  The opportunities and challenges for tissue 
engineering are extensive for both bone and cartilage. 
The extracellular matrix (ECM) in natural tissue provides the structured 
microenvironment with mechanical, biochemical and physical cues that enable the cells 
to interact with each other and with the ECM to allow optimal cell function.  ECM is a 
dynamic structure that consists mainly of fibrous proteins and some glycosaminoglycans, 
which self-assemble into nanofibrillar supramolecular networks (collectively called 
structural/physical signals) to provide structural architecture to support the resident cells 
(Nair, Laurencin 2006).   The native microenvironment is not only composed of ECM, 
but also biomolecules (growth factors, chemokines and cytokines) and ions that are 
bound to the ECM.  Growth factors bind to target cell receptors and induce intracellular 
	   31 
signal transduction that reaches the cell nucleus and determines the biological response 
(Devescovi et al. 2008).  The main growth factors acting on the skeleton are bone 
morphogenetic proteins (BMPs), transforming growth factor β (TGFβ), fibroblast growth 
factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF) and insulin-like growth factors (IGFs) (Linkhart, Mohan & Baylink 1996, 
Baylink, Finkelman & Mohan 1993).   Each biological growth factor has specific roles in 
the growth, maintenance and repair of the skeleton.  In summary, the multifunctionality 
of ECM is achieved through the biochemical signaling from the soluble factors along 
with the unique tissue specific matrix composition and hierarchical structural features.  It 
is therefore pertinent to consider the structural features of ECM along with the biological 
principles that govern cell-cell and cell-matrix interactions while developing novel 
strategies to promote tissue regeneration.  Successful fabrication of a biomimetic scaffold 
requires the biomaterial to be finely tailored toward the dynamic native 
microenvironment and to mimic the intricate and organized meshwork of extracellular 
matrix (ECM).   
 
2.1.1 Hydrogels as skeletal ECM mimetic scaffolds 
Hydrogels are cross-linked, porous networks that exhibit high tissue-like water 
content and elastic properties.  The potential of hydrogels as unique biomaterials was 
reported in the later half of the 20th century when non-degradable methacrylate gels were 
used for developing soft contact lenses.   Subsequently, a wide range of hydrogels were 
developed using synthetic and natural hydrophilic polymers that are biodegradable or 
non-degradable for various biomedical applications in the form of drug/gene/and protein 
delivery, as unique wound dressing materials as well as scaffolds for tissue engineering 
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(Peppas, Sahlin 1996).   Synthetic hydrogels provide more chemically programmable and 
reproducible platform to systematically understand cell-matrix interactions.  
Poly(ethylene glycol) (PEG) is one of the most extensively investigated non-degradable, 
synthetic, hydrophilic polymer for biomedical applications due to its hydrophilicity, good 
tissue compatibility, non-toxicity and availability of reactive end groups for chemical 
functionalization.  Several degradable synthetic polymeric systems have also been 
developed to form hydrogels.  These include co-polymers of PEG with a variety of 
synthetic degradable polymers such as poly(lactic co-glycolic) acid (PLGA), 
poly(propylene fumarate) (PPF), poly(vinyl alcohol) (PVA), poly(propylene oxide) 
(PPO), polyanhydrides and polyphosphazenes (Joa, Engelb & Mikos 2000, Lee et al. 
2007).  Among the natural biodegradable hydrophilic macromolecules investigated for 
hydrogel formation, proteins and polysaccharides form the most prominent members 
(Coviello et al. 2007).  This is due to various advantages such as non-toxicity, 
biocompatibility, availability in large variety of composition and properties, widely 
present in living organisms as well as due to the fact that they can be produced using 
recombinant DNA techniques (Coviello et al. 2007).  Hydrogels made of naturally 
derived, polysaccarides for skeletal repair include agarose, alginate, chitosan and 
hyaluronic acid (Burdick, Prestwich 2011).  Protein-based scaffolds, such as collagen, 
gelatin and fibrin, are very attractive for building bioactive scaffolds due to their ability 
to mimic the extracellular environment, biodegradability and inherent biochemical 
properties (Stenzel, Miyata & Rubin 1974, Dreesmann, Ahlers & Schlosshauer 2007, Liu 
et al. 2009, Spotnitz, Burks 2008).  These biocompatible and biodegradable matrices due 
to their highly swollen three-dimensional environment with large pore sizes, porosity and 
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high water content provide temporary support for cell growth and maintenance as they 
facilitate the transfer of nutrients, gases, metabolic waste and cell signaling molecules.  
Furthermore, convenient tunability of these scaffolds allows for the incorporation of 
sophisticated biochemical cues in these networks to better mimic the native 
microenvironment.    
In addition to preformed hydrogels, injectable in situ forming hydrogels are of 
significant interest for therapeutic and diagnostic applications.   The ability to introduce 
the injectable in situ forming hydrogels via simple injection significantly increases 
patient compliance relative to preformed hydrogels, which must be crosslinked in vitro 
and then surgically implanted in vivo.  The injectable hydrogels can be processed in the 
operating room, can be used to fill irregularly shaped defects as the implants are formed 
in situ at the defect site, can shorten surgical time, minimize surrounding tissue damage 
and reduce postoperative pain and scar size.  Moreover, with injectable gels, the gelation 
takes place under very mild physiological conditions allowing for the successful 
encapsulation of cells and biologically active proteins or peptides for regenerative 
applications (Nguyen, Lee 2010). 
The biological properties of bone and cartilage tissue are highly distinguished 
from each other with regards to physical structure, vascularity, growth factors and cell 
types.   As a result of this uniqueness, there are distinct demands for design and use of 
biomaterials for the regeneration of these tissues.  For cartilage regeneration, hydrogels 
may effectively able to serve as ECM mimics.  However, due to the high mechanical 
strength and structural complexity of bone, hydrogels may be effectively used as carriers 
for biological growth factors and cells to aid bone regeneration. 
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2.1.2 In situ gelling hydrogel systems 
Several criteria need to be met to develop an ideal in situ-forming injectable gel 
for biomedical applications.  These include: 1. Solubility in aqueous media with gelation 
occurring in physiological conditions (temperature, pH and ionic concentration); 2. No 
release of harmful by-products upon gelation; 3. Gelation occur at a sufficiently rapid rate 
for clinical efficacy, however allow adequate time for proper mixing and injection of the 
solution in the presence of additives such as cells and/bioactive molecules (Ma, Elisseeff 
2005).   
Hydrophilic polymers that can undergo gelation in response to different types of 
stimuli have been developed either by modifying existing polymers or by specifically 
designing polymers with stimuli sensitive units along the polymer chain.  The various 
stimuli of interest for biomedical applications include light (photo-polymerizing/photo-
gelling systems), chemical agents (chemical and ionic crosslinking systems) as well as 
environmental stimuli from the physiological environment (temperature, pH and ionic 
strength).  Physical and chemical crosslinking methods can be used to develop hydrogels.  
Physical crosslinking of the polymers is generally considered to be milder than chemical 
crosslinking reactions.  Hydrogels formed by ionic and thermogelation are examples of 
those formed via physical crosslinking. On the downside, the instability and reversibility 
of many of these systems yields low mechanical properties (Nguyen, Lee 2011).  
Chemical crosslinking generally yields more stable hydrogels with better mechanical 
properties relative to those formed by physical crosslinking. The main drawback of 
chemical crosslinking is the need to incorporate reactive compounds and/or 
photoirradiation, which may lead to toxicity problems.  However, recent advances in 
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chemical crosslinking methods led to the development of systems that undergo gelation 
under mild reaction conditions.  Examples of various hydrogel materials and their 
crosslinking mechanism are listed in Table 1. 
Table 1.  Various hydrogel materials, crosslinking initiators and mechanism. 
Material Gel Precursors Crosslink  
Mechanism 
Reference 
Pluronics Macromer(s): PEO-PPO-PEO 
Initiator: temperature (37°C) 
Physical (Ruel-Gariepy, 
Leroux 2004) 
Chitosan-Pluronics Macromer(s): chitosan and pluronics 
Initiator: temperature (37°C) 
Physical (Weng et 
al. 2001) 
Chitosan–AHP  Macromer(s): chitosan and AHP 
Initiator: temperature (37°C) 
Physical (Nair et al. 2007) 
Chitosan-glycerol 
phosphate 
Macromer(s): Chitosan and glycerol phosphate 
Initiator: temperature (37°C) 
Physical (Ahmadi, de Bruijn 
2008) 
PPF-co-ethylene 
glycol  
Macromer(s): hydrophobic PPF and hydrophilic 
PEG  
Initiator: light 
Covalent (Fisher et al. 
2004) 
Hyaluronic acid Macromer(s): tyramine substituted hyaluronic 
acid  
Initiator: HRP enzyme 
Covalent (Darr, Calabro 
2009) 
Hyaluronic Acid-
Pluronics 
Macromer(s): Hyaluronic Acid and pluronics 
Initiator: temperature (37°C) 
Physical (Jung, Park & Han 
2010) 
SMO-PCLA-PEG-
PCLA-SMO 
copolymer hydrogel 
Macromer(s): pH-sensitive SMOs and thermo-
sensitive PCLA-PEG-PCLA  
Initiator: temperature (37°C) and pH (7.4) 
Physical (Shim et al. 2006) 
oxidized alginate, 
gelatin and biphasic 
calcium phosphate  
Macromer(s): oxidized alginate, gelatin and 
biphasic calcium phosphate 
Covalent (Nguyen, Lee 
2011) 
 
2.1.2.1 Physically crosslinked hydrogels 
Thermo-gelation is one of the most extensively investigated strategies to develop 
physically crosslinked in situ gelling polymers.  N-isopropyl-acrylamides (NIPAAm), 
pluronics and various PEG based polymers are some of the most widely used non-
degradable thermo-gels (Ruel-Gariepy, Leroux 2004).  Aqueous solutions of triblock 
copolymers composed of PEO and PPO (PEO-PPO-PEO) exhibit sol-to-gel phase 
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transitions at physiological temperatures and are commercially known as Pluronics.  
Chondrocytes suspended in Pluronics "painted" onto a tissue engineered osseous surface 
resulted in a bone-cartilage interface for mandibular condylar reconstruction (Weng et al. 
2001).  Even though pluronics has advantages such as mild gelation, ability to increase 
the stability of encapsulated proteins, and good biocompatibility, the low mechanical 
integrity of the gel, non-degradability, limited gel stability with quick dissolution and 
high permeability limits its biomedical applications (Liu et al. 2007).  This led to the 
development of several degradable block co-polymers with hydrolytically sensitive 
blocks such as poly(lactic acid/glycolic acid) or poly(caprolactone) and 
pluronics/PEG/NIPAAm units as potential candidates for biomedical applications (Cohn 
et al. 2006, Jeong, Bae & Kim 2000, Chen, Singh 2005).  Thermosensitive chitosan–
pluronic hydrogel has proven itself to be a successful injectable cell delivery vehicle for 
cartilage regeneration (Park et al. 2009).  Composite thermosensitive hydrogel using 
pluronic derivatives and crosslinked hyaluronic acid (X-HA) loaded with TGFβ1 have 
been shown to increase benefits in the induction of chondrogenic differentiation of 
human adipose-derived stem cells in a full-thickness defect of rabbit knee articular 
cartilage model  (Jung, Park & Han 2010). 
A pH- and temperature-sensitive hydrogel of sulfamethazine oligomer, poly(ε-
caprolactone-co-lactide)-poly(ethyleneglycol)-poly(ε-caprolactone-co-lactide) (SMO-
PCLA-PEG-PCLA-SMO) pentablock copolymer was synthesized by adding pH-sensitive 
SMOs to either end of a thermo-sensitive PCLA-PEG-PCLA block copolymer.  This 
copolymer solution forms stable gel under physiological conditions (pH 7.4 and 37°C), 
but not at high pH (pH 8.0) or at increased temperatures (ca. 70°C) (Shim et al. 2006).   
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pH/temperature-sensitive hydrogel of poly(beta-amino ester)-poly(ε -caprolactone)-poly 
(ethylene glycol)-poly(ε-caprolactone)-poly(beta-amino ester) (PAE-PCL-PEG-PCL-
PAE) pentablock copolymer was evaluated as a sustained injectable insulin delivery 
system (Huynh et al. 2009).  Insulin was ionically linked forming an insulin-PAE 
complex and was steadily released for 15 days in a Sprague-Dawley rat subcutaneous 
model (Huynh et al. 2009).  The ability of these systems to undergo gelation under 
physiological conditions (pH 7.4 and 37°C) makes them strong candidates for therapeutic 
applications. 
Apart from synthetic polymers, several natural polymers have also been used to 
develop thermogels mostly due to their innate thermo-sensitivity.  Methyl cellulose, a 
biocompatible polysaccharide can undergo thermogelation around 37°C due to the 
hydrophobic interactions between molecules containing methoxy substitution.   Ghanaati 
et al. evaluated the efficacy of an injectable composite bone substitute composed of β -
tricalcium phosphate (β-TCP), methyl cellulose and hyaluronic acid.   The presence of 
the polymeric phase decreased the degradation time of β-TCP and at the same time 
increased the vascularization of the construct (Ghanaati et al. 2011).  Chitosan is another 
polysaccharide that is attracting significant attention as a biomaterial due to its 
biodegradability, biocompatibility and wound healing properties.  We have developed an 
injectable thermo-gelling system based on chitosan using inorganic phosphate salts as the 
neutralizing and thermo-gelling agent (Nair et al. 2007).  The in situ gelling system was 
developed by adding ammonium hydrogen phosphate (AHP) to chitosan solution at low 
temperature.  The system has been found to be highly versatile with gelling time varying 
from 5 minutes to several hours at 37°C by varying the concentration of the phosphate 
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salt.  The injectability of the system as well as the feasibility of using chitosan–AHP 
thermogels as a cell delivery vehicle has been demonstrated (Nair et al. 2007).  
Biocompatible, chitosan-glycerol phosphate hydrogels have also been demonstrated to 
stimulate mesenchymal stem cell proliferation as a potential vehicle for cell 
encapsulation (Ahmadi, de Bruijn 2008).  Furthermore, chitosan molecules, which share 
glycosaminoglycan (GAG) structural features, have been crosslinked with proteins or 
other GAGs to promote chondrogenesis (Suh, Matthew 2000).  Various reagents such as 
β-glycerophosphate, genipin and glyoxal have been investigated to develop composite 
injectable hydrogels of chitosan with proteins such as collagen (Wang, Stegemann 2010, 
Wang, Stegemann 2011).  Hydroxy butyl chitosan (HBC), a water-soluble 
thermosensitve polysaccharide, can undergo physical gelation under physiological 
conditions and has also been investigated as a cell delivery vehicle (Dang et al. 2006). 
Agarose, a polymer isolated from red algae and seaweed, crosslinked via 
hydrogen bonds has been shown to be well suited for 3D cell encapsulation, especially 
for chondrocytes (Benya, Shaffer 1982, Buschmann et al. 1992).  BMP2-transduced 
mesenchymal stem cells (MSCs) form more cartilage-like tissue in agarose gels than in 
other matrices, such as collagen and alginate.  This has been attributed to the tendency of 
agarose gel to resist blood vessel invasion resulting in low oxygen tension that facilitate 
cartilage tissue formation (Xu et al. 2005).   
Alginic acid, another polysaccharide present in brown algae has also been 
extensively investigated for cell encapsulation.  Alginic acid can undergo rapid ionotropic 
gelation in the presence of various divalent cations, including calcium, zinc and strontium 
(Wee, Gombotz 1998, Rowley, Madlambayan & Mooney 1999, Place et al. 2011).   
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Calcium-alginate gels are studied as a scaffold for encapsulating non-adherent cells such 
as chondrocytes as it does not mediate mammalian cell adhesion due to its poor binding 
of serum proteins (Smetana 1993).  This will allow for maintaining the spherical 
morphology of chondrocytes in alginate gels.  In comparison with the native cartilage 
tissue, the calcium-alginate hydrogels display slightly lower water content and 
compressive modulus but the tensile modulus of these hydrogels match well with that of 
the tissue (Wan et al. 2008).  On the other hand, since osteoblasts may not thrive in a 
non-adhesive hydrogel environment, the chemistry of hydrogels may further be amended 
(i.e., covalent grafting of adhesion peptides (Hern, Hubbell 1998, Mann et al. 1999, 
Rowley, Mooney 2002) and tethering growth factors (Mann, Schmedlen & West 2001)).  
Hydrogels modified with cell surface adhesion peptides, such as arginine-glycine-aspartic 
acid (RGD), can improve osteoblast adhesion and matrix synthesis within the 3D 
polymer network (Burdick, Anseth 2002, Alsberg et al. 2001). 
Gelatin is the denatured form of the ECM’s main component, collagen, and has 
been used successfully as a cell vehicle in chondrogenesis studies (Ponticiello et al. 2000) 
and bone tissue engineering (Payne et al. 2002).  Crosslinking of gelatin polymer has 
been demonstrated in various ways including physical crosslinking due to its 
thermosensitivity.  However, the use of these biodegradable matrices formed via physical 
crosslinking is limited due to their weak structure at physiological temperature (Landers 
et al. 2002). 
Self-assembled peptide-amphiphile (PA) molecules, which consist of a peptide 
segment coupled to a fatty acid chain, into 3D nanofiber networks have been shown to 
support cell processes, including cell migration, proliferation and differentiation within 
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the hydrogel (Paramonov, Jun & Hartgerink 2006, Silva et al. 2004, Hosseinkhani et al. 
2006b).  The formation of self-assembling gels is driven by the hydrophobic core, which 
is composed of closely packed alkyl tails, and the fibrous strands that build-on via 
hydrogen bonds between the amino acids of adjacent PA molecules.  Self-assembly can 
be triggered upon mixture of PA solutions with cell culture media or other physiological 
fluids that contain polyvalent metal ions (Zhang 2002, Zhang 2003).  The PA system 
presents a versatile platform, where in molecules can be designed and developed for 
specific applications. PA system has been developed that allows for mineral deposition 
(Hartgerink 2004), optimized cell adhesion (Harrington et al. 2006, Guler et al. 2006) and 
supports ectopic bone formation (Hosseinkhani et al. 2006b).  Another interesting 
variation of PA systems includes the in situ hydrogel formation through ionic interactions 
between negatively charged PAs and a positively charged basic fibroblast growth factor 
(bFGF) (Hosseinkhani et al. 2006a).  Although these types of self-assembling systems are 
inherently biocompatible and versatile, they may present difficulties for precisely 
controlling the gelation and mechanical properties. 
2.1.2.2 Covalently crosslinked hydrogels 
Visible or near ultra violet light induced photo-polymerization is one of the most 
extensively investigated in situ gelation process for developing injectable covalently 
cross-linked hydrogels.  Biodegradable photocurable polymers form a versatile class of 
injectable biomaterials as the aqueous polymer solution can be introduced to the desired 
site via injection followed by photo curing in situ using fiber optic cables. The most 
extensively investigated route involved water-soluble polymers with acrylic/methacrylic 
side groups that can undergo photo-polymerization via a radical chain polymerization 
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mechanism initiated by appropriate photo-initiators. Moreover, photopolymerization 
allows for temporal and spatial control over scaffold formation, enabling the implantation 
of complex structures such as multilayered hydrogels in a minimally invasive manner 
with minimal heat production.  Multilayered photopolymerizable hydrogels facilitate the 
encapsulation of multiple cell types in a stratified organization and also control of spatial 
presentation of bioactive factors within the scaffold.   Zonal organization of articular 
cartilage is of structural and functional importance.  To achieve zonal distribution of 
multiple cell types, researchers have combined cells with photosensitive polymers that 
could be injected and gelled in situ or photopolymerized in layers, reproducing the 
structures of articular cartilage and osteochondral tissue (Hunziker, Quinn & Hauselmann 
2002, Hu et al. 2001). 
Poly(propylene fumarate) (PPF), a biocompatible and biodegradable polyester 
that can be crosslinked through its fumarate double bond, undergoes cell-friendly 
biodegradation as one of its degradation products include fumaric acid, a substance which 
occurs naturally as a part of the Kreb’s cycle (Kasper et al. 2009).  Peter et al. used PPF 
to successfully produce chemically crosslinked hydrogels in vivo capable of acting as an 
injectable bone cement (Peter et al. 1997).   Furthermore, a polymer-based system of 
copolymer PPF-co-ethylene glycol, formed from hydrophobic PPF and hydrophilic PEG, 
support chondrocyte survival and ECM production (Fisher et al. 2004).  The versatility of 
PPF and its ease of modification lend itself to be an excellent candidate for bone and 
cartilage replacement.  The material property allows it to be injected into irregularly 
shaped bone voids in vivo and provide good mechanical stability to support bone 
regeneration.  Recently, osteoblasts have been added to the PPF construct to improve the 
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rate and extent of new bone formation (Payne et al. 2002).  TGFβ-loaded PPF composite 
scaffolds was shown to act directly on cell migration and differentiation within the 
material (Peter et al. 2000, Lu, Stamatas & Mikos 2000, Lu, Yaszemski & Mikos 2001).  
Porter et al. has developed porous composites from PPF and tricalcium phosphates as 
scaffolds for bone regeneration. The moduli of the composites are on the order of 
magnitude of trabecular bone indicating that these composites are attractive candidates 
for use as a replacement scaffold for trabecular bone (Porter et al. 2000). 
Photo-crosslinkable dendrimers, which are highly branched and regularly 
structured macromolecules composed of natural metabolites (i.e., succinic acid, glycerol, 
and beta-alanine), and non-immunogenic PEG have been synthesized using ester and 
carbamate forming reactions.  Histological analysis of the photo-crosslinked macromer 
solutions in a rabbit osteochondral defect showed good attachment in the defect site and 
presence of collagen II and GAGs in contrast to the contralateral unfilled defects.  The 
strong potential of these dendrimer-based, photocrosslinked hydrogels as scaffolds for 
osteochondral defect repair was illustrated by its good mechanical properties, lower water 
absorption, good adhesion to the defect site, and positive in vivo performance (Degoricija 
et al. 2008). 
Even though degradable injectable photo crosslinkable systems presents unique 
advantages, the gelation process does present some limitations such as residual high 
molecular weight kinetic chains upon gel degradation, mild toxicity associated with the 
photo-initiators, limited control over the network evolution mechanism during chain-
growth and also light attenuation by the initiators restricting the maximum attainable cure 
depth of only a few millimeters (Rydholm, Bowman & Anseth 2005). 
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To circumvent the limitations of photo-polymerization, crosslinking using 
thiolated polymers have been proposed.  The thiolated polymers form degradable 
networks through Michael-addition type reaction when reacted with polymers containing 
acrylate, acrylamide or vinyl sulfone groups (Lutolf, Hubbell 2003, Vernon et al. 2003).  
The thiol based systems has shown to form crosslinked networks with better control over 
the crosslink density, eliminate high molecular weight degradation products as the 
degradable segments get incorporated throughout the network and allow samples to be 
cured to depths exceeding 10 cm and therefore have significant potential as an in situ 
gelling system for cell encapsulation (Rydholm, Bowman & Anseth 2005). 
Polymeric aldehydes derived from polysaccharides having vic-diols using 
periodate chemistry are potential candidates for developing injectable fast gelling systems 
due to their chemical reactivity.  An in situ gelling non-toxic system via the crosslinking 
of oxidized alginate and amino groups of gelatin has been reported (Balakrishnan, 
Jayakrishnan 2005).  Recently, Nguyen et al. fabricated a composite gel consisting of 
oxidized alginate, gelatin and biphasic calcium phosphate as a bone graft substitute 
(Nguyen, Lee 2011).   Covalent crosslinking of the composite was achieved via Schiff-
base reaction between the aldehyde groups of oxidized alginate and amino groups of 
gelatin (Boanini et al. 2010, Liao, Zhang & Chen 2009).  The osteogenic properties of the 
composite have been attributed to the calcium phosphate ceramics, which release calcium 
and phosphate ions upon degradation that are beneficial to bone formation.  Furthermore, 
the system presents excellent tunability wherein the degree of crosslinking, water uptake 
and mechanical strength may be controlled by the degree of alginate oxidation.   With 
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excellent biocompatibility and biodegradability, this composite is an example of a 
promising injectable biomaterial for bone regeneration. 
2.1.2.2.1 Enzymatically crosslinked hydrogels 
Another emerging technique for developing in situ gelling system for biomedical 
applications is based on enzyme-catalyzed crosslinking reactions due to the mild, cell-
friendly and natural crosslinking process involved (Table 2, Figure 3).  Enzymatic 
crosslinking of hydrogels is an innovative alternative to other crosslinking methods, such 
as the photo-polymerization or physical crosslinking.  Drawbacks to other crosslinking 
methods include cytotoxicity in photo-polymerized gels and insufficient mechanical 
strength in physically crosslinked gels. These limitations may be overcome through the 
use of enzymes to covalently crosslink polymers to form hydrogels.  Transglutaminases 
and horseradish peroxidases (HRP) are highlighted as enzyme systems involved in 
hydrogel crosslinking. 
Transglutaminase has been investigated as a biocompatible catalyst to crosslink 
polymers containing glutamine and lysine residues in a calcium-dependent reaction 
(McHale, Setton & Chilkoti 2005a, Yung, Bentley & Barbari 2010, Davis et al. 2010b).  
Tissue transglutaminase is naturally found in vivo during wound healing for the purpose 
of stabilization and organization of the ECM (Greenberg, Birckbichler & Rice 1991).  
Members of the transglutaminase family have been used to crosslink polymers, including 
PEG (Hu, Messersmith 2003, Ehrbar et al. 2007) and elastin-like protein polymers 
(McHale, Setton & Chilkoti 2005a) to form gels. 
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Figure 2. Enzymatically crosslinked recombinant protein by transglutaminase (TG) 
enzymatic crosslinking. 
(A) Schematic of the protein hydrogel formation by tissue transglutaminase enzymatic 
crosslinking. (B&C) Photograph of the precursor solution before and after enzymatic 
gelation with tTG. (D) Photograph of a transparent hydrogel crosslinked by TG. Image 
taken from (Davis et al. 2010a) 
 
Several synthetic and natural polymers functionalized with tyramine, tyrosine or 
aminophenol side groups are currently under development that can form in situ gels by 
phenol or aniline derivative coupling using hydrogen peroxide as an oxidant catalyzed by 
HRP (Kurisawa et al. 2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007a, Lee, 
Wagoner Johnson & Murphy 2010).  HRP-mediated crosslinking takes place at 
physiological pH and temperature and the gelation time can be modulated to a great 
extent by varying the reagent concentrations, making this a potential route to form 
injectable cell and protein delivery vehicles (Sakai et al. 2009, Hu et al. 2009).  For 
example, tyramine substituted hyaluronic acid was developed to form injectable gels in 
the presence of HRP (Darr, Calabro 2009).  The injectable system has several advantages 
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as the gelation time, equilibrium swelling and storage modulus of the gel may be adjusted 
by varying the degree of substitution of tyramine residues and polymer concentration.  
Furthermore, the mild enzymatic crosslinking has shown to be highly suitable for 
chondrocyte encapsulation as it allow for high viability of encapsulated chondrocytes, 
maintenance of the encapsulated cells’ round morphology, increased production of 
glycosaminoglycans and collagen type II (Jin et al. 2010a). 
 
Table 2. Enzyme-catalyzed crosslinkable hydrogels and potential applications. 
Table adapted from (Teixeira et al. 2012) 
Gel	  type/composition	   Enzyme	  type	   Potential	  applications	   References	  
Fibrin	  gel	   Factor	  Xllla	  
(transglutaminase	  
isoenzyme)	  
Angiogenesis	   (Eyrich	  et	  al.	  2007,	  Hall,	  
Baechi	  &	  Hubbell	  2001)	  Bone	  and	  cartilage	  tissue	  
repair	  
8-­‐arm	  PEG-­‐peptide	  
conjugates	  
Factor	  Xllla	  
(transglutaminase	  
isoenzyme)	  
Drug	  delivery	  systems	   (Ehrbar	  et	  al.	  2007,	  Sala	  
et	  al.	  2010)	  
Elastin-­‐like	  polypeptide	  
gels	  
Tissue	  
transglutaminase	  
Cartilage	  tissue	  repair	   (McHale,	  Setton	  &	  
Chilkoti	  2005b)	  
PEG-­‐peptide	  conjugates	   Surgical	  tissue	  adhesives	   (Hu,	  Messersmith	  2005)	  
Cartilage	  tissue	  repair	  
Gelatin	   Microbial	  
transglutaminase	  
Scaffolds	  for	  tissue	  
engineering	  
(Yung	  et	  al.	  2007)	  
Gelatin	   Calcium-­‐independent	  
microbial	  
transglutaminase	  
Microfluidic	  biosensor	  
systems	  
(Chen	  et	  al.	  2003b)	  
Gelatin-­‐chitosan	  
conjugates	  
Tyrosinase	   Tissue	  glue	   (Chen	  et	  al.	  2003a)	  
Gelatin-­‐chitosan	  
conjugates	  
Film	  biofabrication	   (Wu,	  Bentley	  &	  Payne	  
2011)	  
Coil-­‐chitosan	  
bioconjugate	  
Protein	  immobilization	   (Demolliens	  et	  al.	  2008)	  
Coenzyme	  A-­‐
functionalized	  PEG	  
Phosphopantetheinyl	  
transferase	  (surfactin	  
synthetase)	  
Cell	  biology	   (Mosiewicz,	  Johnsson	  &	  
Lutolf	  2010)	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Supramolecular	  tyrosine-­‐
based	  hydrogel	  
Alkaline	  phosphatase	   Assay	  platform	  for	  enzyme	  
inhibitors	  
(Li	  et	  al.	  2010)	  
Chitosan-­‐glycolic	  acid	  
conjugates	  modified	  with	  
phloretic	  acid	  
Horseradish	  
Peroxidase	  
Cartilage	  tissue	  repair	   (Jin	  et	  al.	  2009)	  
Hyaluronic	  acid-­‐tyramine	   Protein	  delivery	   (Lee,	  Chung	  &	  Kurisawa	  
2009b,	  Kim	  et	  al.	  2011)	  Cartilage	  tissue	  repair	  
Carboxymethylcellulose	   Biomedical	  applications	   (Ogushi,	  Sakai	  &	  
Kawakami	  2007)	  
Dextran-­‐tyramine	  
conjugates	  
Protein	  delivery	   (Jin	  et	  al.	  2007b)	  
Dextran-­‐hyaluronic	  acid	  
conjugates	  
Cartilage	  tissue	  repair	   (Jin	  et	  al.	  2010b)	  
Dextran-­‐heparin	   Cartilage	  tissue	  repair	   (Jin	  et	  al.	  2011)	  
Tyramine-­‐terminated	  
PEG	  
Drug	  delivery	   (Tran	  et	  al.	  2010)	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Figure 3. Schematic mechanism of the enzyme-mediated crosslinking systems. 
A) Transglutaminase, B) horseradish peroxidase, C) tyrosinase and D) oxidase 
enzymatically crosslink polymer to form gels.  Figure modified from (Teixeira et al. 2012) 
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2.1.3 Application of hydrogels 
Hydrogels may be utilized as localized delivery vehicles by homogenously 
incorporating cells, growth factors and other bioactive compounds while concomitantly 
allowing diffusion of nutrients and metabolites.  Hydrogels may serve as a transient 
biomimetic scaffold with suitable mechanical and viscoelastic properties in many 
applications such as cartilage regeneration, serve as a suitable vehicle to locally deliver 
appropriate growth factors and cells to facilitate regeneration of tissues such as bone.  
Physical, chemical and biological properties of hydrogels can be modulated by chemical 
and biological modifications by the incorporation of functional groups, cells or growth 
factors to facilitate tissue regeneration (Figure 4). 
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Figure 4. Examples of hydrogels as growth factor, gene and cell delivery systems. 
 
2.1.3.1 Enhancing mechanical properties and mineralization of hydrogels 
As viscoelastic solids, hydrogels characteristically possess low static and dynamic 
moduli due to their high water content and high permeability for oxygen, nutrients and 
other water-soluble metabolites.  Due to the limited mechanical strength of hydrogels, 
they have been widely considered to be excellent therapeutic delivery devices of cells and 
growth factors for soft-tissue engineering and ideal porous scaffolds when load-bearing 
support is unnecessary.  The challenge of tissue-engineered grafts is to also match the 
mechanical properties of native bone or cartilage tissue (Hutmacher 2000).   Recent 
Cell	  
BONE	  
thermoresponsive	  
copolymer	  composed	  of	  
HA-­‐C-­‐NIPAAm	  loaded	  with	  
BMSCs	  	  (Liao,	  Chen	  &	  Chen	  
2011)	  	  
CARTILAGE	  	  
hyaluronan	  hydrogel-­‐
encapsulated	  human	  
embryonic	  stem	  cell	  
(hESC)-­‐derived	  
chondrogenic	  cells	  (Toh	  et	  
al.	  2010)	  
autologous	  chondrocyte	  
implanta^on	  in	  a	  novel	  
alginate-­‐agarose	  (Selmi	  et	  
al.	  2008)	  	  
Growth	  Factor	  
BONE	  
chitosan/	  β–tricalcium	  
phosphate	  (TCP)	  
composite	  hydrogel	  loaded	  
with	  150	  μg	  rhBMP-­‐2	  	  
(Luca	  et	  al.	  2011)	  
	  
Dual	  delivery	  of	  VEGF	  and	  
BMP-­‐2	  from	  gela^n	  
micropar^cles	  (Patel	  et	  al.	  
2008)	  
CARTILAGE	  
CTGF	  in	  a	  gela^n	  hydrogel	  
repair	  of	  damaged	  ar^cular	  
car^lage	  in	  monoiodoace^c	  
acid	  (MIA)-­‐induced	  
experimental	  rat	  
osteoarthri^s	  (Nishida	  et	  
al.	  2004)	  	  
Gene	  
BONE	  
delivery	  of	  BMP-­‐2	  cDNA	  in	  
an	  alginate	  hydrogel	  
(Wegman	  et	  al.	  2011)	  	  
	  
human	  BMP2	  and	  
VEGF165-­‐transfected	  
rabbit	  bone	  marrow	  
stromal	  cells	  (BMSCs)	  
loaded	  on	  coral	  scaffold	  
(Xiao	  et	  al.	  2011)	  
CARTILAGE	  
BMP-­‐4–transduced	  MSCs	  
delivered	  via	  fibrin	  glue	  in	  
full-­‐thickness	  car^lage	  
defect	  in	  the	  trochlear	  
groove	  of	  rabbit	  femurs	  
(Kuroda	  et	  al.	  2006)	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advances in polymer synthesis and processing made it possible to increase the mechanical 
strength of hydrogels in various ways, including addition of covalent crosslinks, 
increasing the crosslinking density, increase of monomer content, addition of fillers and 
biodegradable fibers and preculturing to allow embedded cells to generate functional 
tissue before implantation (Anseth, Bowman & Brannon-Peppas 1996, Kloxin et al. 
2010, Salinas, Anseth 2009). 
One approach commonly used to increase the mechanical properties of hydrogel 
for bone tissue engineering is to develop mineralized composite systems. Various 
strategies have been employed to induce mineralization in inert, non-mineralizing 
hydrogels for the use of bone tissue engineering (Gkioni et al. 2010).  Major strategies for 
hydrogel mineralization include (1) the addition of inorganic particles, (2) the creation of 
nucleation sites by biomimetic methods, and (3) the derivatization of the polymeric 
hydrogel backbone with anionic functional groups.  The addition of inorganic phase 
allows for the dispersed minerals to promote nucleation, subsequent hydroxyapaptite 
formation and provides cell adhesion sites that enable integration with surrounding bone 
tissue (Rea, Best & Bonfield 2004).  Finally, as the temporary hydrogel degrades the on-
going mineralization will allow for replacement by new bone formation and thus increase 
mechanical stability.  
2.1.3.2 Enhancing biological properties by growth factor loading 
Bone regeneration is a coordinated cascade of spatio-temporal events regulated by 
several cytokines and growth factors.  Biomaterial scaffolds are used to retain growth 
factors at the orthopedic defect site for an appropriate period of time to allow native cells 
to migrate to injury site, then proliferate and differentiate.   A recent study used a 
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biopolymer chitosan/ β–tricalcium phosphate (TCP) composite hydrogel loaded with 150 
µg recombinant human BMP2 (rhBMP2) in a 15 mm critical-size defect in the radius of a 
rabbit to demonstrate successful osteoinduction (Luca et al. 2011).   However, many 
other studies have demonstrated that osteogenic factors alone may not be sufficient for 
optimal bone regeneration due to inadequate vascularization.  Therefore, the combined 
delivery of osteogenic and angiogenic factors have been studied to enhance bone 
regeneration.  Since VEGF and BMPs are key regulators of angiogenesis and 
osteogenesis during bone regeneration, various studies have investigated the effect of 
dose and temporal release of these growth factors from hydrogels on bone formation.  
Dual delivery of VEGF and BMP2 from gelatin microparticles for bone 
regeneration in rat model having an 8 mm rat critical size defect led to synergistic effects 
on bone formation and enhancement of bone bridging and union of the critical size 
defect.  At 12 weeks, the dual VEGF/BMP2 release showed bone formation within the 
scaffold pores and along the outer surfaces of the scaffold; osteoid secretion and 
mineralization were apparent, and new bone was often in close or direct contact with the 
scaffold interface (Patel et al. 2008).  A supporting study demonstrated the delivery of 
VEGF and BMP2 to osteoprogenitor cell populations of human bone marrow stromal 
cells (HBMSC) positively effecting bone formation.   HBMSCs seeded onto 
VEGF/BMP2 releasing, biodegradable composite composed of alginate and P(DL)LA 
significantly enhanced new endochondral bone matrix in a critical sized femur defect 
(Kanczler et al. 2010).  
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Since angiogenic growth factors are predominantly expressed during the early 
phases of regeneration for vascularity, whereas osteogenic growth factors are 
continuously expressed during bone formation and remodeling, the effect of sequential 
delivery of VEGF and BMP2 on bone formation was also investigated (Kempen et al. 
2009).  A composite scaffold which consisted of poly(lactic-co-glycolic acid) 
microspheres loaded with BMP2 embedded in a poly(propylene) scaffold surrounded by 
a gelatin hydrogel loaded with VEGF was used for the sequential release of the growth 
factors.  The implantation of this scaffold resulted in a large initial burst release of VEGF 
within the first 3 days and a sustained release of BMP2 over the full 56-day implantation 
period.  In the orthotopic defects, no effect of VEGF on vascularization was found, nor 
was bone formation higher by the combination of growth factors, compared to BMP2 
alone.  Contradictory to the previously mentioned growth factor delivery studies, this 
study demonstrates that a sequential release of VEGF followed by the sustained release 
of BMP2 may not be beneficial for bone regeneration relative to just BMP2 alone.  
Similarly, dual delivery of VEGF and BMP2 from porous PPF scaffolds incorporating 
gelatin microparticles on bone regeneration in a rat critical-size cranial defect model did 
not demonstrate that the addition of VEGF increased bone formation over BMP2 delivery 
alone (Young et al. 2009).  An in vivo dose-dependent decrease in percentage of bone 
regeneration was observed for BMP2. The addition of VEGF was unable to reverse this 
decrease in bone formation, although improvements in the number of bridged defects did 
occur in some groups.    
A significant shortcoming of hydrogel based growth factor delivery is high burst 
release leading to growth factor inactivation.  To overcome this shortcoming and better 
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control the release kinetics, natural and synthetic materials have been functionalized with 
anchoring sites with affinity for the loaded growth factors.  The repeated 
binding/interaction of growth factors to the functionalized recognizing species slows 
down their diffusion and prolongs release rate from the biomaterial.  Key determinants of 
the growth factor release rate include the number of binding sites, the affinity of growth 
factor for the immobilized recognizing species, and the degradation rate of the hydrogel 
(Quaglia 2008).  Heparin has been widely used as an interacting site due to the presence 
of heparin-binding domain on many growth factors.  Heparinized collagen gels (Wissink 
et al. 2000, Steffens et al. 2004) and heparin-immobilized hydrogels based on thiol-
functionalized PEGs (Nie et al. 2007) were synthesized and tested as growth factor 
delivery platform.  More recently, heparin-immobilized macroporous PLGA scaffolds for 
the release of bFGF have been developed (Yoon et al. 2006).  Another study utilized 
poly(L-lactide) and sucrose acetate isobutyrate-based coating around rhBMP2 – loaded 
collagen-chondrotin sulfate to extend rhBMP2 release period from 24 hour to 12 days 
(Keskin et al. 2005).    The extended release of rhBMP2 from the biomaterial allowed for 
histologically well-organized bone formation. 
As discussed before, articular cartilage has a poor healing capacity, and thus 
healing does not always entail cartilage regeneration.  Studies have shown that controlled 
release of various pro-chondrogenic growth factors using hydrogel scaffolds may support 
articular cartilage regeneration.  Intra-articular administration of collagen scaffolds 
loaded with BMP2 induces chondrogenic differentiation of marrow-derived MSCs 
(Mimura et al. 2011).  RT-PCR results showed that the BMP2 administration enhanced 
chondrogenic differentiation. Another study demonstrated that the incorporation of 
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recombinant connective tissue growth factor (CTGF), a hypertrophic chondrocyte-
specific gene product, in a gelatin hydrogel possessed the ability to repair damaged 
articular cartilage in monoiodoacetic acid (MIA)-induced experimental rat osteoarthritis.  
The repaired cartilage histologically looked similar to that of normal articular cartilage.  
Similar results were obtained using a 2 mm diameter, full-thickness rat articular cartilage 
defect treated with CTGF-loaded gelatin gel.  At 4 weeks post treatment, new cartilage 
was found filling the defect (Nishida et al. 2004).  The combined use of cells and growth 
factors loaded on to injectable hydrogels has proven to be constructive in the quest for 
optimal skeletal regeneration.  PLGA microspheres loaded with IGF1 and TGFβ1 and 
bovine articular chondrocytes were photoencapsulated in PEO-based hydrogels 
demonstrated statistically significant changes in GAG production and cell content 
compared to control gels either without microspheres or with blank microspheres after a 
14 day incubation (Elisseeff et al. 2001).   These studies suggest that localized delivery of 
growth factors, such as BMP2, CTGF, IGF1 and TGFβ1 via porous hydrogel scaffolds 
may be useful in therapeutic regeneration of articular cartilage.    
2.1.3.3 Enhancing biological properties by drug delivery 
Hydrogels may also be utilized to enhance the delivery and therapeutic efficacy of 
drugs. Biodegradable hydrogels have the potential to deliver a wide range of water-
insoluble drugs.  Recent studies have demonstrated that a biodegradable gelatin hydrogel 
can be used for the sustained release of water-insoluble simvastatin at a bone defect site 
(Tanigo, Takaoka & Tabata 2010).  The release of biologically active simvastatin was 
accompanied by the biodegradation of hydrogel.  In this study, simvastatin was water-
solubilized by gelatin grafted with L-lactic acid oligomer and mixed with gelatin, 
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followed by chemical crosslinking to obtain gelatin hydrogels incorporating simvastatin.  
Bone healing of critical-sized nasal defects in rabbits by simvastatin in hydrogels has also 
been investigated (Mukozawa et al. 2011).  At 2 and 4 weeks post-implantation, 
increased bone healing and BMP2 expression was seen in the animal groups with 
simvastatin delivered in the hydrogels.   Other studies have also demonstrated the 
increased expression of BMP2, along with VEGF and Cbfa1 upon treatment with statin-
loaded hydrogels (Wong, Rabie 2006).   Thus, the delivery of drugs, such as statins, may 
be achieved via hydrogel delivery to enhance bone regeneration.  
2.1.3.4 Enhancing biological properties by gene delivery 
Another promising method of growth factor delivery in the field of bone-tissue 
engineering is the application of gene therapy (Caplan 2000, Chen 2001), which presents 
a simple approach to evade the difficulties involving the delivery of multiple growth 
factors.  The transfer of genetic material into the genome of the target cell allows for high 
expression of bioactive factors from the local cells in the defect and delivering a more 
biologically active product that can be achieved by exogenous application of recombinant 
proteins.  Gene therapy has the potential to provide control over the timing, distribution 
and level of multiple growth factors that can be either simultaneously or sequentially 
expressed in a tissue-specific manner; this approach may also provide a cure to diseases 
or offer transient growth and regeneration (Franceschi 2005). 
The possibility of achieving osteogenic differentiation as a result of prolonged 
presence of BMP2 was investigated using plasmid DNA-based gene therapy.  The 
delivery of BMP2 cDNA in an alginate hydrogel resulted in an increasing amount of 
biologically active BMP2 released from endogenous cells after 6 weeks of implantation 
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(Wegman et al. 2011).  Combinatorial gene therapy has also been explored; human 
BMP2 and VEGF165-transfected rabbit bone marrow stromal cells (BMSCs) loaded on 
coral scaffold resulted in increased new bone formation, compared with any single factor 
in a critical-sized orbital defect rabbit model (Xiao et al. 2011). 
 
2.1.3.5 Enhancing biological properties by cell encapsulation 
Numerous studies have utilized hydrogels as cell delivery vehicles for skeletal 
regeneration.  Although hydrogels lack mechanical strength, they are extremely valuable 
and efficient in encapsulating and maintaining viable cells.  Various cell types are 
available for engineering organized skeletal tissues.  However, when selecting the 
optimal cell type for therapeutic application, one must consider a few different factors, 
including the ex vivo proliferative capacity of the cells, phenotypic stability and 
immunogenicity.   Cell types that are currently considered for skeletal regeneration 
include fully differentiated cells, mesenchymal stem cells and embryonic stem cells.    
Photoencapsulation of rat calvarial osteoblasts in injectable, non-adhesive PEG 
hydrogel modified with Arg-Gly-Asp (RGD) peptide for bone tissue engineering 
demonstrated increased mineral deposition (Burdick, Anseth 2002).  However, a decrease 
in osteoblast viability of approximately 25% and 38% was seen after 1 day of in vitro 
culture when the macromer concentration was increased to 20 and 30wt%, respectively.  
A later study demonstrated collagen type I hydrogel allowed for the migration, 
proliferation and finally adoption of the osteoblastic fate of rat bone marrow stromal cells 
(rBMSCs) (Hesse et al. 2010).  However, only about one third of the entire rBMSC 
population had the ability to actively migrate.  Although this study contributes to the 
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development of novel bone grafts, it also presents current drawbacks of hydrogels as cell 
delivery vehicles for bone tissue engineering. 
A recent study investigated the need for smart matrices in bone tissue-engineered 
grafts to provide an optimal environment for cells and retain osteoinductive factors for 
sustained biological activity.  Slow-degrading, heparin-incorporated HA hydrogel loaded 
with primary osteoblasts and BMP2 facilitated the increase of bone-related genes after 8 
weeks in rat femor.  An arterio-venous loop provided an angiogenic stimulus and 
supported axial vascularization to provide nutrition for a bio-artificial bone graft.  
However, no significant increase in bone formation was observed histologically which 
might be explained by the absence of biomechanical stimulation as a result of the 
heterotopic isolation chamber.  This suggests that optimization of osteogenic and 
angiogenic conditions are necessary to generate sufficient amounts of vascularized bone 
grafts for reconstructive surgery.  This study also clearly demonstrated that the HA 
hydrogel supported growth and differentiation of osteoblasts in vitro and in vivo and 
allowed sustained release of BMP2 (Rath et al. 2011). 
Also, while designing a cell delivery system, it must be noted that tissues are 
generally not homogenous from a cell perspective; they consist of multiple cell types in 
highly organized frameworks – termed microscale heterogeneity.  For example, skeletal 
tissue consists of various cell types including osteocytes, osteoclasts, endothelial cells 
and chondrocytes.  Engineering osteochondral tissues to have regulatory effects with each 
other, in turn, encourages more functional tissue development.  Co-culture models of 
multiple cell types is especially exciting since different cells act cooperatively and 
bioactive factors secreted by one cell type provides cue for the action of its neighboring 
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cells.  An important study that showed promise in bone regeneration and angiogenesis 
using a vascular endothelial cell/bone marrow MSC co-culture model (Sun et al. 2007).  
A later study went on to demonstrate the patterned microscale capability of 3D co-
culturing endothelial cells and osteoblastic cells in a microchannel (Chueh et al. 2010). 
This simple and reversible hydrogel patterning method for 3D cell culture allowed for 
alginate gel to be formed in select regions of a microfluidic device through light-triggered 
release of caged calcium.  Since microscale heterogeneity is central to cellular niches and 
tissue development, microscale engineering of hydrogels has proven to be a useful tool 
for tissue engineering (Sands, Mooney 2007).  Furthermore, techniques to mimic the 
microscale heterogeneity of the ECM in vitro improve how scientists examine the 
interaction of cells. 
Toti-potent embryonic stem cells possess the potential to differentiate into an 
unlimited array of cell types.  Cartilage repair was seen using hyaluronan hydrogel-
encapsulated human embryonic stem cell (hESC)-derived chondrogenic cells (Toh et al. 
2010).  In this study, hESC-derived chondrogenic cells produced ECM-enriched 
cartilaginous tissue construct when cultured in HA-based hydrogel.  Furthermore, the use 
of this hydrogel/hESC sytem for the repair of rat critical-sized osteochondral defect 
resulted in an orderly spatial-temporal remodeling over 12 weeks into osteochondral 
tissue with good surface regularity and complete integration with the adjacent host 
cartilage.  This study demonstrated the feasibility of using hESC-derived chondrogenic 
cells for cartilage tissue engineering. 
Multi-potent mesenchymal stem cells have the ability to differentiate into several 
cell types to form new repair tissue.  Bone marrow is a major source of mesenchymal 
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stem cells (BMSCs), which may contribute to the regeneration of bone and cartilage.  
Studies have investigated the biocompatibility of thermoresponsive copolymer composed 
of hyaluronic acid-g-chitosan-g-poly(N-isopropylacrylamide) (HA-C-NIPAAm) and its 
efficacy as a cell carrier for bone marrow stem cells (BMSCs).   After 4 months of 
composite hydrogel/BMSCs implantation subcutaneously in nude mice, significant 
ectopic bone formation was confirmed via microCT analysis (Liao, Chen & Chen 2011).  
The most widely studied synthetic gels for MSC encapsulation and cell delivery 
are based on PEG and PVA.  PEG is biocompatible polyester that has been approved by 
FDA for many medical applications.  Non-toxic, biodegradable PEG hydrogels are 
promising matrices for cell encapsulation (Sims et al. 1996, Chen et al. 2003) and has 
been shown to support BMSC chondrogenesis in vitro (Williams et al. 2003).  Successful 
application of photopolymerizable PEG hydrogels towards the engineering of 
multilayered articular cartilage has been demonstrated (Alhadlaq, Mao 2005).   MSCs 
were treated ex vivo for 3-4 days with either chondrogenic or osteogenic supplements and 
loaded into two hydrogel layers and cured via photopolymerization.  Stratified layers of 
chondrogenesis and osteogenesis were observed after 4 weeks of implantation.  In a 
recent study, swine auricular chondrocytes were photoencapsulated into two PEG 
dimethacrylate (PEGDM) copolymer hydrogels of different degradation profiles: 
degradable (PEG-4,5LA-DM) and nondegradable (PEGDM) macromers in molar ratios 
of 60:40 and 70:30.  The less degradable PEGDM hydrogel supported higher 
glycosaminoglycan and hydroxyproline contents in the neotissue.  This study 
demonstrated that PEGDM copolymer hydrogels can support in vivo chondrogenesis by 
photoencapsulating auricular chondrocytes (Papadopoulos et al. 2011).  The control of 
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biomaterial degradation rate is essential for proper matrix synthesis of the encapsulated 
cells.  
Autologous chondrocyte implantation is an established, FDA-approved method of 
treatment for cartilage repair.  This treatment requires the removal of the chondrocytes 
from the patient’s knee, expansion of the chondrocytes and subsequent implantation into 
the defect site.  This procedure entails disadvantages such as donor site morbidity and 
also loss of chondrogenic phenotype during the cell expansion step.  A recent study has 
utilized autologous chondrocyte implantation in a novel alginate-agarose hydrogel to 
demonstrate significant clinical improvement at follow-up at two years with 
predominantly hyaline cartilage-like repair tissue (Selmi et al. 2008).  Another supporting 
study encapsulated bovine chondrocytes from corresponding zones of the femoral 
articular cartilage in photopolymerizing hydrogels to regenerate cartilage with zonal 
organization (Kim et al. 2003).  However, the encapsulation of growth factors for 
modulation of chondrogenesis and osteogenesis may be necessary for further phenotypic 
maintenance of chondrogenic and osteogenic cells derived from MSCs in vivo (Lu, 
Yaszemski & Mikos 2001, Elisseeff et al. 2001).    
Thusfar, no hydrogel biomaterial has been presented in literature to inherently 
increase cell survival, proliferation or osteogenesis (without the use of drugs, gene 
therapy or growth factors).  Such bioactive biomaterial is warranted since these processes 
are necessary for successful bone formation and regeneration.  The bioactivity of protein-
based hydrogels in cell-based therapeutics may encourage encapsulated cells to recognize 
and bind to specific sites within proteins.  The key for a successful regenerative 
biomaterial lies in its ability to interact with the surrounding environment and induce a 
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multitude of cell signaling pathways, including cell survival, proliferation and 
mineralization.  
2.1.4 Conclusions 
For optimal tissue regeneration, biomaterial scaffolds should not serve as a simple 
inert substrate; instead should serve as three-dimensional mediums for the dynamic 
extracellular signaling and facilitators for progenitor cell recruitment, growth and 
differentiation.  Hydrogels may serve as excellent scaffolds for skeletal regeneration 
since their biomimetic properties and high water content presents a cell-friendly, natural 
microenvironment to support cell functions.  The ability to conveniently control the 
chemistry and functionality of the hydrophilic polymers allow tailoring the physical and 
mechanical properties of hydrogels for bone and cartilage regeneration. The use of 
enzymatically-crosslinked hydrogels provides a mild, in situ-forming biomaterial system 
for the localized delivery of cells to support tissue regeneration.  Our ability to 
incorporate specific and controlled biological activities in these hydrogels to modulate 
encapsulated cell performance can significantly increase their efficacy as scaffolds for 
skeletal tissue regeneration.  Attempts have been made to increase the bioactivity of 
hydrogels by incorporating one or more growth factors in the gels.  However, it is to be 
noted that tissue regeneration/healing is a complex process involving several bioactive 
molecules expressed under very tight spatio-temporal control.  Since encapsulated cells 
are capable of producing these bioactive molecules, one attractive strategy will be to 
design and develop bioactive materials as injectable cell delivery vehicles that can induce 
the encapsulated cells to produce appropriate bioactive molecules for regeneration.  We 
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explore the feasibility of developing such a novel injectable biomaterial system in the 
present study. 
 
2.2 Lactoferrin as a biologically active molecule for bone 
regeneration 
LF is described as a “moonlighting” protein as it possesses multifold functions 
(Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009) (Figure 5) and its bioactivity 
is dependent on the specific physiological environment (Baker, Baker 2009).  The 
regulation of LF synthesis, secretion and spatio-temporal distribution in vivo collectively 
play a part in determining its specific biological functions.  Since successful skeletal 
tissue engineering requires concerted efforts of different cell types, the modulatory effect 
of LF on pluripotent cells, osteoblasts, osteoclasts and immune-modulating cells makes 
this glycoprotein a potential molecule to support skeletal tissue regeneration. 
 
Figure 5.  The wide range of beneficial functional properties decribed for LF. 
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Image taken from (Vogel 2012). 
 
2.2.1 Molecular structure and composition 
The structure and composition of a protein play very important roles in 
determining its biological functions. LF is a highly cationic protein with an isoelectric 
point of 8.0-8.5 (van et al. 2001).  Structurally, it is a bilobal globular glycoprotein with a 
molecular weight of approximately 80 kDa.  Anderson et al., reported the three 
dimensional structure of human diferric LF as comprising of two highly homologous 
globular lobes (N and C lobes), each containing one canonical trivalent ferric iron-
binding site and one glycan, linked by an extended α-helix (Anderson et al. 1987). The 
globular lobes of LF can bind to variety of cations such as trivalent Fe3+, Ga3+ and Al3+ 
and di- and trivalent transition metal ions VO2+, Mn3+, Co3+, Cu2+, and Zn2+. However, as 
the name suggests, LF has very high affinity for and is most commonly associated with 
trivalent ferric iron (Harrington 1992).  For each cation bound to LF, one bicarbonate 
anion binds concomitantly and synergistically to the iron-binding crevice.  The presence 
of the bicarbonate anion bound to LF is essential for metal binding and greatly increases 
the saturation of iron (Anderson et al. 1989).  
Because of its ability to reversibly bind iron, LF can exist free of iron (apo-LF) or loaded 
with iron (holo-LF) (Schanbacher, Goodman & Talhouk 1993). As in the case of 
transferrins, the bound iron from LF can be released by the destabilization of the protein, 
which can be triggered perhaps by receptor binding in vivo and by lowering of the pH, 
reduction or the use of small-molecule chelating agents in vitro. The iron binding induces 
substantial structural changes of the globular lobes of LF, consistent with the closure or 
opening of the inter-domain cleft (Grossmann et al. 1992).  The binding of the protein 
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ligands to the ferric iron and bicarbonate leads to the highly compact conformation of 
iron saturated-LF (Anderson et al. 1989).  The presence of iron can also possibly affect 
the stability of the protein towards proteases.   Studies have shown that the protein is 
more resistant to proteolysis, especially in its iron-saturated holo form (Brines, Brock 
1983, Brock et al. 1976).  However, species differences do exist and human apo-LF has 
been found to be more stable compared to bovine apo-LF (Brines, Brock 1983).  It is 
important to note that the vast majority of the molecular surface remains the same when 
LF is “open” or “closed” state, therefore the surface receptor binding sites are likely to be 
unaffected by iron status.  However, the structural dynamics of the open binding cleft of 
apo-LF provides additional sites for molecular interactions compared to holo-LF which 
implies possible differences in their biological functions (Baker, Baker 2009).   
 Another important structural component of LF is the nature and extent of 
glycosylation.  All LFs are glycosylated although the glycosylation profile (the number 
and location of potential glycosylation sites and sites actually used) is species-specific.  
Bovine LF (bLF) has five potential glycosylation sites (Goodman, Schanbacher 1991), 
out of which only four sites are known to be glycosylated.  Native human LF (hLF) 
contains three potential N-glycosylation sites, located at Asn138, Asn479, and Asn623.  
Two sites are glycosylated by complex-type N-glycans and the third putative site 
(Asn623) is unglycosylated (Spik et al. 1982, van Berkel et al. 2002a).  Natural hLF 
contains complex highly branched, highly sialylated and highly fucosylated structures.  
The glycosylation patterns of LF have also been shown to be tissue/cell – specific.  LF is 
often associated with secretion of mucosal tissues and with neutrophilic granules.  Even 
though no significant differences in protein moiety have been reported between the 
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mucosal and neutrophilic LF, they show difference in molecular weight (Levay, Viljoen 
1995b).  It has been reported that the digestion of the two forms with N-glycanase 
resulted into a single protein band of approximately the same apparent molecular weight 
indicating that the difference in molecular weight is mainly due to difference in 
glycosylation (Hurley et al. 1993).  Human milk lactoferrin glycan differs from the 
neutrophilic protein in the presence of α-1,6 and α-1,3 fucose residues and in the degree 
of sialylation (Levay, Viljoen 1995b).  The recombinant forms of LF also show 
differences in the composition of carbohydrate chains and vary according to the specific 
species expression system.  The glycosylation patterns of rhLF have been investigated in 
forms that were expressed in maize, tobacco, rice and cattle transgenic systems (Fujiyama 
et al. 2004, Samyn-Petit et al. 2003, Samyn-Petit et al. 2001, Yu et al. 2010).  The 
recombinant form produced in the milk of transgenic clone cattle has been found to be 
approximately 2 kDa smaller than that of native form, due to the differences in N-
glycosylation (Yu et al. 2010).  As discussed before, neutrophilic LF, unlike the milk-
derived protein, is not fucosylated – however, the difference in the molecular structure 
and functions of the two naturally occurring forms are not completely understood.  On 
the other hand, rhLF, obtained from rice, contains N-glycans that are of high mannose, 
hybrid structures with low sialic acid and fucose, which are common post-translational 
modification patterns (van Berkel et al. 2002a, Nandi et al. 2005).  A recent study 
investigated the difference in properties of glycosylated and non-glycosylated human LFs 
showed that deglycosylation did not affect its iron-binding and/ release as well as thermal 
stability (Baker, Baker 2009).   However, based on some of the reported studies, it is 
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possible that the glycosylation pattern of LF might affect some of the biological activities 
of the protein such as immune-regulatory functions (Yu et al. 2010).       
2.2.2 Role of lactoferrin in ferrokinetics 
LF is a pleiotrophic factor that exhibits a vast range of biological functions, 
including anti-microbial, anti-inflammatory, iron homeostasis, osteogenesis, angiogenesis 
and immuno-modulation (Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009).  
Of the many biological functions credited to LF, the protein was initially well recognized 
for its ability to bind iron.  Among the members of the transferrin family, LF has the 
ability to retain iron over a wide pH range.  LF’s possible role in ferrokinetics is 
attributed to its great affinity for free iron (Brock 2002).  Homeostasis of iron is required 
at specific concentrations for metabolic functions of cells including cell proliferation and 
host defense. Elevated biological concentrations of iron are potentially deleterious; 
consequences include support of microbial growth, suppression of various defense 
mechanisms and cell injury induced by excessive hydroxyl or ferryl radicals.  Iron 
loading conditions, such as hemochromatosis, have been positively correlated with a 
suppression of osteoblast formation and new bone synthesis (Weinberg 2006).   
It is consensual that LF influences the iron availability (Levay, Viljoen 1995a), 
however, it is still not proven to be essential for normal iron homeostasis or intestinal iron 
delivery (Brock 2002, Ward, Paz & Conneely 2005).  LF knockout (LFKO-/-) mice, 
which develop normally and display no overt abnormalities, demonstrated that LF is not 
essential for iron delivery during the postnatal period.  Analysis of adult mice on a basal 
or a high-iron diet revealed no differences in transferrin saturation or tissue iron stores 
between wild-type and LFKO-/- mice on either diet, although the serum iron levels were 
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slightly elevated in LFKO-/- mice on the basal diet (Ward, Uribe-Luna & Conneely 2002).  
Collectively, these results support the notion that LF does not play a major role in the 
regulation of iron homeostasis unlike transferrins.  However, the iron-binding function of 
LF may contribute to alterations in iron metabolism during infection, inflammation or 
other physiological functions (Brock 1995).   
Among LF’s physiochemical properties, which collectively contribute to its 
myriad of functions, are its reversible affinity for iron and resulting three-dimensional 
changes in structural conformation.  Biological properties of LF have been described 
relative to its iron binding states, which differ significantly in structural conformation 
(Baker, Baker 2004).  Apo-LF, the predominating in vivo form, is an “open” molecule 
that has been reported to increase VEGFA-mediated angiogenesis in vivo (Norrby 2004) 
and strongly modulate inflammatory response (Baveye et al. 1999). Holo-hLF has been 
reported to stimulate cell cycle progression through PI3K/Akt pathway (Lee et al. 2009).  
However, iron (FeCl3) supplementation did not significantly promote cell cycle 
progression indicating that the iron content does not induce the proliferative ability of 
holo-hLF, but instead holo-hLF possesses a noble growth regulatory function (Lee et al. 
2009).  Physiological concentrations of apo-LF and holo-LF have been demonstrated to 
result in a suppression of osteoclastogenesis (Cornish et al. 2006, Cornish et al. 2004, 
Lorget et al. 2002).  Cornish et al. assessed the effects of iron-binding of bLF, compared 
to similar size cations (chromium and magnesium), in primary rat osteoblast-like cell 
cultures on cell proliferation.  The rate of proliferation of cells exposed to chromium- and 
manganese-loaded LF was similar to iron-loaded and iron-unloaded LF.  These studies 
indicate that the proliferative effect of LF on osteoblast is independent of cation type and 
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saturation (Cornish et al. 2006).  Further studies are needed to elucidate the molecular 
mechanisms regarding potential differences in response to iron saturation of LF.  Aside 
from its metal bound state, the potent activity of LF on bone cells at peri-physiological 
concentrations indicate that LF might have a physiological role in bone growth and thus 
may serve as a novel bone repair therapeutic.   
2.2.3 Positive skeletal regulator 
Bone is continuously remodeled by the sequential activities of osteoclast-
mediated bone resorption and osteoblast-mediated bone formation (Parfitt 1976).  LF, as 
a multifunctional glycoprotein, is also shown to be a potent anabolic effector of the 
skeleton.  LF’s anabolic effect in bone morphongenesis is attributed to its strong dose-
dependent proliferative and anti-apoptotic actions on osteoblasts and inhibition of 
osteoclastogenesis (Cornish et al. 2004) (Figure 6 & 7).  At physiological concentrations, 
LF promotes proliferation of osteoblasts and cartilage cells in vitro at a magnitude that 
exceeds the response observed relative to other skeletal growth factors such as IGF1 and 
TGFβ (Cornish 2004). 
 A recent study analyzed the immuno-expression of LF in human bone tumors in 
comparison to normal fetal and adult bone tissue (Ieni et al. 2009).  Immunoreactivity of 
this glycoprotein was seen in neoplastic fibroblast like stromal cells as well as 
multinucleated giant cells (MNGCs).  Positive LF immuno-expression was found in 
osteoid osteomas, adamantinomas and chondroblastomas.  Normal fetal bone tissue 
exhibited positive LF immuno-expression, where it was primarily localized in the 
osteoblasts, in the calcified cartilage area as well as the nucleus of chondrocytes in the 
cartilage matrix adjacent to the calcified area.  No LF expression has been found in any 
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of the adult bone tissue samples most likely due to the decrease in osteoblast metabolic 
activity.  The high LF immuno-expression in the human osteoblastic lineage or bone 
forming tumors as well as in human fetal bone supports its significant role in promoting 
bone formation.   
The potency of LF’s anabolic actions on the skeleton requires better understanding of its 
molecular mechanisms. However, the mechanisms and cell signaling pathways involved 
in the transduction of LF’s growth-modulating effects on osteoblasts have not yet been 
comprehensively studied.  Presently, LF’s potent mitogenic effect is accredited to low-
density lipoprotein receptor-related protein (LRP) 1, which signals the activation of 
mitogen-activated protein kinases (MAPKs) to confer increased cell mitogenesis (Grey et 
al. 2004, Naot et al. 2005).  LRP1 and 2 are among the putative LF receptors (Ji, Mahley 
1994, Meilinger et al. 1995, Vash et al. 1998, Willnow et al. 1992).  LRP is a membrane 
glycoprotein that spans the cell membrane and consists of an extracellular 515 kDa heavy 
chain and an 85 kDa light chain (Herz, Gotthardt & Willnow 2000).  The extracellular 
domain of LRP contains four ligand-binding clusters, where hLF interacts with the 
second and fourth cluster of class A cysteine-rich repeats (Neels et al. 1999).  LRPs, 
found on hepatocytes, fibroblasts, immune cells, osteoblasts, and endothelial cells, 
functions as both endocytic receptors and signaling receptors (Herz, Gotthardt & 
Willnow 2000, Neels et al. 1999, Li, Cam & Bu 2001, Strickland, Gonias & Argraves 
2002). The expression of LRP1 by human osteoblasts was demonstrated as a mechanism 
for delivery of lipoproteins and vitamin K1 to bone (Niemeier et al. 2005).  Although 
LRP1 is classically known for its involvement in the endocytic pathway, LF has also 
been demonstrated to transduce cell signaling pathways mediated by LRP1 independent 
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of the receptor’s endocytic properties (Grey et al. 2004).  LF’s proliferative actions on 
osteoblastic cells via LRP1–dependent phosphorylation of p42/44 MAP kinases (Grey et 
al. 2004) suggests that this receptor may also mediate its anabolic effects in skeletal 
tissue.   
LRP5 and 6, are multiligand, nonendocytic members of LRP receptor family and 
have been widely identified as crucial regulators of osteoblast function (Gong et al. 2001, 
Babij et al. 2003).  Thus, it is of question whether these receptors possess overlapping 
functions with LRP1 in the increase of skeletal mass.  Previous reports indicate that 
LRP1 cannot substitute LRP5/6 in the transmission of the Wnt canonical pathway (Tamai 
et al. 2000) and even represses the canonical Wnt pathway (Zilberberg, Yaniv & Gazit 
2004).  LRP1 cytoplasmic domain plays a crucial role in LRP1-mediated signal 
transduction (Howell, Herz 2001).  Thus, to elucidate whether LRP1-mediated signaling 
events directly or indirectly leads to the repression of the canonical Wnt pathway, 
Zilbergerg et al. demonstrated that mLRP4T100, a mini-receptor of LRP1, tailless mutant 
preserved its repressive effect on Wnt signaling.  The study demonstrated that LRP1-
mediated signaling events directly lead to the repression of the canonical Wnt pathway.  
Furthermore, this study excludes the possibility that this repression is attributed to LRP1-
affected signaling pathways that cross-regulate the canonical Wnt pathway.  On the 
contrary, another study has reported that LF causes the significant down-regulation of 
dickkopf homolog 1 (DKK1) mRNA, a Wnt antagonist, in human primary osteoblasts 
(Cornish, Naot 2010) possibly indicating the on-state of the canonical Wnt signaling 
pathway. 
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 LF has been demonstrated to have potent anti-apoptotic effects on osteoblast cells, 
which may also contribute to its anabolic skeletal actions.  At peri-physiological 
concentrations (1-10µg/ml), LF protects both primary rat osteoblast cells and SaOS2 cells 
from serum withdrawal-induced apoptosis (Grey et al. 2006).  Studies have demonstrated 
that LF induce LRP1-dependent phosphorylation of Erk and PI3K-dependent 
phosphorylation of Akt (Grey et al. 2004, Grey et al. 2006).  However, the ability of LF 
to promote osteoblast survival was found to be independent of both of these activities 
(Grey et al. 2006).  Although studies indicate the activation of LRP1 can lead to the 
activation of both PI3K and Erk (Orr et al. 2003), this study clearly indicates the 
existence of unique signaling transduction pathways mediated by LF that subserve its 
anti-apoptotic actions on osteoblasts (Grey et al. 2006).  Thus, collective studies 
demonstrate that LF’s anti-apoptotic activities are not sufficiently explained by signaling 
via LRP1 and most likely mediated by more than one of LF’s putative cell membrane 
bound receptors.  This notion is further be supported by the cationic nature of LF 
allowing it to interact with a heterogenous array of receptors, cells and anionic molecules, 
including DNA (Elass-Rochard et al. 1995, Appelmelk et al. 1994b, Shimazaki et al. 
1998, Mann, Romm & Migliorini 1994, Hutchens, Magnuson & Yip 1989). 
Through the use of microarrays and low-density arrays to investigate the changes 
in gene expression induced by LF treatment in osteoblasts, a recent study indicate the 
significant upregulation of IGF1 mRNA (Cornish, Naot 2010).  As an endocrine and 
paracrine regulator of skeletal homeostasis, IGF1 has been demonstrated to promote 
survival and proliferation in osteoblasts through parallel PI3K and p42/44 MAPK 
signaling pathways (Grey et al. 2003).  IGF binding proteins (IGFBPs) modulate IGF 
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action by inhibiting or enhancing IGF binding to IGF receptors.  Furthermore, LF has 
been indicated to be a high affinity, IGFBP3 binding protein (Baumrucker, Gibson & 
Schanbacher 2003).  Interestingly, holo-LF showed slightly greater binding to IGFBP3 
than the apo form (Baumrucker, Gibson & Schanbacher 2003). This interaction will free 
IGFs (both IGF1 and IGF2) from their association with IGFBP.  Much remains to be 
learned about the interactions involving IGFs, IGFBPs and LF.  The connections between 
the various regulatory signaling pathways need to be further explored to help elucidate 
LF’s effects on modulating skeletal growth. 
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Figure 6.  Through bidirectional signalling, LF enhances osteoblast activity and 
suppresses osteoclastogenesis. 
A) Effects of lactoferrin on rat primary osteoblast proliferation and differentiation. 
Thymidine incorporation in primary cultures of rat osteoblast-like cells treated for 24 
hours with increasing concentrations of rhLF.  The effect of rhLF on areas of mineralized 
bone nodules as determined in primary cultures of rat osteoblast-like cells cultured over 
a period of 3 weeks. Cells were stained for mineral using Von Kossa stain.  Image was 
adapted from (Cornish et al. 2004, Grey et al. 2004). 
B) RAW264.7 cells, induced to differentiate to osteoclasts by the addition of 50ng/ml 
RANKL to the culture media, were treated with increasing concentrations of bLF (x 
µg/ml). TRAP positive multinucleated cells were counted on day 5.  Osteoprotegerin 
(OPG) (0.02 µg/ml) was used as a positive control. Image was adapted from (Cornish, 
Naot 2010). 
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Figure 7.  Anabolic effect on mouse hemi-calvaria in response to bLF after 10 days 
treatment. 
Photomicrographs of calvariae from animals treated with lactoferrin bLF) (4 mg) (A) and 
vehicle (B) for 5 days. Animals were killed 10 day later.  Fluorochrome labels used: 
green, calcein; red, alizarin. Two calcein labels were given 13 day apart. The increased 
new bone growth in the 13-d period (i.e. distance between the two green calcein labels, 
arrowed) can be appreciated in the calvaria from the lactoferrin-treated animal. It can 
also be noted that there is new bone marrow formation occurring within the recently 
formed bone in the lactoferrin-treated calvaria. New bone formed on the injected side of 
the lactoferrin calvaria is partially woven (*). This was seen only in the animals treated 
with the highest dose of lactoferrin and probably reflects the very high rate of matrix 
deposition. Horizontal bar, 50 µm.  Figure was taken from (Cornish et al. 2004). 
 
2.2.4 Lactoferrin as an immunomodulatory protein 
LF is a potent modulator of inflammation, innate and adaptive immune response 
(Legrand et al. 2005, Spadaro et al. 2008).  The presence of LF in neutrophil granules 
indicates its important role in host defense.  High affinity LF receptors have been 
identified on cells such as lymphocytes, monocytes and macrophages.  The modulatory 
effects of LF have been attributed to its ability to interact with pro-inflammatory bacterial 
components as well as through interactions with epithelial and immune cells via specific 
cellular receptors even though the exact mechanisms have not been fully elucidated yet.  
At the cellular level, LF is known to modulate antigen presenting cells (monocytes, 
macrophages, dendritic cells) migration and activation as well as affects the expression of 
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soluble immune mediators such as cytokines, chemokines and other effector molecules.  
Several factors such as concentration of LF, iron content and composition have shown to 
have an effect on its immune-modulatory function.       
 The immunotropic regulation of LF in the innate immune system includes a 
multitude of host-protective effects against microbial infections, septic shock, 
inflammation, allergy and cancer (van Hooijdonk, Kussendrager & Steijns 2000). 
Supporting data indicates that patients with congenital or acquired LF deficiency are 
subjected to recurring infections (Breton-Gorius et al. 1980). Enhanced Th1 response to 
Staphylococcus aureus (S. aureus) infection was demonstrated in transgenic mice 
expressing human LF (Guillen et al. 2002).  Oral LF administration demonstrates a 
protective effect during lethal bacteraemia and septic shock (Lee et al. 1998, Zagulski et 
al. 1989).  Degree of iron saturation of LF has been demonstrated to play an interesting 
role in LF’s ability to inhibit or promote L. pneumophila intracellular multiplication in 
mononuclear phagocytes at sites of inflammation (Byrd, Horwitz 1991).  Apo-LF 
completely inhibited L. pneumophila multiplication in non-activated monocytes, whereas 
iron-saturated LF had no effect on the already rapid rate of L. pneumophila multiplication 
in non-activated monocytes.  Increased levels of LF during inflammatory and immune 
responses target the monocytic cell line with high affinity (4.5 x 1O-9M) through a 
receptor-mediated mechanism (Bennett, Davis 1981, Birgens et al. 1983). However, 
lower affinity of LF is demonstrated for adherent mononuclear cells (Bennett, Davis 
1981, Birgens et al. 1983) and alveolar macrophages (Campbell et al. 1992).  
Furthermore, LPS-induced TNFα, IL1β, IL6, and IL8 production is inhibited by LF in 
various human monocytic cell lines (Haversen et al. 2002).  LPS-induced endotoxaemia 
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is associated with an up-regulation of nitric oxide synthase (Lauw et al. 2000).  However, 
the inducible nitric oxide synthesized in response to E. coli infection is inhibited by the 
administration of LF (Zagulski et al. 1989).  LF also promotes lytic cell activity by 
increasing the number of natural killer cells (Shimizu et al. 1996, Yamauchi et al. 1998), 
which results in a phagocytosis-enhancing effect (Szuster-Ciesielska, Kamiaska & 
Kandefer-Szerszea„ 1995, Wakabayashi et al. 2003).  LF activating effect is also due to 
the modulation of natural killer cell cytotoxicity and an increased sensitivity of target 
cells to lysis (Damiens et al. 1998).  LF-enhanced phagocytosis of pathogens could be 
due to its direct binding to PMNs and opsonin-like activity (Miyauchi et al. 1998).  The 
adjuvant effect of LF in the generation of delayed-type hypersensitivity due to its binding 
on the mannose receptor of immature antigen-presenting skin cells is further supportive 
of its immunotropic activity (Zimecki, Kocieba & Kruzel 2002).  The ability of LF to 
directly activate macrophages (Actor et al. 2002, Sorimachi et al. 1997) and also inhibit 
effector phases of cellular immune responses (Zimecki, Machnicki 1994) are 
contradictory and therefore require greater knowledge of the conditions during the 
administration of LF.  
The anti-inflammatory properties of LF have been extensively studied.  LF’s anti-
inflammatory properties may be partially explained by its iron-independent regulatory 
role during cytokine response to decrease pro-inflammatory cytokines, such as tumor 
necrosis factor α (TNFα), M-CSF, IL1β, IL6 and IL8 (Sawatzki, Rich 1989, Broxmeyer 
et al. 1987, Machnicki, Zimecki & Zagulski 1993, Kruzel et al. 2002) and to increase 
anti-inflammatory cytokines, such as IL4 and IL10 (Legrand et al. 2005, Togawa et al. 
2002).   
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The anti-inflammatory activity of LF is applicable to infectious and non-
infectious pathologies, such as allergies, rheumatoid arthritis, inflammatory bowel 
disorders and neurodegenerative disorders (Ward, Uribe-Luna & Conneely 2002). The 
effects of exogenous pro-inflammatory molecules, such as bacterial lipopolysaccarides 
(LPS) (Miyazawa et al. 1991) and bacterial unmethylated CpG-containing 
oligonucleotides (Britigan et al. 2001), are alleviated by LF.  The binding of LPS to LF 
inhibits LPS signaling, in turn blocking the activation of the serum LPS-binding protein 
(LBP) and soluble CD14 (sCD14), as well as, membrane CD14 (mCD14) on monocytes 
and L-selectins on PMNs (Elass-Rochard et al. 1998, Baveye et al. 2000b).  The strong 
interaction between LF and sCD14 interferes with the formation of the sCD14-LPS 
complex and ultimately inhibits the expression of endothelial adhesion molecules, E-
selectin and ICAM-1 and reactive oxygen species production in neutrophils (Baveye et 
al. 2000a).  Furthermore, the lactoferricin domain of LF was demonstrated as a high-
affinity lipid A binding protein (Elass-Rochard et al. 1995, Appelmelk et al. 1994a).  The 
charge-charge interaction that occurs between LF and lipid A can result in exposure of 
the unbound portion of lipid A to recognize LPS receptors, such as Toll-Like Receptor 4 
(TLR4).  This complex recognition would, in turn, activate macrophages. Potentially 
separate pathways for LF-mediated macrophage activation events are demonstrated by 
LF-induced, TLR4-dependent CD40 expression and the LF-induced, TLR4-independent 
IL6 secretion (Curran, Demick & Mansfield 2006). 
In addition to inducing systemic immunity, in vivo studies show promotion of 
skin immunity and inhibition of allergic responses by LF (Elrod et al. 1997, Griffiths et 
al. 2001).  Through dose-dependent inhibition of Langerhan cell migration and 
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accumulation of dendritic cells in lymph nodes, LF is able to protect the immune system 
against skin allergies.  The overexpression of LF in patients with allergies (Zweiman et 
al. 1990) involves mast cell and basophil activation and IL1β and TNFα- induced 
migration of antigen-presenting cells.  The interaction of LF and keratinocytes results in 
the inhibition of TNFα release by keratinocytes (Kimber et al. 2002).  
 Furthermore, the iron-dependent anti-inflammatory activity is associated with iron 
sequestration by apo-LF, which is released by neutrophils at the septic site.  LF 
participates in detoxification by reducing the tissue-toxic hydroxyl radicals produced by 
the granulocytes.  During inflammation, the Fenton/Haber-Weiss reaction produces 
damaging hydroxyl radicals as a result of free iron accumulation reacting with the 
reactive oxygen species released from the synovial macrophages.  The chelation of iron 
by LF limits the concentration of radicals at the inflammation site and thus decreases 
lipid peroxidation and cell damage (Kruzel 2003).   
 Glycosylation patterns are known to impact immunogenicity and biological 
activity of various glycoproteins (Dwek 1995, Walsh, Jefferis 2006). Granulocytic LF, 
which is present in exocrine secretions and secondary granules of neutrophils, is known 
to have potent immunomodulatory functions. The two forms of LF show similar amino 
acid sequences and differ only in their glycosylation, indicating that glycosylation pattern 
can significantly affect LF’s immunomodulatory functions. Recombinant human LF 
identical in glycosylation pattern to natural neutrophilic counterpart was recently 
bioengineered using Pichia pastoris expression system (Choi et al. 2008).  The 
glycosylated recombinant protein showed potent immune regulatory properties and 
effectively reduce methotrexate induced suppression of secondary humoral immune 
	   80 
responses in sheep erythrocytes.  The study also suggests that the terminal N-
acetylneuraminic acid plays a significant role in LF mediated immune response.  Even 
though the mechanism is not fully understood, it is suggested that the milk-derived, 
fucosylated LF has lower affinity to receptors that are responsible for signal transduction 
in immune cells.   
 Similarly, talactoferrin alfa (TLF), a recombinant human LF that differs from 
native human LF only in its glycosylation patterns, has been demonstrated to have potent 
immune modulatory functions (Engelmayer, Blezinger & Varadhachary 2008, de et al. 
2008). TLF has recently been used as a therapeutic agent for several cancers and healing 
of diabetic wounds (Varadhachary et al. 2004, Wolf et al. 2007, Hayes et al. 2006).  TLF 
rapidly mounts responses to pathogens by chemoattracting monocytes, promoting 
leukocytes and activating dendritic cells (de et al. 2008).  The ability of TLF to recruit 
and activate antigen-presenting cells and to enhance antigen-specific immune responses 
are characteristic of alarmins, which are a group of endogenous mediators of the immune 
system that link innate and adaptive immune systems (de et al. 2008).  The effects of TLF 
on macrophage function ultimately leads to attenuation of excessive inflammation and 
stimulation of host response against pathogen threats (Puddu, Valenti & Gessani 2009).  
Whether immunogenicity is affected by the different glycosylation pattern of rhLF as 
compared with the native form should be investigated further. 
2.2.5 Lactoferrins’s link to osteoimmunology 
 The emerging heuristic field of osteoimmunology poses the interesting question 
of whether LF’s regulation of bone homeostasis is a consequence of its cytokine 
modulation properties.  The crosstalk and shared mechanisms between the skeletal and 
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immune systems is complex and multifold with shared cytokines, receptors, signaling 
molecules and transcription factors (Takayanagi 2005).  For example, a mutation in 
macrophage colony-stimulating factor (M-CSF) gene produces a defect in both 
macrophage and osteoclast formation, indicating that immune and bone cells are derived 
from the same cell origin (Yoshida et al. 1990).  Thus, the effect of molecules with 
osteoimmunological pleiotropy, such as LF, is not limited to modulation of inflammation 
and immune function, but also directly involved with associated inhibition of 
osteoclastogenesis. 
LF has been shown to significantly decrease bone resorption (Lorget et al. 2002, 
Cornish 2004, Blais et al. 2009).  At a concentration of 100 µg/ml, LF completely inhibits 
osteoclastogenesis in mouse bone-marrow culture.  However, LF shows no effect on 
calvarial organ culture, implying LF does not affect mature osteoclast function (Cornish 
2004).  Collectively, data indicates that LF treatment decreases bone resorption by 
reducing osteoclast number formed from precursor cells.  LF is able to directly inhibit 
osteoclastogenesis, independent of osteoblastic factors.   Differentiation of murine 
macrophage RAW264.7 cells by the addition of receptor activator of NF-κβ ligand 
(RANKL) to the cell culture medium allows for a controlled study of LF effects on 
osteoclastogenesis independent of osteoblasts, as opposed to heterogeneous bone marrow 
derived culture systems.  LF inhibits RANKL-induced osteoclastogenesis in RAW264.7 
in a dose-dependent manner (Cornish, Naot 2010) measured by a significant decrease in 
TRAP positive multinucleated cells.  Furthermore, the addition of LRP1-inhibitor RAP 
did not significantly alter LF-induced inhibition of osteoclasts (Cornish, Naot 2010), 
suggesting LRP1 is not involved in the LF-inhibition of osteoclasts. 
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The OPG/RANK/RANKL molecular triad is known to be a main regulator of 
osteoclastogenesis and osteoclast activity.  Interestingly, it has been suggested that the 
mode of action of bLF in CD14—selected cells undergoing osteoclast differentiation, is 
independent of the RANK/RANKL/OPG molecular triad (Lorget et al. 2002). 
Osteoprotegerin (OPG), the physiological antagonist of RANKL, and RANKL mRNA 
was not detected either in the presence or absence of bLF.  mRNA for RANK was 
detected in the CD14—selected culture system, however its expression was not 
modulated by bLF.  This data is supported by previous studies that demonstrate 
mediators, other than the OPG/RANK/RANKL triad, are responsible for 
osteoclastogenesis.  Proinflammatory cytokines, such as TNFα or IL1, induce osteoclast 
formation independent of the triad (Fox, Fuller & Chambers 2000, Fuller et al. 2002, 
Kudo et al. 2002).  On the contrary, LF has been linked to the triad through the down-
regulation of LPS-induced cytokine production in monocytic cells by NFκβ.  Haversen et 
al. demonstrated the capacity of LF to translocate to the nucleus and block NFκβ 
activation, resulting in a decrease of the LPS-induced binding of NFκβ to the TNFα 
promoter.   This inhibition is also associated with LF’s ability to inhibit LPS-induced IL6 
and IL10 secretion in monocytic cells (Haversen et al. 2002). 
Recent reports revealed significant LF-induced stimulation of nuclear factor of activated 
T cells 1 (NFATc1) transcription, which is critical for lineage selection in T-cell 
differentiation, osteoblast differentiation and osteoclastogenesis (Cornish, Naot 2010, 
Zhao et al. 2010).  NFATc1 is a master regulator of osteoclasts and plays a pivotal role in 
osteoclast activation via stimulation of various genes responsible for osteoclast adhesion, 
migration, acidification, and degradation of inorganic and organic bone matrix.  The 
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calcineurin-NFAT signaling pathway is strongly implicated in osteoblast-mediated 
osteoclast differentiation and also in promoting osteoblast proliferation and 
differentiation (Stern 2006, Winslow et al. 2006).  Constitutively active nuclear 
NFATc1nuc mutant mice showed an increase in osteoclast number and markers of 
osteoclast activity and increased bone resorption (Winslow et al. 2006).  This regulation 
is independent of RANKL and OPG, which correlates to the negative osteoclast 
regulation of LF, also independent of the RANKL/OPG pathway (Lorget et al. 2002).   
Furthermore, mice expressing this NFATc1 variant displayed rapid Wnt-mediated 
osteoblastogenesis, independent of Runx2.  The effect of rapid osteogenesis was 
suggested by histological analysis, which revealed that bone in mutant mice had a less 
organized appearance than normal tissue.  The expression of the NFATc1 variant was 
found exclusively in osteoblasts, and the bone phenotype was marked by a significant 
increase in osteoblast number and bone volume.  Furthermore, markers of osteoblast 
activity, serum osteocalcin and serum alkaline phosphatase, were greater than doubled.  
Other studies demonstrated NFATc1-activation of type 1 collagen through stimulation of 
Osterix suggesting the possibility of the formation of a novel NFATc1-Osterix complex.  
A contradiction in these sets of data includes LF’s stimulation of NFATc1 transcription, 
but reported decreases in osteoclastogenesis by this protein.  Therefore, further 
exploration to elucidate this regulation may provide useful knowledge for the application 
of osteoclast-activated physiology and pathophysiology.  These studies lend the question 
of possible LF signaling mediating osteoblasts and osteoclastogenic pathways through 
NFATc1. 
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2.2.5.1 Lactoferrin and periodontitis-induced bone loss 
The interplay between LF’s immuno-modulation and bone homeostatic properties 
has recently been investigated using lipopolysaccaride (LPS)-induced periodontitis 
models (Yamano et al. 2010) (Figure 8). Periodontitis is an inflammatory disease 
instigated by infection with various oral plaque-associated periodontopathic bacteria, 
which includes Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and 
Prevotella intermedia and bacterial LPS.  The induced inflammation ultimately leads to 
destruction of the periodontium, which includes the gingiva and the surrounding alveolar 
bone.  This destruction is induced by pro-inflammatory cytokines, including TNFα and 
IL-1β, which subsequently leads to a significant increase receptor activator of NFκβ 
ligand (RANKL)-induced osteoclastogenesis (Clowes, Riggs & Khosla 2005, 
Weitzmann, Pacifici 2007). 
. 
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Figure 8. Comparison of periodontitis versus healthy/LF treated tissue. 
 
LF is a component of exocrine secreted saliva and an important constituent of 
neutrophilic granules of leukocytes.  This glycoprotein is seen to be an important immune 
defense factor against oral pathogens and periodontopathic bacteria and a good marker 
for periodontitis (Wakabayashi et al. 2003), since it is not synthesized in healthy gingival 
tissues and is produced by invading inflammatory cells in response to the inflamed 
periodontal tissue (Eberhard et al. 2006).  LF has been reported to inhibit the LPS 
interaction with CD14 by competition with LPS-binding protein.  Furthermore, LF may 
also bind directly to soluble CD14 receptor (Baveye et al. 2000a), which is expressed on 
the membrane of osteoclast precursors (Nicholson et al. 2000).  In vitro assays have 
demonstrated that bLF inhibits LPS-induced osteoclastogenesis through the reduction of 
TNFα and RANKL expression and elimination of OPG suppression in osteoblastic cells 
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with LPS stimulation.  Through liposomalization of bLF, which acts to increase protein 
stability, Yamano et al. demonstrated a significant inhibitory effect on LPS-induced 
osteoclastogenesis through orally administering this stabilized form of the protein 
(Yamano et al. 2010). Periodontal bone resorption occurs due to the significant increase 
in RANKL-stimulated osteoclastogenesis; on the other hand, LF causes an increase in 
osteoblast activity and inhibits osteoclastogenesis.    
LF inhibits the growth of periodontopathic bacteria.  As a major innate host 
defense factor, LF binds and sequesters LPS, thus preventing pro-inflammatory pathway 
activation, sepsis and tissue damage. LF may down-regulate LPS-induced cytokines 
following its internalization, nuclear localization and interference with NFκβ activation 
(Haversen et al. 2002).  Furthermore, this glycoprotein decreases pro-inflammatory 
cytokines, such as IL1α and TNFα, and increases anti-inflammatory cytokines, IL4 and 
IL10. LF inhibits the adhesion of bacteria to fibroblasts and epithelial cells. MMPs, 
which are known to lead to periodontal ligament and tissue destruction in periodontitis, 
which have been demonstrated to be inhibited by LF in rabbit preterm delivery model 
(Mäkelä et al. 1994, Nakayama et al. 2008).   
   
2.2.5.2 Lactoferrin and osteoporotic bone loss 
Recent studies explored the crosstalk between LF’s regulation of bone homestasis 
and immuno-modulatory characteristics using ovariectomized animal models (Figure 9).  
Postmenopausal osteoporotic bone loss is regarded as a consequence of estrogen 
deficiency, which in turn increases osteoclastogenesis.  Estrogen deficiency is known to 
increase pro-inflammatory cytokines, including TNFα, which, in turn, increases RANKL-
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induced osteoclastogenesis.   Due to the presence of LF in secretory granules of 
neutrophils, the production of LF is understood to be predominantly influenced by 
inflammatory stimuli.  LF possesses strong immunomodulatory effects, including a 
decrease in the secretion of osteolytic cytokines, such as TNFα and IL1β.   Therefore, it is 
possible that this effect may contribute to its anabolic effects on the skeleton by 
counterbalancing the catabolic osteoclastogenesis caused by some of the mediators in the 
inflammatory bone turnover response.  
 
Figure 9. Schematic representation of the role of estrogen deprivation and bLF on bone 
loss and bone resorption markers through APC and T cell modulation. 
bLF can prevent osteoclastogenesis directly or indirectly by modulation of: i) T cell 
activation, ii) antigen presenting capacity (APC) and iii) Cytokines released in bone 
micro-environment particularly through a down-regulation of TNFα release.  Image was 
taken from (Malet et al. 2011). 
Recently, LF treatment was shown to improve bone status of ovariectomized mice 
in vivo and in vitro (Blais et al. 2009).  Oral supplementation of LF to the diet dose-
dependently improved bone mineral density and femoral failure load.  Furthermore, 
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periphysiological concentrations of bovine LF treatment to primary cultures of murine 
bone cells was demonstrated to stimulate cell growth and differentiation of osteoblastic 
cells and inhibit the growth of preosteoclastic cells in vitro (Blais et al. 2009). 
Milk basic protein (MBP) has been demonstrated to have positive bone effects in 
vitro and in vivo (Toba et al. 2000).  Interestingly, a component of MBP that is 
responsible for anti-osteoclastic activity has recently been demonstrated to also possess 
pro-angiogenic activities due to its identical structure to 14 kDa milk angiogenin (Morita 
et al. 2008).  In a recent study, a ribonuclease (angiogenin)-enriched LF supplementation 
improved bone-formation markers while reducing bone resorption markers in 
postmenopausal women (Bharadwaj et al. 2009).  Due to its strong anabolic bone effects, 
LF can be considered as a potential molecule for bone regeneration. 
 
2.2.6 Angiogenesis modulator 
Angiogenesis is a complex physiological process whereby new blood vessels 
form from pre-existing blood vasculature and is imperative for successful tissue 
regeneration.  This complex process occurs during embryonic development, wound 
repair, and tumor growth.  Basic fibroblast growth factor (bFGF) and vascular endothelial 
growth factor (VEGF) are two key mitogens involved in endothelial cell proliferation and 
migration, which are important components of the angiogenic processes.  VEGF-A is 
stimulated during hypoxic condition and is key factor linking ischemia and collateral 
compensatory angiogenesis (Schaper, Ito 1996).  Angiogenesis is essential in a variety of 
physiological and pathological processes, such as wound healing, tumor growth, 
metastasis and hypoxia (Isner, Asahara 1999). 
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Human and bovine LFs have been shown to modulate VEGF-A—mediated 
angiogenesis in vivo.  Apo-hLF and apo-bLF exert specific and contrary angiogenesis-
modulating roles in VEGF-A—mediated angiognesis in vivo.  Apo-hLF significantly 
enhances VEGF-A—mediated angiogenesis, but does not affect bFGF-mediated 
angiogenesis (Norrby 2004). These studies indicate that this endogeneous protein by 
itself lacks angiogenesis-modulating activity, but apparently is able to enhance VEGF-
A—mediated angiogenesis systematically. On the other hand, apo-bLF does not 
significantly affect IL1α—mediated angiogenesis (Norrby et al. 2001), while it 
significantly suppresses VEGF-A—mediated angiogenesis (Norrby 2004).  Furthermore, 
bLF administration, both orally and intraperitoneally, significantly suppressed tumor-
induced angiogenesis in mice (Shimamura et al. 2004).  The opposing effects of apo-hLF 
and apo-bLF on VEGF-A—mediated angiogenesis could be due to the differences in the 
three-dimensional structure of the protein, amino acid sequence and composition 
(Goodman, Schanbacher 1991, Spik et al. 1982). 
Mechanistically, the actions of bLF on angiogenesis have been described in 
various lights.  The investigation of bLF’s inhibition of tumor-induced angiogenesis lead 
to the notion that bLF’s inhibition of angiogenesis can be explained by the blocking of 
endothelial cell function and induction of IL18 production (Shimamura et al. 2004).  In 
this study, bLF potently suppressed bFGF- or VEGF-induced proliferation of mouse 
endothelial KOP2.16 cells (Shimamura et al. 2004).  Other studies have investigated 
bovine lactoferricin (LfcinB), a peptide fragment of iron- and heparin-binding LF, 
inhibits bFGF and 165-kd isoform of VEGF (VEGF165)-induced angiogenesis.  LfcinB 
inhibits receptor-stimulated angiogenesis by complexing with heparin-like binding sites 
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on the endothelial cell surfaces that are involved in the binding of bFGF and VEGF165 to 
their respective receptors (Mader et al. 2006).  
VEGF-A is recognized by two receptors, KDR/Flk-1 and Flt-1, and thereby 
induces angiogenesis. In an attempt to elucidate the molecular mechanism underlying the 
effects of hLF on VEGF-A—mediated angiogenesis, Kim et al. (Kim et al. 2006) 
demonstrated that apo-hLF stimulates VEGF-mediated human umbilical vein endothelial 
cell (HUVEC) migration and proliferation through the up-regulation of KDR/Flk-1 
mRNA expression and protein levels. Furthermore, exposure of apo-hLF to HUVECs 
was also correlated with a significantly increased VEGF-induced Erk MAPK 
phosphorylation and endothelial cell proliferation.   
Pretreatment of endothelial cells with 5 µg/ml apo-hLF for 12 hours and 
subsequent exposure to 10 ng/ml VEGF stimulated cell proliferation approximately 3-
fold over VEGF alone (Norrby 2004).  However, it should be noted that apo-hLF did not 
induce endothelial cell migration by itself, but did so with the concurrent administration 
of VEGF-A.  It was also observed that holo-hLF did not enhance HUVEC migration, 
even in the presence of VEGF-A.   This data is consistent with a previous claim that apo-
hLF, not holo-hLF, enhanced VEGF-A—mediated angiogenesis in vivo (Norrby 2004). 
LF treatment of rodent osteoblast was reported to cause increased transcription of 
prostaglandin-endoperoxide synthase 2 (Ptgs2), which is also known as cyclooxygenase 
2 (Cox2) (Cornish, Naot 2010).  This transcription factor modulates angiogenesis by 
increasing the production of angiogenic factors, such as VEGF (Tsujii et al. 1998).  
However, it is important to note that the source and iron saturation of the LF used and the 
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time course was not specified in the above study making it difficult to derive definitive 
conclusion.     
2.2.7 Candidate for bone regeneration applications 
An important goal of bone regeneration therapy is directed differentiation of 
heterogenous populations of undifferentiated pluripotent mesenchymal cells to the 
osteoblastic lineage.  Increased mRNA and protein expression of Runx2 and Sox9, tissue-
specific differentiation markers for osteoblasts and chondroblasts, respectively, occurred 
in LF-treated pluripotent C2C12 mesenchymal cells.  Levels of MyoD, a differentiation 
marker of skeletal muscle, and PPARγ, a critical transcription factor of adipocyte 
differentiation, significantly decreased upon LF treatment in this undifferentiated 
mesenchymal cell culture line (Yagi et al. 2009).  This set of data suggests that LF 
appears to positively regulate undifferentiated mesenchymal cell population toward the 
osteoblastic and chondroblastic lineage, and inhibits myogenic and adipogenic 
differentiation.  
The production of rhLF provides vast benefit for its use in regenerative bone 
tissue engineering, as it possesses similar physical, biochemical and biological 
characteristics from the native protein.  The similarities that have been reported include 
anti-microbial and thermostability and ability to bind Fe3+ (van Berkel et al. 2002a, 
Huang et al. 2008).  The small difference in molecular mass between the recombinant and 
native form of hLF is accounted for in differential glycosylation patterns (van Berkel et 
al. 2002a).  This cost-effective alternative provides a great option for regenerative 
therapeutic use of this protein.  The use of the recombinant form of LF provides a 
foundation for producing consistent and predictable results.  
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 Holo-rhLF, purified from rice, has been demonstrated to increase thymidine 
incorporation in primary rat osteoblast cultures.  Holo-rhLF concentration of 100 µg/ml, 
almost doubled osteoblast proliferation over a 24 hour time course.  A direct correlation 
between rhLF iron saturation levels and cell proliferation has been reported.  It has been 
reported that holo-rhLF possesses stronger growth promoting effects compared to apo-
rhLF (Huang et al. 2008) on HT-29 cells. On a commercial basis, this source of rhLF is 
now used as a growth factor for media to promote cell growth and cell productivity. 
Since rhLF technology has made its way to the commercialized world as a 
nutritional supplement and as a clinical product with perceived benefits to the consumer.  
rhLF, expressed in milk, rice and microorganisms is now used commercially as a dietary 
supplement.  Talactoferrin, an immunomodulatory rhLF preparation, has been 
demonstrated to be effective in the treatment of patients with diabetic neuropathic foot 
ulcers (Spadaro et al. 2008), non-small cell lung cancer therapy in combination with 
cisplatin treatment and renal cell carcinoma (Jonasch et al. 2008).  
The potent modulating effects on the skeletal system support the prospect of rhLF 
application for regenerative bone tissue regeneration. The use of various biomaterials, 
such as type 1 collagen membrane (Takayama, Mizumachi 2009) and biodegradable 
gelatin hydrogels (Takaoka et al. 2011), have been used as carriers to provide a sustained 
localized release profile of LF.   LF-embedded collagen membrane has been shown to 
promote osteogenic differentiation of MG63 human osteosarcoma-derived cells.  
Increased alkaline phosphatase activity and osteocalcin production was induced by the 
LF-embedded collagen membranes (Takayama, Mizumachi 2009).  A recent study 
demonstrated significant bone regeneration at cranial defects following the implantation 
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of LF-incorporated gelatin hydrogels (Mäkelä et al. 1994, Takaoka et al. 2011).  These 
studies concluded LF as a general osteogenic growth factor for bone tissue engineering.   
2.2.8 Conclusions 
The bidirectional signaling of LF that suppresses osteoclastogenesis and enhances 
osteoblast proliferation and survival supports the notion that LF is a strong candidate for 
bone tissue engineering.  This candidacy of the glycoprotein is further supported by the 
multifunctional ability of hLF to promote neovascularization and its key modulating role 
in inflammation.  Although LF osteogenic research has made great strides, shortcomings 
of LF research includes the lack of detail in terms of procedure and specific forms of LF 
(iron saturation and source).  Furthermore, the variations in preparation, which includes 
heat treatment and processing, may also account for in consistencies in the reported LF 
data.  Thus, it makes it difficult to compare and analyze published data thus far when 
lacking such indispensable information.  It is imperative to investigate the effects of LF 
and report findings with specific details with regards to the molecular state of LF.  
Investigations should focus on the mechanisms by which LF concomitantly regulates the 
immune and skeletal systems.  Such advances will provide a comprehensive 
understanding of LF’s role in bone regeneration. 
The studies discussed thusfar, provided great insights on the potential bioactivity 
of LF and well as its ability to increase bone regeneration.  All these studies used soluble 
LF protein to evaluate the biological functions of the protein.  However, to exploit the 
biological functions of the protein for regenerative application, it needs to be developed 
as a biomaterial that can be localized at the defect site to present an osteogenic 
microenvironment.    The preliminary study discussed here examines the feasibility of 
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developing an injectable biomaterial from LF, which might serve as an osteogenic 
microenvironment to support bone regeneration.  
 
3 Preliminary studies 
3.1 Enzymatically—crosslinked bovine lactoferrin hydrogel 
as an osteogenic cell delivery vehicle 
3.1.1 Introduction 
As discussed previously (section 2.2.3), the anabolic effect of bLF on osteoblasts 
and its potent inhibition of osteoclastogenesis in vitro suggests that bLF may have 
positive effects on bone mass in vivo. The administration of bLF over the right 
hemicalvaria of adult male mice resulted in a dramatic increases in bone area in the 
calvariae compared with PBS control.  Four groups of mice were given daily injections of 
one of 3 doses of bovine lactoferrin (0.04 mg, 0.4 mg or 4 mg) or vehicle over the right 
hemicalvaria for 5 consecutive days.  New bone formation was dose-dependently 
increased by bLF.   Both 0.4 mg and 4 mg of lactoferrin produced an increase in new 
bone formation, however the 4 mg dose induced changes of 4-fold greater than those 
observed in control animals.  Local injections of bLF also increased the mineral 
apposition rate and the bone formation rate (Cornish 2004).  However, repeated injections 
of bLF over 5 consecutive days were used in this study to achieve the significant anabolic 
effect demonstrating that retention of the protein at the defect site for prolonged time may 
be required to activate the regenerative process. 
In another recent study, murine preosteoblast MC3T3 cells revealed greater 
proliferation rates by the repeated addition of bLF compared to single addition of the 
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protein at the same dose (Takaoka et al. 2011).  Attempts have been made to retain the 
protein at the defect site using a controlled protein delivery approach.  Type 1 collagen 
membrane was used as a sustained delivery vehicle for bLF.  Approximately 27% of bLF 
embedded on the collagen membrane was burst released within the first hour followed by 
a slower release (Takayama, Mizumachi & Takezawa 2002).  The embedded bLF 
collagen membranes promoted MG63 cell calcium deposition, ALP activity and 
osteocalcin production (Takayama, Mizumachi & Takezawa 2002). 
A recent in vivo study evaluated the efficacy of a sustained delivery vehicle in 
promoting bone formation.  The study used biodegradable gelatin hydrogel to allow bLF 
release in vivo in a sustained fashion.  Upon subcutaneous implantation into the dorsum 
of mice, the gelatin hydrogel incorporated with bLF demonstrated an extended retention 
of bLF at the site of implantation than that of bLF solution injection. The remaining 
radioactivity on days 1 and 3 of 125I-labeled LF solution injected subcutaneously was 2.96 
and 0.82%, respectively.   In contrast, the remaining radioactivity on days 1 and 3 of 125I-
labeled LF in the hydrogel incorporated form was 10.14 and 5.26%.  Upon implantation 
of gelatin hydrogels incorporating bLF into rat cranial defects, improved bone 
regeneration at the defect was observed than in control gelatin gel.  The study 
demonstrated that the retention of bLF at the defect site enhanced bone regeneration 
(Takaoka et al. 2011) (Figure 10).   However, a significant limitation of this study was 
that approximately 90% of the bLF incorporated in the gelatin gel was released within 24 
hours.   This necessitates the encapsulation of high concentrations of bLF since much of 
it will be lost due to burst release from the carrier gelatin gel.  Furthermore, the high 
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concentration (30 mg) of bLF needed to induce significant bone growth may further 
induce negative systemic side effects.  
 
 
Figure 10. (A) Promoting effect of bLF—embedded collagen membrane on ALP activitiy 
and osteocalcin production in MG63 cells. 
MG63 cells were plated onto a control collagen membrane (open bar) and a bLF 
embedded collagen membrane (closed bar).  Upon confluence, the cells were shifted to 
osteogenic conditions for 2 weeks.  ALP activity and osteocalcin production were 
calculated per well and values are represented as mean ± standard deviation of three 
separate measurements.  *p< 0.05 significant difference.  Image was adapted from 
(Takayama, Mizumachi & Takezawa 2002).  (B) X-ray radiographs of rat calvarial defect 
8 weeks after implantation of gelatin hydrogels incorporating 0, 0.3, 3 and 30 mg bLF.  
The lower stand value indicated the average percentage of area ossified in an 8 x 8 mm 
square around the bone defect.  No statistical significant differences were observed 
between the bLF 0 and 0.3 mg group.  * p< 0.05 significant difference from the 
percentage of ossified area in a square around the defect implanted with gelatin 
hydrogels without bLF (Takaoka et al. 2011). 
 
A potential approach to overcome these limitations is to develop a biomaterial where in 
LF is immobilized.  Such approach may significantly decrease the amount of LF 
introduced in the body as it can be used to localize the molecule for a prolonged time to 
induce maximum regenerative response.  Considering the cell instructive properties of 
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LF, the ideal immobilization method might be to develop an injectable hydrogel, wherein 
cells can be encapsulated within the gel and can serve as a localized microenvironment 
for modulating the cell response.  However, several challenges exist while developing 
such an approach.  Even though the bioactivity of bLF is known, the mechanism of action 
of bLF is not completely known.   Bioactive proteins may activate cellular processes 
through two different phenomenas – cell internalization/endocytosis or receptor-mediated 
signal transduction.  It is therefore not known if an immobilized polymer, which is 
incapable of being endocytosed, will be bioactive or not.  One study that supported our 
hypothesis determined that internalization of LF by osteoblastic cells is not necessary for 
activation of mitogenic signaling and that the endocytic function of LRP1 is independent 
of its signaling function (Grey et al. 2004).   
 For developing injectable biomaterials, we selected HRP-mediated, enzymatic 
crosslinking method of protein due to the reasons summarized below.  As discussed 
before in section 2.1.2, hydrogels may be crosslinked through various mechanisms 
including photo-polymerization, covalent, ionic and enzymatic crosslinking.  Enzymatic 
crosslinking, as previously discussed in section 2.1.2.2.1, involves a mild, cell-friendly 
and natural crosslinking process.  Polymers functionalized with tyramine, tyrosine or 
aminophenol side groups can form crosslinked hydrogels by phenol derivative coupling – 
this reaction is driven by H2O2, as the oxidant, and HRP, as the enzyme (Kurisawa et al. 
2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007a, Amini, Nair 2012).  HRP-
mediated, enzymatic crosslinking was selected for developing LF-based injectable gels 
since this enzyme-mediated crosslinking may take place at physiological pH and 
temperature, making this a potential route to form injectable cell and protein delivery 
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vehicles (Sakai et al. 2009, Amini, Nair 2012, Lee, Chung & Kurisawa 2009a).   Other 
advantages of these hydrogel injectable systems include the flexibility of gelation time, 
equilibrium swelling and storage modulus – which may be modulated by varying the 
degree of substitution of tyramine residues and reagent concentrations.    The efficacy of 
the reaction has been demonstrated by various systems listed in Table 2.  
Standard carbodiimide-mediated coupling of amino groups of tyramine with the 
carboxyl groups of LF was used to increase phenolic content of LF.  Although LF 
contains phenolic amino acids, such as tyrosine, the phenolic content of LF is much lower 
than what is needed to develop an effectively cross-linked matrix via the enzyme-
catalyzed coupling (Figure 11 & 12).  The reaction of LF with tyramine increases 
polymer crosslinking by increasing the number of phenolic groups (Figure 13).  Similar 
chemical reactions have been used to increase the phenolic content of other polymers 
such as chitosan and hyaluronic acid (Darr, Calabro 2009, Sakai et al. 2009, Lee, Chung 
& Kurisawa 2009a).  
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Figure 11.  (A) Structure of Human LF.  (B) Tyrosine amino acid groups contained in 
human LF.  (C) Carboxylic acid containing amino acid groups (aspartate and glutamate) 
in human LF.  (D) Theoretically available crosslinking amino acid sites after tyramine 
modification of human LF. 
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Figure 12.  Amino acid sequence of human lactoferrin.   
Tyrosine (y) amino acids are highlighted as they represent the possible crosslinking sites 
for LF gel.  Glutamic acid (e) and aspartic acid (d) are also highlighted as they may be 
modified with phenolic groups and also serve as additional crosslinking sites. 
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Figure 13.  Schematic showing the modification of LF’s acidic groups with tyramine to 
yield greater enzymatic crosslinking sites.  Addition of HRP and H2O2 yields a LF 
crosslinked gel. 
 
The objective of our preliminary studies was to test the feasibility of crosslinking 
bLF using HRP-enzymatic reaction to be used as a localized delivery of bLF protein for 
increased osteoblast function.  The second objective of the study was to test our 
hypothesis that the immobilized bLF based gel will be bioactive.  
 
3.1.2 Methods 
3.1.2.1 Synthesis of bLF-tyramine conjugates (modified bLF) 
bLF was tyramine modified for 1, 5, 15 and 24 hours (reaction time) as per the protocol 
described in the Appendix of Protocols (section 7.9.2.1.1).  
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3.1.2.2 Quantification of tyramine modification of bLF 
Tyramine concentration of modified bLF was measured as described in Appendix of 
Protocols (section 7.9.2.1.1.1).  A tyramine standard curve was used to determine the 
concentration of a tyramine in the modified bLF samples (Figure 77).  Standard curve 
stock was made by diluting 10.5 mg tyramine in 2 ml MES buffer.   0 - 40 µl of stock 
solution was diluted in increments of 5 µl further in 900 µl MES buffer (n=4) and diluted 
samples were measured by spectrophotomer at 275 nm. 
3.1.2.3 Gelation time 
Sol to gel time was determined via vial inversion method according to Appendix of 
Protocols (Section 7.9.2.2.1).   The effect of modified bLF (10 – 50 mg/ml), HRP (10 – 
50 U/ml) and 0.25% H2O2 (1 - 10 µl) concentration on gelation time was investigated.  
Variables were individually varied and tested for effect on gelatin time.  
3.1.2.4 Morphology 
The morphology of the bLF gels formed from modified bLF solutions of 10 mg/ml was 
visualized by scanning electron microscope to evaluate the gel microstructure.  10 mg/ml 
bLF gel was formed according to Appendix of Protocols (Section 7.9.2.1.2.2) on an SEM 
stub, flash frozen the samples using liquid N2, lyophilized and then visualized according 
to Appendix of Protocols (Section 7.9.2.2.3). 
3.1.2.5 Protein expression analysis of encapsulated cells 
3.1.2.5.1 Western Blot Analysis 
Cells exposed to soluble bLF (2D studies): MC3T3 cells were plated on 10 cm2 tissue 
culture plates (200,000 cells/plate), grown to 90% confluence in basal media and then 
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serum starved for 6 hours.  Cells were stimulated with 100 μg/ml of bLF or untreated 
(control) for 24 hours. Cells encapsulated in bLF gel (3D studies): MC3T3 cells 
(2,000,000 cells/ml) were encapsulated in 1 ml of 10 mg/ml bLF.  After 24 hours of 
incubation, total protein was lysed from cells and western blot analysis was performed as 
described in Appendix of Protocols (Section 7.2.2.3). 
3.1.2.5.2 Immunofluorescence 
Cells exposed to soluble bLF (2D studies): 50,000 cells were plated on 35 mm sterile 
glass bottom culture plates and then stimulated with 100 μg/ml of bLF or untreated 
(control) for 24 hours.   
Cells encapsulated in bLF gel (3D studies): MC3T3 cells were cultured on 35 mm sterile 
glass bottom culture plates.  For 3D cell encapsulation studies, 500,000 cells/ml were 
encapsulated in 10 mg/ml bLF gels.  bLF gel formation and cell encapsulation was 
performed according to Appendix of Protocols (Sections 7.9.2.1.2.2 and 7.9.2.4). The 
encapsulated cells were then maintained in basal media at 37ºC for 2 days. Protein 
expression was analyzed via immunofluorescence according to Appendix of Protocols 
(Section 7.2.2.5). 
 
3.1.3 Results 
3.1.3.1 Development of injectable gels from tyrosinated bLF 
Figure 14a shows the phenolic content of tyramine modified and unmodified bLF 
as a function of reaction time under the described reaction conditions.  The phenolic 
content of unmodified bLF is due to the presence of tyrosine.  The study showed that the 
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extent of phenol group substitution significantly depends on the reaction time.  The 
substitution of tyramine groups in bLF (modified bLF) and the phenolic content of the 
modified bLF after 24 hours was approximately 1.5 times higher than the unmodified 
bLF (0 hour reaction time).   
bLF gels were prepared by the HRP-mediated oxidative coupling of modified bLF 
in the presence of H2O2.  Various concentrations of modified bLF ranging from 10 mg/ml 
to 50 mg/ml were dissolved in 10 U/ml HRP (dissolved in H2O).  Gelation was initiated 
by the addition of 0.25% H2O2.   Figure 14b shows the gelation time of modified bLF at 
room temperature when treated with HRP and H2O2.  As can be seen from the figure, the 
reaction time significantly effects gelation time.  The 1 hour reacted bLF was found to 
behave similar to that of unmodified bLF, and unable to undergo gelation under the tested 
reacted conditions.  The 5 hours reacted bLF underwent gelation in ~15 minutes and the 
gelation time significantly decreased for the 15 hours reacted samples.  The 24 hours 
reacted sample underwent gelation in about 2 minutes, which falls in the clinically 
feasible injection time.  This condition was therefore used for the rest of the studies. 
 
 
Figure 14. Effect of modification time on (A) bLF phenolic content and (B) gelation time. 
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The morphology of 10 mg/ml bLF gel after lyophilization was evaluated using 
SEM.  Figure 15 shows the morphology of the gel at three different magnifications.  The 
gels presented a flacky morphology with an open, irregular porous structure.   
 
 
Figure 15.  Morphology of 10 mg/ml bLF gel.  
 
3.1.3.2 Bioactivity of bLF gels 
Figure 16a (lane 2) is a western blot showing the expression of phosphorylated Akt by 
MC3T3 cells when cultured in the presence of 100 µg/mL bLF compared to the untreated 
control (Figure 16a, lane 1).  Cells that were not treated with bLF did not show positive 
expression of phosphorylated Akt, whereas, cells treated with bLF showed significant 
expression of p-Akt.  Since soluble bLF can significantly upregulate phosphorylated Akt 
in MC3T3 cells after 24 hours in culture, the protein was used as a bioactive marker to 
test the bioactivity of bLF injectable gels.   Figure 16a (lane 3) is a western blot showing 
the expression of phosphorylated Akt by MC3T3 cells encapsulated in injectable bLF gel 
(10 mg/ml).  As in the case of soluble bLF, the bLF injectable gel also showed significant 
upregulation of phosphorylated Akt by the encapsulated MC3T3 cells indicating the 
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retention of bioactivity by the gel.  Equal protein loading in the above experiments were 
confirmed by equivalent levels of tubulin in all lanes (Figure 16c). 
 The bioactivity of the injectable gel was further confirmed by following an 
osteoblast osteogenic marker (active β catenin).  Similar to phosphorylated Akt, increased 
β catenin activation was seen in MC3T3 preosteoblast cells when treated with 100 µg/ml 
soluble bLF after 24 hours of culture (Figure 16b; lane 2) relative to untreated MC3T3 
cells (Figure 16b; lane 1).  Due to the significant accumulation of β catenin in MC3T3 
cells treated with soluble bLF, the same was tested in cells encapsulated in bLF gels.  
Figure 16b (lane 3) is the western blot showing the expression of active β catenin by 
MC3T3 cells encapsulated in injectable bLF gel (10 mg/ml).  After 24 hours of culture, 
the encapsulated cells showed positive expression of active β catenin. 
Our lab and others have shown the ability of bLF to induce MC3T3 cells to 
produce various osteogenic factors such as FGF2 and VEGF  (Nakajima et al. 2011, 
James et al. 2011).  The production of these cytokines by MC3T3 cells was followed by 
immunofluorescence.  Figure 17 shows an immunofluorescence image of MC3T3 cells 
treated with soluble bLF and control PBS for 24 hours stained for VEGF and IGF2 
expression. As can be seen, treatment of MC3T3 cells with bLF led to significant 
increase in expression of VEGF and IGF2 relative to untreated control.  Figure 18 shows 
the immunofluorescence image of MC3T3 cells encapsulated in bLF gel (10 mg/ml) for 2 
days.  As in the case of soluble bLF, the encapsulated cells showed significant expression 
of these two proteins further confirming the cell instructive capability of bLF.  
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Figure 16.  Increased stabilization of β catenin and phosphorylation of Akt in MC3T3 
after 24 hour treatment of 100 µg/ml bLF solution and encapsulation in 10 mg/ml bLF 
gel. 
100 µg/ml bLF treatment (lane 2) and 10 mg/ml bLF gel (lane 3) was compared to 
untreated (lane 1) MC3T3 cells.    
 
 
Figure 17.  Effect of 100 µg/ml bLF solution on MC3T3 protein expression after 24 hours 
treatment. 
Expression of 100 µg/ml bLF treated cells were compared to that of untreated control.  
Propidium iodide (red) was used to stain nuclei and FITC-tagged (green) secondary 
antibodies were used to visualize positive expression of protein. 
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Figure 18.  Increased IGF2 and VEGFα expression in 10 mg/ml bLF gel encapsulated 
MC3T3 cells after 2 days of culture. 
Propidium iodide (red) was used to stain nuclei and FITC-tagged (green) secondary 
antibodies were used to visualize positive expression of protein. 
 
3.1.4 Discussion 
The efficiency of cell-based therapeutics in tissue engineering is based on 
successful delivery of cells to sites of repair or regeneration.  Hydrogels allow for simple 
implantation via injection to fill irregularly shaped defects and accommodation of 
homogeneous incorporation of cells.  Several hydrogel systems have been developed to 
localize cells at the defect site.  In addition to localizing the cells, our ability to modulate 
cellular performance using these artificial matrices will be highly beneficial for positive 
regenerative outcomes.  One method commonly used to modulate cellular performance is 
by encapsulating growth factors along with the cells as discussed before (section 2.1.3.2).  
Growth factor encapsulation, eventhough it has showed improved performance, has 
significant drawbacks.  Hydrogels are highly permeable matrices and is associated with 
subsequent burst release of these growth factors upon implantation, and growth factors 
will not be available to the encapsulated cells for a prolonged time, which could 
significantly decrease the efficacy.  Also, as discussed before, wound healing is a 
complex process involving several bioactive molecules expressed in a temporal and 
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spatial manner.  Encapsulating one or two growth factors in the gel will not be able to 
recapitulate such a complex microenvironment.  Cells are capable of producing much of 
the bioactive molecules required for the regenerative process.  So the ideal approach will 
be to develop a cell-instructive, injectable hydrogel that could induce the production of 
these bioactive molecules by the encapsulated cells.  Such a biomaterial does not exit so 
far.  The preliminary studies discussed here aims to evaluate the feasibility of developing 
a cell instructive biomaterial using bLF, which has shown to have bioactivities to support 
bone formation. 
Natural bLF contains phenolic amino acids such as tyrosine.  We first evaluated the 
feasibility of crosslinking bLF using the HRP mediated enzymatic crosslinking using 
H2O2.  However, we found that the phenolic content of natural bLF is much lower than 
what is needed to develop an effectively crosslinked matrix via the enzyme-catalyzed 
coupling.  Therefore, attempts were made to increase the phenolic content of the bLF by 
chemically substituting the carboxyl groups of bLF with tyramine molecules to form 
modified bLF (Figure 11 & 13).   The extent of tyramine substitution was analyzed using 
UV spectrophotometry at wavelength of 275 nm.  The time of reaction was shown to 
have a significant effect on the extent of tyramine substitution with extent of substitution 
increases with increase in reaction time.  For clinical application of injectable gels as 
cells or factor delivery vehicles, a gelation time of 1-2 minutes is considered ideal 
(Miljkovic et al. 2009).  Therefore, gelation time was used to determine the ideal 
concentration of phenolic group in modified bLF that will give the injectable solution a 
gelling time of ~1 minute.  As indicated in Figure 14, the 24-hour modified bLF showed 
a gelation time in that range and was therefore used for the rest of the study. 
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The preliminary studies thus confirmed the feasibility of developing a clinically-
relevant injectable hydrogel based on LF using the mild, enzymatic crosslinking method.  
The gel also showed a porous structure that might be conducive to support cell 
attachment and proliferation.  However, before exploring the clinical applications of the 
biomaterial, it is important to confirm the bioactivity of the injectable gel, even though it 
is produced from a bioactive protein for reasons summarized below.    
The bioactivities of the proteins are mostly governed by the composition as well as 
the three dimensional structure of the protein.  Changes in the composition and or 
structure of the protein can significantly affect their bioactivities.  Since only a very small 
amount of phenolic groups were substituted in modified bLF, we hypothesize that the 
modification might not completely alter the bioactivity of the protein.  Similarly, previous 
studies have demonstrated the ability of bLF to improve osteoblast survival, proliferation 
and differentiation – however, the mechanism behind bLF’s bioactivity is not completely 
understood.  The role of LRP1 in mediating the bLF-induced signal transduction in 
promoting osteoblast proliferation has been shown to induce phosphorylation of MAP 
kinase signaling transducution cascade (Grey et al. 2004).  Ligand-induced, receptor-
mediated signal transduction are known to occur in an avidity-controlled manner, where 
1) the extracellular ligands can activate the receptors without internalization, 2) it is 
consumption-controlled – meaning the extent of activation depends on the ability to 
internalize surface-bound ligand and 3) dual-sensitivity where both the avidity and 
consumption parameters are important.  In the case of bLF, even though the exact 
mechanism is not known, a previous study revealed that the internalization of LF by 
LRP1 is not necessary for activation of mitogenic signaling (Grey et al. 2004).  Thus, if 
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the internalization of bLF ligand is not required, then it is possible that the crosslinked 
injectable gel from bLF could show the same bioactivity as soluble bLF.  The bioactivity 
of the injectable bLF was followed by determining the expression of several key signal 
transduction molecules and cytokines in MC3T3 cells induced by soluble bLF.  
Phosphorylated Akt is commonly considered as a marker for cell survival.  Akt promotes 
cell survival by inhibiting apoptosis through phosphorylation and inactivation of several 
targets, including Bad, forkhead transcription factors, c-Raf, and caspase-9 (Cardone et 
al. 1998, Brunet et al. 1999, Zimmermann, Moelling 1999).  bLF is known to increase the 
phosphorylation of Akt, however, a recent study demonstrated the anti-apoptotic action 
induced by bLF is not dependent on the phosphorylation of Akt (Grey et al. 2006).   
Although pAkt is known to play a critical role in cell survival and apoptosis, its function 
has also been reported to play an important role in glycogen metabolism and cell growth 
(Nave et al. 1999, Hajduch, Litherland & Hundal 2001).  As shown in Figure 16a, similar 
to solution bLF, injectable bLF gel significantly upregulated the expression of pAkt in 
MC3T3 cells.  Even though bLF has shown to significantly increase osteogenic 
differentiation markers, such as ALP, collagen 1, Runx2 and OCN (Ying et al. 2012), the 
molecular mechanism of the osteogenic effect of bLF has not yet been demonstrated.  
Our studies demonstrated the ability of soluble bLF to activate β catenin in MC3T3 cells.  
This is interesting from the context of bLF’s ability to support osteoblast differentiation 
since the de-phosphorylation and subsequent accumulation of β catenin is a key step in 
osteogenic signaling pathway.  The present study demonstrated that similar to soluble 
bLF, the inejctable bLF gel may stabilize β catenin and promote its significant 
accumulation.   
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Bone regeneration is a coordinated cascade of spatio-temporal events regulated by an 
array of cytokines and growth factors (Amini, Nair 2011b).  Bioactive biomaterials that 
are capable of locally inducing the production of endogenous cytokines and growth 
factors necessary for bone regeneration could serve as an excellent microenvironment to 
promote the regenerative process.  These biomaterial scaffolds may serve as delivery 
vehicles to introduce donor cells at the defect site or can be be used to allow native cells 
to migrate to the injury site, then proliferate and finally differentiate to regenerate the 
tissue.  The combination of osteogenic and angiogenic growth factors have been shown to 
enhance bone regeneration (Kanczler et al. 2010, Patel et al. 2008).  
For example, our studies demonstrated that bLF-crosslinked gel increased IGF2 
protein expression in MC3T3 encapsulated cells after 2 days.  As a member of the IGF 
signaling system, IGF2 plays an important role in prenatal growth and development 
(Randhawa, Cohen 2005).   IGF2 activates various pathways including PI3K/Akt or 
MAPK signaling transduction pathways, via IGF receptors (O'Dell, Day 1998).  Recent 
studies have also indicated that IGF2 potentiates BMP9-induced osteogenic 
differentiation and bone formation (Chen et al. 2010).  Other studies reported that 
stimulated bone turnover via increased osteoblast number and function is directly and/or 
indirectly caused by local IGF1 and IGF2 production (Bouillon 1991).  LF also activates 
the PI3K/Akt signaling pathway and increases mRNA levels of IGF1, but the functional 
significance of these remains to be determined (Cornish, Naot 2010). 
Our studies also demonstrated a positive expression on VEGF in MC3T3 cells after 2 
days of bLF gel encapsulation.   Furthermore, previous LF study has reported that apo-
hLF significantly enhances VEGF-A—mediated angiogenesis (Norrby 2004).  VEGF is a 
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key mitogen involved in endothelial cell proliferation and migration, which are important 
components of angiogenesis (Schaper, Ito 1996).  Angiogenesis is a complex 
physiological process whereby new blood vessels form from pre-existing blood 
vasculature and is imperative for successful tissue regeneration.  This complex process 
occurs during embryonic development, wound repair, and tumor growth.    Human and 
bovine LFs have been shown to modulate VEGF-A—mediated angiogenesis in vivo.  
3.1.5 Conclusions 
The preliminary studies discussed here demonstrate the feasibility of developing an 
injectable biomaterial from bLF using the mild enzymatic crosslinking method.   We also 
showed initial evidence regarding the ability of injectable biomaterial in retaining the 
bioactivities of soluble bLF.  bLF, either in the soluble form or as injectable gel, was 
capable of regulating signal transduction molecules as well as inducing cytokine 
production which could play key roles in promoting osteoblast survival, proliferation and 
differentiation.  These encouraging results formed the basis for exploring the 
development of novel injectable biomaterials based on recombinant human LF as a cell 
delivery vehicle, which will be discussed in sections 4 and 5.   
4 Evaluation of the bioactivity of recombinant human 
lactoferrins 
4.1 Evaluation of the bioactivity of recombinant human 
lactoferrins (apo-, pis- and holo-) towards murine MC3T3 
preosteoblast cells  
4.1.1 Introduction  
LF protein, which belongs to the iron-binding transferrin family, is present in 
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exocrine secretions and is an important regulator of the levels of free iron in the body 
fluids (Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009). LF harbors two iron-
binding motifs, which are each responsible for the sequestration of a ferric Fe3+ molecule 
(Anderson et al. 1990, Anderson et al. 1989).  The glycoprotein’s degree of iron 
saturation has a pivotal influence on its physical structure (Baker, Baker 2009).  When 
fully iron saturated (holo), LF presents as a stable “closed” structure, as opposed to its 
“open” iron-free state (apo) (Haridas, Anderson & Baker 1995, Grossmann et al. 1992).  
Furthermore, the structure of this protein, although differs throughout species (Anderson 
et al. 1989, Baker et al. 1991), retains essentially identical high affinity (KD ~10-22 M) 
iron binding sites (Aisen, Leibman 1972). 
The role of iron concentration and the resulting changes in protein conformation 
in modulating the bioactivity of LF is not clearly understood.   Jiang et al. investigated 
the effect of apo- and holo-hLF on Caco-2 cell proliferation under standard cell culture 
conditions.  The study demonstrated that even though both the proteins were internalized 
by LF receptor they differentially affected Erk-signaling and cell proliferation.  Apo-hLF 
showed significant increase in cell proliferation and activation of Erk cascade compared 
to holo-hLF (Jiang et al. 2011).  Similarly, a study using mouse crypt cells demonstrated 
the differential effects of apo- and holo-hLFs on cell functions.  The proliferation of crypt 
cells was significantly enhanced by apo-hLF compared to holo-hLF.  Moreover, different 
signaling pathways were involved in holo and apo-hLF mediated activation of the cells.  
Only apo-hLF was capable of activating the Erk signaling pathway, and both apo and 
holo-hLFs were capable of activating the PI3K/Akt pathway to modulate crypt cell 
proliferation (Jiang, Lonnerdal 2012).  Francis et al. studied the iron dependent effect of 
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hLF on neutrophil survival (Francis et al. 2011) and concluded that only apo-hLF and not 
holo-hLF is capable of inhibiting neutrophil apoptosis. These studies indicate the 
possibility that iron concentration may play a significant role in LF bioactivity.    
Cornish et al. investigated the effects of bLF’s structure-activity relationship 
(Cornish et al. 2006) and reported that the degree of bLF iron saturation did not 
significantly affect the proliferation of primary rat osteoblasts.  Furthermore, the 
substitution of bLF’s iron with cations of similar size (i.e., magnesium and chromium) 
did not significantly change the extent of cell proliferation compared to iron (Cornish et 
al. 2006).  Compared to the previous studies this data indicates that the iron content of 
bLF may not significantly affect the biological activities of this glycoprotein towards 
osteoblast.  However, most of the studies reported thus far to understand the effect of LF 
on osteoblasts and osteoclasts were performed using LF isolated from bovine milk (bLF).    
Another important factor that may play an important factor in LF’s bioactivity is its 
degree of glycosylation, as discussed in section 2.2.1. 
Transgenic, rice-derived recombinant human LF (rhLF) has recently been made 
commercially available in three different iron saturation forms, ranging from apo-rhLF 
(iron depleted, <10% iron), pis-rhLF (partially iron saturated, ~50% iron), holo-rhLF 
(>90% iron saturated) (Huang et al. 2008).  The advent of the recombinant human protein 
technology offers a cost-effective alternative and a foundation for producing consistent 
and predictable results for potential clinical applications.  Biochemical and biophysical 
analyses indicate that rhLF is similar to native hLF and supports mammalian cell 
proliferation (Huang et al. 2008, Tang et al. 2010).  Huang et al. reported a “bell shaped” 
dose response curve for the proliferative effect of apo-, pis- and holo-rhLF on HT-29 
	   115 
intestinal cells after 24-hour treatment.  The maximal stimulatory effect was seen at a 
concentration of 1000 μg/ml for all three forms of rhLF.  However, of the rhLF forms, 
holo-rhLF showed approximately 3.5 times greater proliferation as indicated by [3H]-
thymidine incorporation over apo- and pis-rhLF.  Furthermore, a dose-dependent increase 
in cell growth was seen in rat osteoblast with the treatment of holo-rhLF up to 100 μg/ml 
(Huang et al. 2008). 
The objective of this study is to investigate the biological effect of apo-, pis- and 
holo-rhLFs on MC3T3 cells to understand the effect of iron concentration on rhLF 
bioactivity in order to identify the suitable polymer to develop injectable hydrogels for 
bone tissue engineering application.  MC3T3 cell line was selected to evaluate the 
bioactivities of rhLFs since it is a well-characterized murine osteoblast cell line (Sudo et 
al. 1983) that has been used extensively as a model for osteoblasts in vitro.  The dose and 
iron concentration dependent mitogenic activity of rhLF toward MC3T3 cells was 
evaluated using thymidine assay.  The ability of rhLF to induce MC3T3 cells to activate 
transcription factors, signaling molecules, chemokines and cytokines were determined by 
following β-catenin activation, phosphorylation of Akt, VEGF and IL-6 expression.  
Protein and phosphorylation levels were followed using western blot and 
immunocytochemical analysis.  Moreover, a global microarray analysis was performed to 
study the overall pattern of gene regulation in MC3T3 cells when cultured in the presence 
of different rhLFs for 24 hours. 
4.1.2 Methods 
4.1.2.1 Cell proliferation 
 The effect of varying concentrations of apo-, pis- and holo-rhLF on MC3T3–E1 cell 
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proliferation was measured through thymidine incorporation. MC3T3 cells were 
maintained in basal MEMα medium for 6 hours to allow proper cell adhesion and 
maintained in serum-free medium overnight. The cell culture was then performed upon 
supplementation with 0, 10, 100, and 1000 μg/ml of apo-, pis- and holo-rhLFs and [3H] 
thymidine for 24 hour incubation at 37°C. Incorporation of [3H] thymidine radioactivity 
was performed as described in Appendix of Protocols (Section 7.6.2.2).   Data was then 
normalized to untreated control sample and expressed as fold change over control. 
4.1.2.2 Protein expression analysis 
4.1.2.2.1 Western blot analysis 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for 6 hours.  Cells were 
stimulated with 100 μg/ml of apo-, pis-or holo-rhLF or untreated (control) for 24 hours. 
Total protein was lysed from cells and western blot analysis was performed as described 
in Appendix of Protocols (Section 7.2.2.3).    
4.1.2.2.2 Immunocytochemistry 
MC3T3 cells were plated on glass-bottom tissue culture plates (50,000 cells/plate) to 
90% confluence in basal media and then serum starved for 6 hours.  Cells were either 
untreated (control) or stimulated with varying iron saturations of 100 μg/ml rhLF for 24 
hours.  Immunocytochemistry was performed as described in Appendix of Protocols 
(Section 7.2.2.5). 
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4.1.2.3 Microarray gene expression analysis 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for 6 hours.  Cells were 
stimulated with 100 µg/ml of apo-, pis- or holo-rhLF or untreated (control) for 24 hours.  
RNA extraction, purification and microarray analysis was performed as described in 
Appendix of Protocols (Sections 7.3.2.1 and 7.3.2.3).  The ratio of the signal intensity of 
each experimental sample (100 µg/ml apo, pis, holo-rhLF treatment) and the signal 
intensity of untreated control was represented as the fold change relative to control ( 
Table 3, 4 & 5).   
4.1.2.4 Statistical data analysis 
All data is presented as mean ± S.D. (standard deviation) for n = 3, unless stated 
otherwise. Statistical analyses were performed by t-test; p < 0.05 was considered 
statistically significant. 
4.1.3 Results 
Figure 19 shows the effect of rhLF and iron concentration on the proliferation of 
MC3T3 cells after 24 hour treatment. Irrespective of the iron concentration, LF did not 
show significant increase in MC3T3 cell proliferation compared to control culture at a 
protein concentration of 10 µg/ml.  However, significant increase in cell proliferation was 
observed when cells were cultured in rhLFs at concentrations of 100 and 1000 µg/mL 
rhLF treatment relative to untreated control.  At any of the protein concentrations studied, 
no significant differences in cell proliferation was observed when cells were treated with 
apo-, pis- or holo-rhLF.   
	   118 
 
Figure 19.  Effect of rhLF concentration and iron saturation on MC3T3 cell proliferation 
after 24 hour treatment measured by thymidine incorporation. 
Data is expressed relative to control and astrices represent statistical significance  
(p<0.05) relative to control and n=4 biological replicates. 
 
 LF is a pleotropic protein with multiple functions and is known to activate various 
cell signaling pathways in cells including osteoblast cells.  In addition to the mitogenic 
effects, LF is known to increase cell survival, cause significant phosphorylation of Akt 
and support osteogenic differentiation.  Bovine LF has been demonstrated to activate 
LRP1-independent, PI3K/Akt signaling in osteoblastic cells (Grey et al. 2006, Amini, 
Nair 2011c).  Similarly, our studies demonstrated an increased Akt phosphorylation 
(Figure 20) and LRP1 expression (Figure 21) relative to untreated control by rhLF 
treatment in MC3T3 cells after 15 and 30 minutes irrespective of the iron concentration.    
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Figure 20.  Effect of rhLF iron concentration on Akt phosphorylation in MC3T3 cells. 
Cells were treated for both 15 and 30 minutes in culture.   Anti-tubulin was used as a gel 
loading control. 
 
 
Figure 21.  Effect of rhLF iron concentration on LRP1 expression in MC3T3 cells. 
Cells were treated for both 15 and 30 minutes in culture.   Anti-tubulin was used as a gel 
loading control.   
 
The molecular mechanisms underlying the anabolic effects of LF have not yet 
been clearly elucidated. β catenin-dependent signaling pathway has been well 
documented as an osteogenic signaling pathway (Novak, Dedhar 1999).  The 
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phosphorylation of Disheveled (Dsh) leads to the destabilization of the β catenin 
destruction/ubiquitination complex – which includes a series of events including Gsk3β 
phosphorylation.  These actions ultimately lead to the stabilization of cytoplasmic β 
catenin.  Irrespective of the iron concentration, all the rhLFs showed significant increase 
in phosphorylation of Dishevelled 2, Gsk3β and increased activation (de-
phosphosphorylation) of β catenin relative to untreated control (Figure 22).   
 
Figure 22. Effect of rhLF iron concentration on Dishevelled 2, Gsk3β phosphorylation 
and β catenin activation in MC3T3 cells. 
Cells were treated for 24 hours in culture.   Anti-tubulin was used as a gel loading 
control.   
 
Furthermore, through immunocytochemistry, we demonstrated that the 
accumulation of β catenin in the cytoplasm resulted in the translocation of β catenin to 
the nucleus (Figure 23a) upon 100 μg/ml apo- and holo-rhLF supplementation for 24 
hours.   
We also investigated the effect of iron concentration of rhLF in inducing the 
production of growth factors and chemokines by MC3T3 cells when cultured in the 
presence of apo, and holo-rhLFs.  Immunocytochemistry studies were performed to 
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confirm the production of IL6 and VEGF by MC3T3 cells in the presence of apo- and 
holo-rhLF to evaluate whether the expression of the cytokines and chemokines is 
dependent on iron concentration.  Figures 20b and c show the immunofluorescence 
images of MC3T3-E1 cells exposed to 100 μg/ml of apo and holo-rhLF indicating 
positive stains for both IL6 and VEGF.  The data demonstrates that rhLF is capable of 
inducing the expression of IL6 and VEGF in MC3T3 cells and the effect is independent 
of the iron concentration.  
 
Figure 23.  Immunocytochemistry analysis of (A) active β catenin, (B) IL6 and (C) 
VEGFα of 100 µg/ml of apo- or holo-rhLF treated + or untreated (control). 
Cells were treated for 24 hours in culture.  Nuclei were detected using propidium iodide 
(red) and protein expression was detected using FITC-labelled (green) secondary 
antibodies. 
 
Microarray gene expression analysis was performed on MC3T3 cells treated with 
rhLF at the three varying iron saturations (apo, pis, holo) for 24 hours (Figure 24).  Data 
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quality and reproducibility is supported by the use of three biological replicates per 
sample and also high level of bead-type redundancy (up to an average of 30 beads per 
probe) on each array. Of the 45,200 gene transcripts present in the gene array only 251 
genes were significantly regulated by rhLF.  We compared the relative expression of 251 
regulated genes by rhLF of different iron concentrations normalized to untreated control.  
Approximately 94% of the 251 genes were regulated similarly by rhLFs irrespective of 
the iron concentration.  Only 6% genes of the 251 statistically significant genes were 
found to be affected by rhLF iron concentration. For example, Ccl7 was up-regulated 
1.77-, 4.75-, and 3.48- fold over control respectively by apo-, partial- and holo-rhLFs.  
Ccl2, which is under the control of NFκβ and expressed by mature osteoclasts and 
osteoblasts (Matsuo, Irie 2008), was up-regulated 1.46-, 3.69-, 2.74-fold over control, 
respectively, by apo-, pis- and holo-rhLFs.  Nfkbiz, a gene that encodes for NFκB 
inhibitor zeta, was also positively regulated by rhLF.  Interestingly, this cluster of genes – 
Ccl7, Ccl2 and Nfkbiz, were all more up-regulated upon treatment with rhLFs with higher 
iron concentration (pis- and holo-) relative to the form with the lowest iron concentration 
(apo-).  Tfrc, a gene that encodes for transferrin receptor, was the only gene found to be 
differentially regulated by the rhLFs with high (pis and holo) and low (apo) iron 
concentration.   Iron-deficient (apo) rhLF up-regulated Tfrc 1.32-fold, whereas, pis- and 
holo-rhLF down regulated the gene by 1.20- and 1.26-fold, respectively.  Table 3, 4 & 5, 
present the list of genes that were up-, down- or differentially-regulated in MC3T3 cells 
by 100 μg/mL of rhLFs of three different iron concentrations after 24 hours in culture.   
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Figure 24.  Global expression profiles in MC3T3 murine preosteoblasts treated with 
varying iron saturations of rhLF. 
Cultures were treated for 24 hours with 100 µg/ml apo-, pis- and holo-rhLF.  Data is 
expressed as fold change over 24 hour untreated control sample. Red signifies up-
regulation, and green signifies down-regulation.  251 genes had statistically significant 
regulation by the three iron saturated rhLFs relative to the untreated control sample.  
 
 Table 3.  Genes up-regulated by rhLF of different iron concentrations. 
	   	   Fold	  change	  of	  100	  μg/ml	  (x-­‐rhLF)	  relative	  to	  untreated	  control	  PROBE_ID	   Gene	  Symbol	   Apo-­‐rhLF	   Pis-­‐rhLF	   Holo-­‐rhLF	  ILMN_1239230	   Aurkb	   1.308	   1.161	   1.161	  ILMN_1229455	   D11Ertd759e	   1.272	   2.677	   1.166	  ILMN_1259564	   AI481100	   2.027	   5.613	   1.166	  ILMN_1229827	   St7	   1.237	   1.162	   1.174	  ILMN_2420939	   scl0002624.1_576	   1.308	   1.182	   1.179	  ILMN_1224855	   AA175286	   1.26	   1.837	   1.186	  ILMN_2830661	   Top2a	   1.255	   1.196	   1.195	  ILMN_1250410	   Prkr	   1.367	   2.285	   1.198	  ILMN_1243129	   Slc11a2	   1.273	   1.454	   1.202	  ILMN_2546272	   Gng12	   1.191	   1.193	   1.206	  ILMN_2681232	   D12Ertd647e	   1.331	   1.175	   1.208	  ILMN_2984828	   Ly6e	   1.321	   2.467	   1.213	  ILMN_1257771	   Ifi205	   1.457	   2.709	   1.22	  ILMN_2717127	   Ddx58	   1.462	   2.47	   1.222	  ILMN_2956102	   Ncapd2	   1.242	   1.18	   1.231	  ILMN_2924419	   H2-­‐Q7	   1.518	   2.832	   1.234	  ILMN_2688075	   Cyp51	   1.322	   1.304	   1.237	  ILMN_1231392	   Melk	   1.232	   1.193	   1.238	  ILMN_2431619	   Ube2l6	   1.264	   2.154	   1.24	  ILMN_2711401	   3200002M19Rik	   1.299	   1.276	   1.244	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ILMN_2770585	   BC027061	   1.194	   1.24	   1.249	  ILMN_1230020	   Fmod	   1.171	   1.527	   1.249	  ILMN_2661289	   Csprs	   1.334	   2.892	   1.25	  ILMN_2593196	   Stat1	   1.427	   2.531	   1.257	  ILMN_1243616	   Cdkn3	   1.228	   1.165	   1.26	  ILMN_3161897	   Dync1li2	   1.183	   1.21	   1.267	  ILMN_2511868	   2310002B06Rik	   1.184	   1.159	   1.272	  ILMN_2630852	   Il7	   1.262	   1.417	   1.277	  ILMN_3083163	   Cp	   1.369	   2.168	   1.277	  ILMN_2739999	   B2m	   1.344	   1.691	   1.278	  ILMN_1248132	   Stmn1	   1.404	   1.277	   1.28	  ILMN_2708340	   1700029F09Rik	   1.27	   1.195	   1.282	  ILMN_1229210	   2610318C08Rik	   1.245	   1.175	   1.285	  ILMN_3096592	   Epb4.1l1	   1.204	   1.243	   1.287	  ILMN_2816754	   Ndc80	   1.317	   1.242	   1.293	  ILMN_1238000	   Srpx	   1.181	   1.325	   1.3	  ILMN_1221817	   Ii	   1.706	   3.788	   1.3	  ILMN_1234539	   Irgm	   1.587	   2.834	   1.304	  ILMN_3135781	   Anxa3	   1.213	   1.237	   1.308	  ILMN_2944666	   Ifit3	   2.17	   10.802	   1.309	  ILMN_2625451	   Ankrd1	   1.359	   1.367	   1.318	  ILMN_2757870	   Psmb10	   1.293	   1.81	   1.318	  ILMN_1256257	   G1p2	   3.222	   14.31	   1.318	  ILMN_2832219	   Cdca3	   1.255	   1.181	   1.324	  ILMN_2755915	   Pet112l	   1.212	   1.37	   1.328	  ILMN_1216746	   B2m	   1.39	   1.777	   1.331	  ILMN_2737163	   Sqle	   1.318	   1.213	   1.348	  ILMN_1237375	   Scd1	   1.352	   1.304	   1.35	  ILMN_2588139	   H2-­‐K1	   1.575	   3.047	   1.351	  ILMN_2693940	   Psmb8	   1.49	   2.104	   1.353	  ILMN_2773981	   0610007P14Rik	   1.211	   1.164	   1.358	  ILMN_2657376	   Nipsnap3b	   1.191	   1.237	   1.36	  ILMN_2696339	   Fgfr1op	   1.42	   1.491	   1.363	  ILMN_1224110	   Bst2	   2.278	   6.542	   1.365	  ILMN_2919433	   Cdc45l	   1.257	   1.187	   1.366	  ILMN_1257574	   Esm1	   1.458	   2.115	   1.381	  ILMN_1233449	   Ifi205	   1.344	   2.391	   1.383	  ILMN_2636110	   Sgol2	   1.257	   1.206	   1.387	  ILMN_2711772	   A930021H16Rik	   1.289	   2.022	   1.391	  ILMN_2878355	   Kpna2	   1.447	   1.296	   1.409	  ILMN_2866970	   Kif11	   1.337	   1.27	   1.411	  ILMN_1225730	   Fdps	   1.37	   1.37	   1.413	  ILMN_2914843	   Psmb10	   1.196	   1.693	   1.419	  ILMN_1223045	   2810417H13Rik	   1.373	   1.32	   1.429	  ILMN_2711075	   Mmp9	   1.303	   1.672	   1.433	  ILMN_1260362	   LOC223594	   1.283	   1.257	   1.439	  ILMN_2531281	   LOC271490	   1.427	   1.265	   1.447	  ILMN_3122961	   Gbp2	   1.319	   2.728	   1.454	  ILMN_3006767	   Mlkl	   1.264	   1.602	   1.462	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ILMN_2687156	   Galm	   1.347	   1.342	   1.465	  ILMN_2711112	   Shcbp1	   1.231	   1.258	   1.467	  ILMN_2612774	   Hrbl	   1.31	   1.231	   1.472	  ILMN_1225718	   Hmgcr	   1.327	   1.213	   1.475	  ILMN_2738921	   2410187C16Rik	   1.432	   1.65	   1.509	  ILMN_2737302	   Cxcl12	   1.313	   1.399	   1.51	  ILMN_2709478	   Sh3kbp1	   1.211	   1.283	   1.513	  ILMN_1230065	   LOC245892	   1.458	   1.421	   1.513	  ILMN_1256817	   Slpi	   1.277	   1.903	   1.515	  ILMN_2701271	   Plscr1	   1.38	   1.963	   1.54	  ILMN_1216764	   Ier3	   1.232	   1.564	   1.556	  ILMN_1226839	   Hist1h2ag	   1.402	   1.186	   1.559	  ILMN_2732795	   Mylc2pl	   1.443	   1.473	   1.567	  ILMN_2528456	   LOC219106	   1.406	   1.197	   1.582	  ILMN_2638548	   Atoh8	   1.428	   1.417	   1.583	  ILMN_2662803	   Ptx3	   1.362	   1.55	   1.588	  ILMN_2960214	   8430423A01Rik	   1.266	   1.17	   1.594	  ILMN_2811737	   Casp4	   1.345	   2.538	   1.595	  ILMN_2652857	   Ifi47	   1.608	   2.837	   1.621	  ILMN_1235327	   Rbbp4	   1.484	   1.329	   1.623	  ILMN_1217929	   LOC328752	   1.259	   1.187	   1.635	  ILMN_2662802	   Ptx3	   1.275	   1.579	   1.667	  ILMN_2930203	   Ugt1a10	   1.345	   1.972	   1.706	  ILMN_1254561	   Csf1	   1.19	   1.635	   1.713	  ILMN_2618918	   Slc2a6	   1.532	   2.227	   1.719	  ILMN_1248830	   Hist1h2an	   1.533	   1.174	   1.769	  ILMN_2459899	   Tsrc1	   1.392	   2.178	   1.781	  ILMN_1238276	   Hist1h2ai	   1.472	   1.231	   1.799	  ILMN_2725402	   Nsdhl	   1.353	   1.329	   1.799	  ILMN_2594525	   Nsdhl	   1.37	   1.361	   1.831	  ILMN_2856095	   Zc3h12a	   1.458	   2.131	   1.849	  ILMN_1219574	   Hist1h2af	   1.556	   1.225	   1.912	  ILMN_2759484	   C3	   3.17	   9.662	   1.993	  ILMN_1228557	   Id2	   1.404	   1.532	   2.003	  ILMN_1231814	   Ccl5	   4.426	   26.037	   2.045	  ILMN_1255416	   Ly6a	   1.481	   3.841	   2.18	  ILMN_1222543	   Ugt1a9	   1.564	   2.528	   2.248	  ILMN_2493826	   Ugt1a10	   1.462	   2.4	   2.254	  ILMN_2795040	   Hist1h2ad	   1.742	   1.302	   2.276	  ILMN_2896200	   Tnn	   2.149	   3.585	   2.329	  ILMN_2755008	   Nfkbiz	   1.758	   3.666	   2.599	  ILMN_2835117	   Ccl7	   1.523	   3.372	   2.637	  ILMN_1245710	   Ccl2	   1.463	   3.685	   2.736	  ILMN_2771176	   Ccl7	   1.769	   4.753	   3.48	  
 
Table 4.  Genes down-regulated byrhLF of different iron concentrations 
	   	   Fold	  change	  of	  100	  μg/ml	  (x-­‐rhLF)	  
	   126 
relative	  to	  untreated	  control	  PROBE_ID	   Gene	  Symbol	   Apo-­‐rhLF	   Pis-­‐rhLF	   Holo-­‐rhLF	  ILMN_1216322	   Hmgcs2	   -­‐2.41	   -­‐2.60	   -­‐3.04	  ILMN_1248998	   Xpnpep2	   -­‐1.61	   -­‐2.03	   -­‐2.49	  ILMN_2742426	   Selenbp1	   -­‐1.44	   -­‐1.77	   -­‐2.29	  ILMN_2944508	   Bglap2	   -­‐1.80	   -­‐1.48	   -­‐2.25	  ILMN_1220829	   Bglap2	   -­‐1.83	   -­‐1.56	   -­‐2.19	  ILMN_1233122	   Bglap-­‐rs1	   -­‐1.71	   -­‐1.40	   -­‐2.16	  ILMN_2727309	   Selenbp2	   -­‐1.38	   -­‐1.63	   -­‐2.10	  ILMN_3101908	   Bglap1	   -­‐1.73	   -­‐1.46	   -­‐1.98	  ILMN_2445249	   Krt1-­‐5	   -­‐1.25	   -­‐2.05	   -­‐1.97	  ILMN_2695085	   Sorcs2	   -­‐1.45	   -­‐1.66	   -­‐1.95	  ILMN_1245864	   Ifitm5	   -­‐1.48	   -­‐1.94	   -­‐1.93	  ILMN_1244099	   LOC386192	   -­‐1.56	   -­‐1.38	   -­‐1.88	  ILMN_2687165	   Chst2	   -­‐1.40	   -­‐1.92	   -­‐1.88	  ILMN_2724942	   Ptgis	   -­‐1.47	   -­‐1.76	   -­‐1.86	  ILMN_2816180	   Lbh	   -­‐1.44	   -­‐1.37	   -­‐1.85	  ILMN_2692244	   Itga10	   -­‐1.52	   -­‐1.64	   -­‐1.83	  ILMN_3162005	   BC054438	   -­‐1.48	   -­‐1.57	   -­‐1.81	  ILMN_1230648	   Rerg	   -­‐1.44	   -­‐1.66	   -­‐1.80	  ILMN_2479977	   1110065P19Rik	   -­‐1.39	   -­‐1.68	   -­‐1.79	  ILMN_2760254	   Mrgprf	   -­‐1.28	   -­‐1.62	   -­‐1.77	  ILMN_2980663	   Aqp1	   -­‐1.53	   -­‐1.79	   -­‐1.76	  ILMN_2633350	   Mfap4	   -­‐1.27	   -­‐1.45	   -­‐1.75	  ILMN_2643241	   Accn2	   -­‐1.31	   -­‐1.59	   -­‐1.74	  ILMN_1225348	   C230093N12Rik	   -­‐1.51	   -­‐1.56	   -­‐1.71	  ILMN_1229745	   Sertad4	   -­‐1.43	   -­‐1.71	   -­‐1.70	  ILMN_2980661	   Aqp1	   -­‐1.55	   -­‐1.69	   -­‐1.66	  ILMN_2829262	   Ltbp4	   -­‐1.32	   -­‐1.62	   -­‐1.64	  ILMN_1250569	   B230105J10	   -­‐1.37	   -­‐1.36	   -­‐1.62	  ILMN_2796472	   Vldlr	   -­‐1.27	   -­‐1.64	   -­‐1.61	  ILMN_2601833	   Plcg2	   -­‐1.30	   -­‐1.61	   -­‐1.61	  ILMN_1217102	   Tpcn1	   -­‐1.24	   -­‐1.29	   -­‐1.61	  ILMN_2746738	   Htra1	   -­‐1.20	   -­‐1.37	   -­‐1.60	  ILMN_2756486	   Aqp1	   -­‐1.34	   -­‐1.79	   -­‐1.56	  ILMN_2625197	   Ptprv	   -­‐1.40	   -­‐1.41	   -­‐1.56	  ILMN_3063340	   Ibsp	   -­‐1.49	   -­‐1.75	   -­‐1.55	  ILMN_1252294	   Eef2	   -­‐1.27	   -­‐1.27	   -­‐1.54	  ILMN_2695143	   Capn6	   -­‐1.23	   -­‐1.33	   -­‐1.52	  ILMN_2818294	   Srpx2	   -­‐1.32	   -­‐1.49	   -­‐1.52	  ILMN_2616164	   Itga3	   -­‐1.27	   -­‐1.30	   -­‐1.52	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ILMN_2939012	   1500012F01Rik	   -­‐1.28	   -­‐1.36	   -­‐1.51	  ILMN_1237485	   2310040A07Rik	   -­‐1.32	   -­‐1.55	   -­‐1.51	  ILMN_2744603	   2010323F13Rik	   -­‐1.32	   -­‐1.72	   -­‐1.50	  ILMN_1218264	   Vldlr	   -­‐1.27	   -­‐1.55	   -­‐1.50	  ILMN_1221178	   Pdlim2	   -­‐1.33	   -­‐1.39	   -­‐1.50	  ILMN_2954195	   Scyl1	   -­‐1.45	   -­‐1.34	   -­‐1.50	  ILMN_1230152	   Adamts4	   -­‐1.22	   -­‐1.19	   -­‐1.50	  ILMN_2770088	   Ibsp	   -­‐1.47	   -­‐1.69	   -­‐1.48	  ILMN_2428931	   4631426J05Rik	   -­‐1.32	   -­‐1.50	   -­‐1.48	  ILMN_1221264	   Klf4	   -­‐1.32	   -­‐1.36	   -­‐1.48	  ILMN_1259339	   Cdk5r1	   -­‐1.25	   -­‐1.50	   -­‐1.48	  ILMN_1237421	   scl0003519.1_175	   -­‐1.27	   -­‐1.35	   -­‐1.48	  ILMN_1251301	   1200014P03Rik	   -­‐1.28	   -­‐1.31	   -­‐1.47	  ILMN_3139693	   Rab11fip5	   -­‐1.26	   -­‐1.24	   -­‐1.47	  ILMN_2438962	   2900054C01Rik	   -­‐1.34	   -­‐1.39	   -­‐1.47	  ILMN_1248099	   Col16a1	   -­‐1.22	   -­‐1.28	   -­‐1.46	  ILMN_2718096	   Sema3b	   -­‐1.30	   -­‐1.39	   -­‐1.46	  ILMN_1232884	   Sphk1	   -­‐1.20	   -­‐1.31	   -­‐1.45	  ILMN_2826816	   Ppox	   -­‐1.27	   -­‐1.23	   -­‐1.45	  ILMN_3141106	   Ibsp	   -­‐1.41	   -­‐1.48	   -­‐1.44	  ILMN_2911520	   Hexdc	   -­‐1.25	   -­‐1.32	   -­‐1.44	  ILMN_2457408	   Zswim4	   -­‐1.31	   -­‐1.30	   -­‐1.44	  ILMN_3112922	   Hdac5	   -­‐1.26	   -­‐1.23	   -­‐1.44	  ILMN_1255166	   Ctxn	   -­‐1.29	   -­‐1.32	   -­‐1.43	  ILMN_2592823	   Cdc42ep5	   -­‐1.19	   -­‐1.18	   -­‐1.43	  ILMN_2604029	   Klf2	   -­‐1.45	   -­‐1.46	   -­‐1.42	  ILMN_1228385	   Itpr3	   -­‐1.48	   -­‐1.42	   -­‐1.42	  ILMN_3064283	   Pde4dip	   -­‐1.26	   -­‐1.31	   -­‐1.41	  ILMN_2966104	   Htra1	   -­‐1.20	   -­‐1.31	   -­‐1.41	  ILMN_1260064	   Pfn2	   -­‐1.33	   -­‐1.43	   -­‐1.41	  ILMN_2620145	   Plcd3	   -­‐1.23	   -­‐1.19	   -­‐1.41	  ILMN_2920736	   Bbc3	   -­‐1.25	   -­‐1.30	   -­‐1.41	  ILMN_2418426	   Wig1	   -­‐1.22	   -­‐1.29	   -­‐1.41	  ILMN_2622500	   B230208J24Rik	   -­‐1.35	   -­‐1.40	   -­‐1.40	  ILMN_2698728	   Srpx2	   -­‐1.29	   -­‐1.44	   -­‐1.38	  ILMN_2602185	   40795	   -­‐1.43	   -­‐1.35	   -­‐1.37	  ILMN_2490252	   Spred1	   -­‐1.27	   -­‐1.27	   -­‐1.37	  ILMN_2592093	   Ift20	   -­‐1.25	   -­‐1.32	   -­‐1.37	  ILMN_2696592	   C77080	   -­‐1.24	   -­‐1.18	   -­‐1.36	  ILMN_1214899	   Phospho1	   -­‐1.36	   -­‐1.56	   -­‐1.36	  ILMN_2648098	   Srgap2	   -­‐1.39	   -­‐1.36	   -­‐1.36	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ILMN_2909211	   Msrb2	   -­‐1.21	   -­‐1.25	   -­‐1.35	  ILMN_2618696	   D15Ertd405e	   -­‐1.34	   -­‐1.24	   -­‐1.35	  ILMN_2750258	   Mea1	   -­‐1.18	   -­‐1.17	   -­‐1.35	  ILMN_2753323	   Eif4b	   -­‐1.21	   -­‐1.53	   -­‐1.34	  ILMN_1215524	   9330161C17Rik	   -­‐1.22	   -­‐1.19	   -­‐1.34	  ILMN_2815138	   Myom1	   -­‐1.23	   -­‐1.26	   -­‐1.34	  ILMN_2664155	   Pycr1	   -­‐1.34	   -­‐1.36	   -­‐1.33	  ILMN_2615559	   Dab2ip	   -­‐1.34	   -­‐1.32	   -­‐1.33	  ILMN_2744492	   D10Bwg0940e	   -­‐1.29	   -­‐1.44	   -­‐1.33	  ILMN_2925711	   Dusp6	   -­‐1.41	   -­‐1.39	   -­‐1.33	  ILMN_2871628	   Mapk8ip1	   -­‐1.18	   -­‐1.23	   -­‐1.32	  ILMN_2734391	   Ramp1	   -­‐1.31	   -­‐1.57	   -­‐1.32	  ILMN_1227494	   Egr3	   -­‐1.46	   -­‐1.42	   -­‐1.32	  ILMN_1237579	   1810062O18Rik	   -­‐1.33	   -­‐1.36	   -­‐1.32	  ILMN_1234746	   AI790298	   -­‐1.31	   -­‐1.26	   -­‐1.32	  ILMN_1232621	   Ank	   -­‐1.23	   -­‐1.31	   -­‐1.31	  ILMN_2619767	   Pdlim2	   -­‐1.23	   -­‐1.30	   -­‐1.30	  ILMN_1226259	   Adamts2	   -­‐1.26	   -­‐1.30	   -­‐1.30	  ILMN_2907214	   Tcea3	   -­‐1.29	   -­‐1.21	   -­‐1.30	  ILMN_2650356	   Pthr1	   -­‐1.32	   -­‐1.38	   -­‐1.30	  ILMN_1241903	   Klf4	   -­‐1.29	   -­‐1.34	   -­‐1.30	  ILMN_2757916	   2810037C14Rik	   -­‐1.30	   -­‐1.22	   -­‐1.30	  ILMN_2450096	   Zfp30	   -­‐1.18	   -­‐1.20	   -­‐1.30	  ILMN_2617820	   Ppp3cc	   -­‐1.28	   -­‐1.20	   -­‐1.29	  ILMN_2483811	   2210408F11Rik	   -­‐1.25	   -­‐1.29	   -­‐1.29	  ILMN_1245549	   6330404C01Rik	   -­‐1.44	   -­‐1.41	   -­‐1.29	  ILMN_2701750	   2310061J03Rik	   -­‐1.36	   -­‐1.23	   -­‐1.29	  ILMN_2593774	   1190002H23Rik	   -­‐1.21	   -­‐1.48	   -­‐1.28	  ILMN_2643377	   Slc24a6	   -­‐1.26	   -­‐1.19	   -­‐1.28	  ILMN_2548010	   1110018K11Rik	   -­‐1.30	   -­‐1.29	   -­‐1.28	  ILMN_2594779	   5430431G03Rik	   -­‐1.20	   -­‐1.22	   -­‐1.28	  ILMN_1237061	   Dm15	   -­‐1.21	   -­‐1.33	   -­‐1.28	  ILMN_2509830	   A730063M14Rik	   -­‐1.23	   -­‐1.24	   -­‐1.28	  ILMN_2637714	   Rasa3	   -­‐1.24	   -­‐1.33	   -­‐1.27	  ILMN_2594031	   BC011468	   -­‐1.24	   -­‐1.23	   -­‐1.27	  ILMN_2443618	   2900026A02Rik	   -­‐1.21	   -­‐1.22	   -­‐1.27	  ILMN_1230145	   Acvr2b	   -­‐1.23	   -­‐1.26	   -­‐1.26	  ILMN_2476329	   Whrn	   -­‐1.26	   -­‐1.20	   -­‐1.26	  ILMN_1256950	   1190009E12Rik	   -­‐1.32	   -­‐1.29	   -­‐1.26	  ILMN_2599657	   Fmnl3	   -­‐1.27	   -­‐1.24	   -­‐1.25	  ILMN_2765047	   Chrd	   -­‐1.19	   -­‐1.31	   -­‐1.24	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ILMN_2732642	   Kptn	   -­‐1.18	   -­‐1.17	   -­‐1.23	  ILMN_1232146	   1700021C14Rik	   -­‐1.22	   -­‐1.23	   -­‐1.23	  ILMN_2799596	   AI662250	   -­‐1.29	   -­‐1.33	   -­‐1.23	  ILMN_2776619	   Ltbp3	   -­‐1.23	   -­‐1.26	   -­‐1.23	  ILMN_2490820	   2310005L22Rik	   -­‐1.29	   -­‐1.19	   -­‐1.22	  ILMN_1239386	   5230401C23Rik	   -­‐1.25	   -­‐1.32	   -­‐1.22	  ILMN_2890357	   2610027C15Rik	   -­‐1.19	   -­‐1.28	   -­‐1.21	  ILMN_2776283	   Tcea3	   -­‐1.28	   -­‐1.29	   -­‐1.20	  ILMN_2613306	   Efhd1	   -­‐1.19	   -­‐1.33	   -­‐1.20	  ILMN_2704822	   Acaa2	   -­‐1.27	   -­‐1.23	   -­‐1.19	  ILMN_2687032	   Fbxo31	   -­‐1.22	   -­‐1.17	   -­‐1.18	  ILMN_3106053	   Slc39a7	   -­‐1.24	   -­‐1.23	   -­‐1.18	  ILMN_2754027	   Nit1	   -­‐1.21	   -­‐1.23	   -­‐1.17	  ILMN_2674575	   Mmd	   -­‐1.20	   -­‐1.21	   -­‐1.17	  ILMN_2671755	   Ceecam1	   -­‐1.28	   -­‐1.22	   -­‐1.17	  ILMN_2528440	   LOC380927	   -­‐1.21	   -­‐1.32	   -­‐1.15	  
 
 
Table 5.  Genes differentially regulated by rhLF of different iron concentrations 
	   	   Fold	   change	   of	   100	   μg/ml	   (x-­‐rhLF)	  relative	  to	  untreated	  control	  PROBE_ID	   Gene	  Symbol	   Apo-­‐rhLF	   Pis-­‐rhLF	   Holo-­‐rhLF	  ILMN_2619848	   Tfrc	   1.32	   -­‐1.20	   -­‐1.26	  
 
4.1.4 Discussion 
In this study, the effect of iron concentration on the biological activity of rice-
derived rhLFs towards MC3T3 cells was examined.  LF is a known pleiotropic factor 
with unique antimicrobial, antiviral, immunomodulatory properties and anabolic effects 
in bone at physiological concentrations.  The molecular mechanisms behind the favorable 
pleiotropic properties of LF are largely unknown, however, the role of various cell 
surface receptors in mediating LF biological response have been identified.  One of our 
long-term goals is to develop bioactive biomaterials using unique ligand molecules that 
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can activate specific receptor mediated signaling pathways.  We have previously 
demonstrated the feasibility of developing LF-based biomaterials via an enzymatic 
process irrespective of the iron content of the protein (Amini, Nair 2011a, Amini, Nair 
2012a).    The aim of the present study was to evaluate whether the iron content of the 
protein can make a significant difference in the bioactivity towards pre-osteoblast cells, 
to determine the most effective protein to form LF based biomaterials to support bone 
regeneration.    
Bovine LF has been shown to induce the proliferation of primary ostoeblasts and 
osteoblastic cell lines.  rhLF derived from rice has shown to have mitogenic effects 
towards a variety of cells types such as intestinal cells, hybridoma cells, osteoblast cells 
and embryonic kidney cells (Huang et al. 2008).  Based on LFs mitogenic activity on 
different cell types two possible mechanisms have been suggested.  The possibility of 
iron acting as a nutrient to support cell proliferation and LF regulated gene expression in 
cells through putative cell surface receptors.   Statistically significant dose-dependent 
proliferation of MC3T3 cells cultured in the presence of 100 and 1000 μg/ml apo-, pis- 
and holo-rhLFs relative to untreated control demonstrated the significant mitogenic effect 
of rhLF towards MC3T3 cells.  However, lack of difference in mitogenic effect between 
apo-, partial- and holo LFs at all the concentrations studied indicates that the mitogenic 
effect of rhLF towards MC3T3 is independent of iron concentration and therefore 
potentially mediated by modulation of gene expression via cell surface receptors.  The 
observed results show a significant difference in behavior of rice-derived rhLFs towards 
HT-29 intestinal cells which might be due to the different receptors involved in the 
signaling cascade (Huang et al. 2008).  The mitogenic effect of bLFs towards osteoblasts 
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is known to be mediated at least partially via LRP1 receptors, whereas in the intestinal 
cells, the ERK1/2 signaling cascades is mediated via lactoferrin receptor (LfR) (Jiang, 
Lonnerdal 2012). Interestingly, LF receptor mRNA has been found to be undetectable in 
osteoblastic cells (Naot et al. 2011). 
Another unique bioactivity of lactoferrin is its ability to increase cell survival, 
even though the mechanism behind the anti-apoptotic activity of LF is unknown.  
Previous studies using osteoblasts have demonstrated the ability of bLF to induce PI3K-
dependent Akt signaling independent of LRP1 receptor activation (Grey et al. 2006).  
MC3T3 cells cultured in presence of rhLFs showed significant increase in Akt 
phosphorylation irrespective of iron concentrations indicating that as in the case of 
mitogenic activity Akt phosphorylation of rhLF is mediated by a mechanism independent 
of iron concentration and potentially mediated through modulation of gene expression 
induced by the protein LF. 
The β catenin-dependent signaling pathway has been documented as a potential 
osteogenic signaling pathway (Novak, Dedhar 1999).  The phosphorylation of Disheveled 
(Dsh) leads to the destabilization of the β catenin destruction/ubiquitination complex – 
which includes a series of events including Gsk3β phosphorylation.  These actions 
ultimately lead to the stabilization of cytoplasmic β catenin.  Accumulation of β catenin 
in the cytoplasm prompts its translocation to the nucleus, where it interacts with members 
of the TCF/LEF family of transcription factors and induces the transcription of target 
genes. Figure 19 demonstrates that, irrespective of the iron concentration, rhLF increases 
phosphorylation of Dsh2, Gsk3β and activation (de-phosphosphorylation) of β catenin in 
MC3T3 cells relative to untreated control.  The translocation of the stabilized β catenin to 
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the nucleus was confirmed by immunocytochemistry (Figure 20a).  The stabilization of β 
catenin has been known to occur via Wnt-dependent as well as Wnt-independent 
pathways.  Wnt and growth factor signaling can act through convergent pathways and 
possibly synergistically on GSK3β and β catenin (Jin, George Fantus & Sun 2008).  
Among Wnt proteins, Wnt3a has been extensively investigated as a potent molecule to 
induce stabilization of β catenin, which then cooperatively regulate gene expression with 
LEF/Tcf transcription factors (Mbalaviele et al. 2005, Chen, Alman 2009, Baron, Rawadi 
2007).  Signaling pathways affecting GSK3β (e.g. PI3K/Akt) can also modulate β catenin 
transcriptional activity. LRP6 phosphorylation by various protein kinases is considered 
another crucial factor for β catenin stabilization.   In summary, the data shown here 
demonstrate the ability of rhLF to stabilize β catenin in preosteoblast cells and that the 
effect is independent of the iron concentration.  More details on the possible mechanism 
of β catenin stabilization and the transcriptional activity will be discussed in section 
4.3.3.2.1.   
The pleiotropic functions of LF have also been attributed to its ability to induce 
the synthesis of growth factors, cytokines and chemokines by the cells.  Cell signaling 
molecules, such as growth factors and cytokines, play an important part in the bone 
regenerative process. IL6, a pleiotrophic cytokine, has been demonstrated to be an 
important regulator for bone maturation during development (Yang et al. 2004).   IL6, is 
also known to be involved in initiating signaling cascades required for bone regeneration 
following injury (Mountziaris, Mikos 2008).  Immunofluorescence study demonstrated 
the expression of IL6 protein in MC3T3 cells after 24 hours in culture in the presence of 
100 μg/mL apo- and holo-rhLFs. The results concur with the up-regulation of IL6 mRNA 
	   133 
in MC3T3 cells treated with 50 μg/ml bLF after 2 hours (Naot et al. 2011). Collectively, 
the results demonstrate that rhLF is capable of inducing IL6 expression in MC3T3 cells 
irrespective of the iron concentration. 
VEGFα is another major angiogenic factor that has been demonstrated to be an 
essential component of skeletal development and repair.  Recent studies demonstrated the 
ability of bLF in inducing the synthesis of the angiogenic factors VEGF and FGF2 in 
MC3T3 cells via the p44/p42 MAPK pathway (Nakajima et al. 2011, James et al. 2011). 
Other studies demonstrated the ability of hLF in stimulating VEGFα – mediated 
endothelial cell proliferation and migration (Kim et al. 2006).  It has been demonstrated 
that exposure of human umbilical vein endothelial cells (HUVECs) to hLF significantly 
increased VEGF-induced Erk MAPK phosphorylation (Kim et al. 2006).  Similarly, 
bovine milk LF induces synthesis of the angiogenic factors (VEGF) in MC3T3 cells via 
the p44/p42 MAP kinase pathway (Nakajima et al. 2011, Amini, Nair 2011a).  Studies 
have also demonstrated that increased skeletal VEGF can enhance β catenin activity and 
results in excessively ossified bones (Maes et al. 2010).  The present study demonstrates 
that rhLF is capable of inducing VEGFα expression in MC3T3 cells and the expression is 
also independent of rhLF iron concentration.   
The global whole-genome array study was performed to understand the effect of 
iron concentration on the overall gene expression profile of MC3T3 cells.  The regulated 
genes cover a broad range of functional activities of LF ranging from immunity, cell 
cycle progression and bone metabolism.  The data reported to our knowledge is the first 
genetic profile of rhLF treated MC3T3 cells and provide better understanding of the 
molecular mechanism behind the pleiotropic effect of rhLF towards osteoblasts.  Only a 
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limited number of genes with known osteoblast relevant functions are discussed here.  A 
number of known genes regulated during osteoblast differentiation were found to be 
down-regulated in MC3T3 cells for 24 hours when cultured in basal media in the 
presence of rhLFs irrespective of the iron concentrations.  These include mature 
osteoblast markers, osteocalcin (Bglap) and bone sialoprotein (Ibsp), transcription factors 
parathyroid hormone receptor 1 (Pthr1) and prostaglandin 12 synthase (Ptgis).  Adamts2 
(A disintegrin and metalloproteinase with thrombospondin motifs 2), which is responsible 
for processing several types of procollagen proteins (Wang et al. 2003), was also down-
regulated approximately 1.28-fold by all iron saturation forms.  Interestingly, FGF2-
treated MC3T3 cells also showed similar results of significant down-regulation of 
osteoblast differentiation-associated genes (i.e., BMP2, osteocalcin, Runx2 and collagen 
1) at 24 hours in culture (Hughes-Fulford, Li 2011).  On the other hand, matrix 
metalloproteinase 9 (MMP9), a key regulator in the development of the growth plate 
during endochondral bone formation (Pratap et al. 2005), was stimulated by all iron 
saturation forms (apo-, pis-, holo-) by 1.30-, 1.67-, 1.43-fold, respectively. 
The gene array however, demonstrated an up-regulation of early osteoblastic 
induction and proliferation markers.  One example is Cxcl12 (chemokine (C-X-C motif) 
ligand 12) or SDF1 (stromal cell-derived factor 1), which is an early marker of 
ostoeblastic induction modulated by growth factors, which include VEGF, PDGF and 
PTH (Jung et al. 2006).  Cell division cycle associated 3 (Cdca3), which is required for 
entry into mitosis, was also up-regulated an average of 1.25-fold across the three rhLF 
concentrations above untreated control. 
Three genes that are significantly stimulated by rhLFs with higher iron concentrations 
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(pis and holo) are Ccl7, Ccl2 and Nfκβiz (NFκβ inhibitor zeta).  Studies have 
demonstrated Nfκβiz to be an activator of IL6 production and also involved in the 
induction of inflammatory genes activated through TLR/IL1 receptor signaling 
(Yamamoto et al. 2004).  Nfκβiz is a gene that encodes for a family of proteins known to 
play a role in the inflammatory response to LPS by their interaction with NFκβ proteins 
(Eto et al. 2003).   Ccl2 is expressed by mature osteoblasts and is under the control of 
NFκβ (Li et al. 2007).  Other studies demonstrated that Ccl2 mediates fibroblast survival 
through IL6 (Liu et al. 2007).  The regulation of Ccl7, Ccl2 and Nfκβiz were significantly 
affected by high iron saturation of rhLF, however this differential effect of rhLF iron 
saturation was not seen in IL6 protein expression.  As discussed before, IL6 expression 
was found to be stimulated by 100 μg/ml of both apo- and holo-rhLF treatments relative 
to untreated control.  Perhaps, this occurrence is due to the change in molecular 
confirmation in rhLF induced by iron saturation not significantly affecting the 
upregulation of IL6.     
The only gene found to be differentially regulated by the iron concentration of 
rhLF is Tfrc (transferrin receptor) (Table 5).  Interestingly, previous studies using cells 
such as monocytes and intestinal cells have demonstrated a binding site for LF different 
from the transferrin receptor.  Only with high molar excess of both ligand proteins, 
(lactoferrin and transferrin), did a small percentage of the ligands cross-react with the 
receptor for the other.  This most likely occur due to the structural similarity of the two 
glycoproteins (Roiron et al. 1989, Birgens et al. 1983, Hu et al. 1988).  With regards to 
transferrin and iron, the transferrin family is known to be potent regulators of iron 
homeostasis (Cairo et al. 2002), and transferrin receptor 1 is the primary target of 
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transferrin in the iron transport system.  It has been reported that low iron concentrations 
can lead to up-regulation of this protein (Lambert 2012) which may explain why Tfrc was 
differentially regulated by the iron unsaturated and saturated forms. 
4.1.5 Conclusions 
The present study investigated the effect of rhLF iron saturation on pre-
osteoblasts.  Recombinant human LF was found to have a significant effect on MC3T3 
cell proliferation, Akt phosphorylation, β catenin activation, Dishevelled 2 and Gsk3β 
phosphorylation at all iron concentrations studied over untreated control after 24 hour 
treatment.  Up-regulation of chemokines and cytokines, such as VEGF and IL6, was 
induced by rhLF in MC3T3 cells independent of the iron concentration.  Microarray 
analysis of the effect of various iron saturated rhLF forms on MC3T3 cells demonstrated 
only one gene, transferrin receptor, to be differentially regulated by the iron 
concentration of rhLF.  Since there wasn’t a significant difference of bioactivity of the 
various iron saturation forms of rhLF, we choose to use holo-rhLF for our future 
studiesas this form is widely available.   
 
4.2 Bioactivity of holo-rhLF towards MC3T3 murine 
preosteoblast cells and NHOst primary cells: a 
comparative study 
4.2.1 Introduction 
In vivo studies allow for the analysis of biomolecules on a complete biological 
system with a vast array of cell types, growth factors and cytokines.  However, in an 
isolated in vitro study, the effect of biomolecules is studied on a controlled, artificial 
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environment.  Therefore, the selection of an isolated cell type to study the effect of a 
biomolecule on a particular system may result in pertinent or non-pertinent results.   
Thus, it is crucial to select a cell culture system that is pertinent to the organ of clinical 
interest and one that will also allow for the accurate study of a biomolecule’s effect on 
that organ of interest.   
To understand the biological activity of rhLF, we chose to use murine MC3T3 
preosteblast cells due to reasons summarized below.   MC3T3 cells are clonal cells 
established from newborn mouse calvaria.  Compared to primary calvarial cells that 
contain a limited percentage of osteoblast precursors capable of forming mineralized foci 
(Bellows, Heersche & Aubin 1990), confluent MC3T3 cells form a more continuous layer 
of cells and mineralized extracellular matrix (Sudo et al. 1983, Nakano, Addison & 
Kaartinen 2007, Wang et al. 1999).  Moreover, studies have shown that MC3T3 cells 
have the capacity to differentiate into osteoblasts and osteocytes and to form calcified 
bone tissue in vitro (Sudo et al. 1983).  With good culture maintenance, MC3T3 cells 
exhibit very high phenotype stability and biological reproducibility.  In summary, 
MC3T3 cells have a long history of being used as a model osteoblast cell to understand 
osteoblast behavior (Sudo et al. 1983).  However, while developing biomaterials to 
support tissue regeneration, it is important to confirm the translational potential of the 
material for applications in humans.  Therefore, we compared the bioactivity of holo-
rhLF towards MC3T3 cells and Normal Human Osteoblasts (NHOst) cells to confirm that 
rhLF is equally effective towards NHOst and MC3T3 cells.   NHOst cells are primary 
cells isolated from human bone tissue. Therefore, the objective of the following studies 
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was to evaluate whether holo-rhLF would similarly affect MC3T3 and NHOst cell 
proliferation and differentiation.     
4.2.2 Methods 
4.2.2.1 Proliferation assays 
4.2.2.1.1 Thymidine incorporation 
The effect of varying concentrations of holo-rhLF on MC3T3 cell proliferation was 
measured through thymidine incorporation as described in Section 4.1.2.1.  Briefly, the 
cell culture was then performed upon supplementation with 0, 10, 100, and 1000 μg/ml of 
apo-, pis- and holo-rhLFs and [3H]thymidine for 24 hour incubation at 37°C.  Thymidine 
incorporation was analyzed; data was normalized to untreated control sample and 
expressed as fold change over control. 
4.2.2.1.2 MTS assay 
NHost cells were plated at a density of 15,000 cells/well in a 48-well plate with basal 
media. After 24 hours, treatments were administered at various concentrations (n=4 
biological replicates).  The cell culture was then performed upon supplementation with 0, 
10, 100, and 1000 μg/ml of holo-rhLF for 24 hour incubation at 37°C. The proliferation 
of NHOst cells was determined by MTS assay as described in Appendix of Protocols 
(Section 7.6.2.1).  Data was then normalized to untreated control sample and expressed as 
fold changeover control. 
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4.2.2.2 Differentiation assays 
4.2.2.2.1 Alkaline phosphatase assay 
MC3T3 and NHOst cells were plated at a density of 50,000 cells/well in a 24 well plate 
with basal media.  Cells were grown to confluence in basal medium and then changed to 
mineralization media.  The cell culture was then performed upon supplementation with 0, 
100, and 1000 μg/ml of holo-rhLFs (n=4 biological replicates).  Mineralization media 
supplemented with and without rhLF treatments was changed every 3 days and samples 
were harvested on day 7, 14, 21 and alkaline phosphatase activity was determined as 
described in Appendix of Protocols (Section 7.7.2.1). 
4.2.2.2.2 Mineralization assay 
MC3T3 and NHOst cells were plated at a density of 50,000 cells/well in a 24-well plate 
with basal media. Cells were grown to confluence in basal medium and then changed to 
mineralization media.  The cell culture was then performed upon supplementation with 0, 
100, and 1000 μg/ml of holo-rhLF (n=4 biological replicates).  Mineralization media with 
and without rhLFs was changed every 3 days and samples were harvested on day 7, 14, 
21 days the extent of mineral deposition was followed as described in Appendix of 
Protocols (Section 7.7.2.2). 
4.2.2.3 Protein expression 
MC3T3 and NHOst cells were plated at a density of 200,000 cells/plate on 10 cm tissue 
culture plates, grown to 90% confluence in basal medium.  The cells were then 
maintained in basal serum-free medium overnight.  The cell culture was then performed 
with supplementation with 0, 100 and 1000 µg/ml of holo-rhLF for 24 hours.  Total 
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protein was lysed from cells and western blot analysis was performed as described in 
Appendix of Protocols (Section 7.2.2.3). 
4.2.3 Results 
Thymidine incorporation and MTS assay, two traditional cell proliferation assays, 
were used to test the effect of holo-rhLF on MC3T3 and NHOst cells, respectively.  
Holo-rhLF led to a significant increase in proliferation of MC3T3 cells – concentration of 
100 and 1000 µg/ml. Similarly, holo-rhLF led to a significant increase in proliferation of 
NHOst cells – at all concentrations tested 10, 100, 1000 µg/ml (Figure 25).  Unlike 
MC3T3 cells, NHOst showed significant increase with 10 µg/ml holo-rhLF treatment 
after 24 hours.  100 µg/ml holo-rhLF treatment led to a 61% and 43% increase in 
proliferation over untreated control of MC3T3 and NHOst cells, respectively, after 24 
hours treatment.  
 
Figure 25.  Effect of holo-rhLF treatment on MC3T3 and NHOst cell proliferation. 
Cells were treated for 24 hours in culture.  Cell proliferation was measured in MC3T3 
and NHOst cells by thymidine incorporation and MTS assay, respectively. Data was 
normalized to untreated control sample and expressed as fold change over control. 
Statistical significance (p<0.05) is represented as * relative to appropriate control. 
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Both cell types, MC3T3 and NHOst cells, demonstrated a significant increase in 
ALPase activity after 7, 14, 21 days of holo-rhLF treatment relative to untreated control 
samples (Figure 26).   MC3T3 cells displayed a dose-dependent increase in ALP activity 
at 14 and 21 days.  However, this effect was not seen in NHOst cells – 1000 µg/ml holo-
rhLF induced a less significant increase in ALP activity relative to 100 µg/ml holo-rhLF 
at 14 and 21 days of culture.  Significant increase in calcium deposition by MC3T3 and 
NHOst cells was measured by Alizarin Red staining after 14 and 21 days of holo-rhLF 
treatment (Figure 27).  Trends in increase mineralization (Alizarin Red staining) were 
similar in MC3T3 and NHOst cells during the 21 day culture period. 
An effect of holo-rhLF on signaling molecule production was exhibited by both 
MC3T3 and NHOst cells.  As discussed before holo-rhLF can induce phosphorylation of 
Akt in MC3T3 cells.  Holo-rhLF increase phosphorylation of Akt in MC3T3 cells (Figure 
32) and NHOst cells (Figure 28a) after 24 hours treatment relative untreated control 
samples.   Similarly, activation (de-phosphorylation) of β catenin was increased by holo-
rhLF treatment relative to control in MC3T3 cells (Figure 22) and NHOst cells (Figure 
28b) after 24 hours.  Equal protein loading was confirmed in western blotting using anti-
tubulin blot 
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Figure 26.  Alkaline phosphatase activity in MC3T3 and NHOst cells treated with holo-
rhLF. 
Alkaline phosphatase assay was performed on MC3T3 and NHOst cells maintained in 
mineralization media for 7, 14 and 21 days and treated with 100 or 1000 μg/ml holo-rhLF 
or untreated (-). Statistical significance (p<0.05) is represented as * relative to 
appropriate control. 
 
 
Figure 27.  Mineral deposition by MC3T3 and NHOst cells treated with holo-rhLF. 
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Alizarin Red assay was performed on MC3T3 and NHOst cells maintained in 
mineralization media for 7, 14 and 21 days and treated with 100 or 1000 μg/ml holo-rhLF 
or untreated (-). Statistical significance (p<0.05) is represented as * relative to 
appropriate control.   
 
 
 
Figure 28.   Holo-rhLF increases (a) phosphorylation of Akt and (b) activation of β 
catenin in NHOst cells after 24 hours of treatment. 
 
4.2.4 Discussion 
Bone developmental sequence can be characterized in three stages: (1) osteoblast 
proliferation, (2) matrix maturation, and (3) mineralization (Siggelkow et al. 1999).  This 
sequence has been most extensively studied in the rat calvarial cell system (Aronow et al. 
1990b, Collin et al. 1992, Nefussi et al. 1997, Owen et al. 1991, Pockwinse et al. 1995) 
and murine MC3T3 cells (Quarles et al. 1992).  Differentiation of human osteoblasts is 
not as widely characterized, however studies thusfar indicate an analogous process in 
developing human bone (Dodds et al. 1994, Mundlos 1994). 
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Fetal and neonatal rat calvaria cells are the most widely used source of primary 
osteoblasts.  These calvarial cells are proteolytically released and in early passage are 
heterogeneous and not immortalized.  However, enrichment of cultures for committed 
osteoblasts can be obtained by proper sub-confluent passaging and 0.1 µM 
dexamethasone treatment (Aronow et al. 1990a).  Cells released at later times of 
proteolytic digestion have increased osteogenic potential as they express osteoblast 
phenotypic markers and form mineralized nodules with time in culture (Kawaguchi et al. 
1995).  
Clonal osteoblast-like MC3T3 cell line, which is established from newborn 
C57B/6 mouse calvaria, provides an excellent in vitro model of bone development. This 
system resembles osteogenic cells in numerous ways as it undergoes the three orderly 
time-dependent phases characterized by proliferating pre-osteoblasts, hydroxyapatite 
crystal matrix deposition by differentiating osteoblasts, which results in the formation of 
multilayered bone nodules (Vary et al. 2000).  This cell line provides one of the most 
convenient and physiologically relevant culture systems for osteoblast studies.  The 
MC3T3 cell line is an immortalized cell line selected by the 3T3 passaging protocol 
(Sudo et al. 1983).  At confluence, this cell line differentiates along the osteoblast linage 
and sequentially expresses characteristic osteoblast phenotypic markers (including bone 
sialoprotein and osteocalcin) similar to that of primary calvarial osteoblasts cultures of 
fractions 3-5 (Vary et al. 2000, Franceschi, Iyer 1992, Franceschi, Iyer & Cui 1994).   
Moreover, post-confluent cultures of MC3T3 cells cultured in the presence of ascorbic 
acid and β-glycerolphosphate will mineralize and accumulate hydroxyapatite (Sudo et al. 
1983).   MC3T3 cell phenotype is very stable if the stocks are well maintained and 
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passaged accordingly before confluence.  This cell line is a physiologically relevant 
model commonly used for studying osteoblasts – as it provides a model for signal 
transduction cascades and their interactions with osteoblast transcription factors.   
MC3T3 and NHOst cells displayed all three stages of the bone developmental 
sequence in response to holo-rhLF treatment.  A significant increase in MC3T3 and 
NHOst cellular proliferation induced by holo-rhLF treatment was measured by thymidine 
incorporation and MTS assay, respectively, after 24 hours of treatment.  However, unlike 
MC3T3 cells, NHOst cells showed a significant increase in cell proliferation with only 10 
µg/ml holo-rhLF treatment.  Previous studies by Cornish et al. demonstrated similar 
effects of rhLF on rat primary osteoblast proliferation via thymidine incorporation after 
24 hours treatment at concentrations of 10 and 50 µg/ml (Cornish et al. 2004).  Although 
the response of MC3T3 cells to many growth factors and hormones mimics that of 
primary cultures of rodent osteoblastic cells (Delany, Canalis 1998), studies have 
demonstrated differential regulation of growth factors on osteoblast cells based on their 
differentiation stage.   For example, FGFs induce immature osteoblastic cells to 
proliferate, whereas mature osteoblasts respond by unaltered or decreased proliferation 
(Hurley, Marie 2002).  This reasoning may be used to explain the more sensitive response 
of primary NHOst cells to the lower concentration (10 µg/ml) of holo-rhLF relative to 
pre-osteoblastic MC3T3 cells.  
Increased osteogenic differentiation was induced by holo-rhLF supplementation 
of mineralization media, which included 10 µg/ml L-ascorbic acid and 3 mM β-
glycerophosphate.  Osteogenic differentiation was assessed by increased alkaline 
phosphatase and mineralized matrix deposition at 7, 14 and 21 days.   Choi et al.  
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reported the phenotypic increase of alkaline phosphatase activity during early matrix 
formation/maturation period (approximately day 10) (Choi et al. 1996).  In our studies, 
MC3T3 and NHOst cells demonstrated a significant increase in ALP activity during early 
matrix formation period of day 7 and 14.   This increase in alkaline phosphatase was 
further sustained in both cell types by holo-rhLF at 21 day culture.   A previous study 
using MG63 osteoblast-like cells showed similar results as LF treatment led to significant 
increase in ALP activity at days 14 and 21 days (Takayama, Mizumachi 2008).   
Similar to ALP activity, the presence of holo-rhLF significantly increased the 
mineral deposition by MC3T3 and NHost cells at 14 and 21 days of culture in 
mineralization media.    Other studies report that mineralization of extracellular matrix, 
which marks the final phase of osteoblast phenotypic development, begins approximately 
16 days after culture (Quarles et al. 1992).  Even at 21 days, the extent of mineralized 
matrix formed in the presence of rhLF was significantly higher than the control indicating 
the potential of rhLF to produce overall higher amount of matrix compared to control.   
Interestingly, there was no statistical significant increase in mineral deposition produced 
by 1000 µg/ml holo-rhLF treatment relative to 100 µg/ml.   Thus, the concentration of 
100 µg/ml of holo-rhLF is sufficient to induce significant mineral deposition in NHOst 
and MC3T3 cells. 
These studies also showed similar response of MC3T3 and NHOst cells towards 
holo-rhLF treatment regarding Akt phosphorylation and β catenin activation.   These 
results concur with results from our previous studies with MC3T3 cells (Section 4.1.3) 
and also previously published studies using primary rat osteoblasts and bLF to induce 
PI3K-dependent Akt signaling (Grey et al. 2006).  The β catenin-dependent signaling 
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pathway has been documented as a potential osteogenic signaling pathway (Novak, 
Dedhar 1999). 
4.2.5 Conclusions 
The effect of holo-rhLF on the signaling and functional properties on NHOst and 
MC3T3 cells was compared to demonstrate the translational potential of rhLF-based 
materials.  The study demonstrated NHOst followed the same pattern of transcriptional 
factor expression, cell proliferation and differentiation.   The study confirmed that the 
bioactivities of rhLF may be reproduced in human cells similar to mouse clonal cells, 
thereby demonstrating the translational potential of rhLF based biomaterials.  
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4.3 Evaluation of the mechanism behind the anti-apoptotic 
and osteogenic activity of rhLF towards MC3T3 cells 
4.3.1 Introduction 
Cell-based bone tissue engineering encompasses the use of cells and biomaterials 
for the regeneration or repair of damaged bone tissue. The challenges in cell-based 
therapy are two-fold, which include biological and biomaterial obstacles.  The biological 
challenges involve the survival of the implanted cells at the defect site (Manassero et al. 
2012).   The biomaterial challenge includes localizing the implanted cells at the defect 
site for prolonged time, positively modulating the activity of encapsulated cells in the 
microenvironment to support accelerated regeneration and maintain the survival of the 
cells.  The significant cell death and decreased activity of cells after implantation at 
orthotopic sites have been demonstrated using various cell-based modalities in small 
animals, as well as human clinical trials.  A recent study investigated the success of 
human mesenchymal stem cell survival after implantation to rat femoral defect.  
Unfortunately, less than 2% of the initial cell number was viable after 30 days of 
implantation (Figure 29) (Manassero et al. 2012). 
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Figure 29.  Representative bioluminescence imaging of a mice transplanted with human 
mesenchymal stem cells in a critical-size segmental femoral defect and in vivo kinetic 
cell survival quantification.   
 
A recent human clinical trial investigated the potency of bone tissue engineering to 
reconstruct jaw defects.   After 4 months of reconstructing an intra-oral bone defect, bone 
formation by implanted stem cells was shown to be feasible in only 1 out of 6 patients by 
the tissue-engineered construct (Meijer et al. 2008).  To make bone tissue engineering 
techniques involving cells suitable for reconstructing an osseous defect, the problem of 
cell apoptosis and lack of osteogenic induction must be solved.  Biomaterial with inherent 
anti-apoptotic and osteogenic properties would be highly beneficial as a cell-delivery 
vehicle as it would address the two major existing concerns in cell-based therapy.  
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LF has raised significant interest as a bioactive protein due to its wide array of 
physiological effects on many different cell types  (Amini, Nair 2011c). The diverse list 
of LF’s multifunctional roles includes immuno-modulatory, anti-cancer, anti-bacterial, 
and anti-viral properties  (Spadaro et al. 2008, Legrand et al. 2005).  Some of the recent 
studies have demonstrated LF as an effector molecule in the skeleton (Cornish, Naot 
2010, Cornish 2004), due to its ability to increase osteoblast proliferation, survival and 
differentiation (Grey et al. 2006, Cornish et al. 2004, Cornish 2004) and decrease 
osteoclast survival (Lorget et al. 2002, Blais et al. 2009).  Many of the biological 
activities of LF have been attributed to its ability to induce signal transduction pathways 
through cell surface receptors.  LRP1 has been established as one of the putative 
receptors in osteoblasts.  The activation of this receptor by bLF has been shown to induce 
MAPK-mediated osteoblast mitogenesis (Grey et al. 2004).  However, the anti-apoptotic 
properties of this glycoprotein have been attributed to a PI3K/Akt-independent, and 
LRP1-independent pathway (Grey et al. 2006).  The anabolic effect of bLF (Cornish 
2004) has also been attributed to bLF’s possible positive effects on osteogenic 
differentiation (Yagi et al. 2009).  Yagi et al. demonstrated the ability of bLF to push the 
differentiation of pluripotent mesenchymal stems cells towards the osteoblastic or 
chondroblastic lineage, and prevent the differentiation towards myloblastic and or 
adipocytic lineages (Yagi et al. 2009).  Furthermore, hLF stimulates keratinocytes 
proliferation via MAPK signaling cascade, which is a pathway similar to FGF2-
stimulated mitogenesis, cell migration and cell survival implying its potential to promote 
wound re-epithelialization (Tang et al. 2010).  Recent studies indicate the ability of bLF 
to promote FGF-2 and VEGF synthesis by osteoblasts via the p44/p42 MAP kinase 
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pathway (Nakajima et al. 2011, James et al. 2011).  Additionally, bLF has been shown to 
inhibit osteoclastogenesis in primary culture of murine bone cells at a concentration as 
low as 10 μg/ml (Lorget et al. 2002). Collectively, these studies substantiate LF as a 
positive regulator of the skeleton. 
 
Figure 30.  Schematic showing the summary of known mechanisms of action of LF in 
osteoblasts. 
Binding of LF to LRP1 receptor on osteoblasts induces endocytosis of the LF-LRP1 
complex as well as activation of the p42/44 MAP kinases signaling pathway. Inhibition of 
the MAPK pathway blocks the mitogenic effect of lactoferrin in osteoblasts. LF also 
activates the PI3K/Akt signaling pathway and increases mRNA levels of IGF1, Nfatc1 
and Ptgs2 but the functional significance of these remains to be determined. The 
mechanisms involved in the activities of LF as a survival factor and as a promoter of 
osteoblast differentiation are unknown yet.  Image was taken from (Cornish, Naot 2010). 
 
Fetal bovine serum, the most widely used serum animal supplement, provides 
broad spectrum of macromolecules, carrier proteins, attachment and spreading factors, 
low molecular weight nutrients, and hormones and growth factors (Boone et al. 1971).  
Serum deprivation has been shown to efficiently induce apoptosis in several cell types 
(Aoki et al. 1997, Hara et al. 2012, Braun et al. 2011).   Thus, serum deprivation model 
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was used to study holo-rhLF effect on cellular apoptosis.  Furthermore, we investigated 
the osteogenic effect of holo-rhLF on MC3T3 cells.  The objective of the following 
studies was to test the anti-apoptotic and osteogenic activity of holo-rhLF on MC3T3 
cells to evaluate the efficacy of using holo-rhLF as a potential biomaterial to develop 
novel injectable cell delivery vehicles.  We also went on to investigate the molecular 
mechanisms underlying holo-rhLF’s anti-apoptotic and osteogenic effects to gain a better 
understanding of the signal transduction pathways induced by this bioactive molecule. 
4.3.2 Methods 
4.3.2.1 Cell viability/ survival assays 
4.3.2.1.1 Serum starvation and cell viability assay 
MC3T3 cells were plated at a density of 50,000 cells/well in a 12-well plate with basal 
media for 24 hours.  Cells were then maintained in serum-free basal media and the cell 
culture was then performed upon supplementation with 0 or 100 μg/ml of holo-rhLF.  
Live/dead viability assay was then performed as described in Appendix of Protocols 
(Section 7.5.2.1). 
4.3.2.1.2 Protein expression (Immunocytochemistry) 
MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2 
days in basal media and then serum starved for 6 hours.  Cells were either untreated 
(control) or stimulated with holo-rhLF 100 μg/ml for 24 hours.  Immunocytochemistry 
was performed as described in Appendix of Protocols (Section 7.2.2.5). 
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4.3.2.1.3 Wnt signalling pathway 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for overnight.   Cells were then 
maintained in serum-free basal media overnight and the cell culture was then performed 
upon supplementation with 0 or 100 µg/ml of holo-rhLF for 24 hours.  RNA was 
extracted, purified and Wnt signaling pathway array was performed as described in 
Appendix of Protocols (Section 7.9.2.1). 
4.3.2.1.4 Inhibitor studies for signalling pathway probing 
4.3.2.1.4.1 Protein expression (Western blot analysis) 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for overnight.  Inhibitor treatment 
of select inhibitors (10 µM LY294002 and 30 µM H-89) for 2 hours was followed by 
treatment with 100 µg/ml holo-rhLF or 100 ng/ml Wnt5a for 24 hours.  Total protein was 
lysed from cells and western blot analysis was performed as described in Appendix of 
Protocols (Sections 7.2.2.3 and 7.8.2.1). 
4.3.2.1.4.2 Bioluminescent caspase-3 assay 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for overnight.  Inhibitor treatment 
of select inhibitors (10 µM LY294002 and 30 µM H-89) for 2 hour was followed by 
treatment with 100 µg/ml holo-rhLF, 100 ng/ml Wnt5a or 100 ng/ml BMP2 for 24 hours.  
50 µM Z-VAD-FMK was also used as a positive control apoptosis inhibitor.  Total 
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protein was lysed from cells and caspase assay was performed as described in Appendix 
of Protocols (Section 7.5.2.2). 
4.3.2.1.5 Osteogenesis assays 
4.3.2.1.5.1 Protein expression 
4.3.2.1.5.1.1 Total β catenin expression  
4.3.2.1.5.1.1.1 Canonical Wnt signaling pathway activation 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media.  Cells were then maintained in serum-free basal media 
overnight and the cell culture was then performed upon supplementation with 0 or 100 
µg/ml of holo-rhLF or 10 mM LiCl for 15 minutes or 100 ng/mlWnt3a for 6 hours.  Total 
protein was extracted and western blot analysis was performed as described in Appendix 
of Protocols (Section 7.2.2.3). 
4.3.2.1.5.1.1.2 Time course of β catenin expression 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media.  Cells were then maintained in serum-free basal media 
overnight and the cell culture was then performed upon supplementation with 100 µg/ml 
of holo-rhLF for 0, 0.25, 1, 3, 6 and 24 hours.  Total protein was extracted and western 
blot analysis was performed as described in Appendix of Protocols (Section 7.2.2.3). 
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4.3.2.1.5.1.2 Nuclear/cytoplasmic β catenin expression 
4.3.2.1.5.1.2.1 Western blot 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media.  Cells were then maintained in serum-free basal media 
overnight and the cell culture was then performed upon supplementation with 0 or 100 
µg/ml of holo-rhLF for 24 hours.  Total protein was extracted, nuclear and cytoplasm 
fractions were separated and western blot analysis was performed as described in 
Appendix of Protocols (Sections 7.2.2.3 and 7.2.2.4). 
4.3.2.1.5.1.2.2 Immunocytochemistry 
MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2 
days in basal media and then serum starved for 6 hours.  Cells were either untreated 
(control) or stimulated with varying iron saturations of 100 μg/ml rhLF for 24 hours.  
Immunocytochemistry was performed as described in Appendix of Protocols (Section 
7.2.2.5). 
4.3.2.1.5.2 RNA expression 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media.  Cells were then maintained in serum-free basal media 
overnight and the cell culture was then performed upon supplementation with 0 or 100 
µg/ml of holo-rhLF for 0, 12 and 24 hours.  RNA was extracted, purified and PCR 
analysis was performed as described in Appendix of Protocols (Section 7.3.2.2). 
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4.3.2.1.5.3 Inhibitor studies for signaling pathway probing 
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to 
90% confluence in basal media and then serum starved for overnight.  Inhibitor treatment 
of select inhibitors (100 ng/ml DKK1 and 30 µM H-89) for 2 hour was followed by 
treatment with 100 µg/ml rhLF, 100 ng/ml Wnt5a or 100 ng/ml BMP2 for 24 hours.  
Total protein was lysed from cells and western blot analysis was performed as described 
in Appendix of Protocols (Section 7.2.2.3). 
4.3.3 Results 
4.3.3.1 Anti-apoptotic effect of holo-rhLF toward MC3T3 cells 
We investigated the ability of holo-rhLF to protect the cells against serum starvation–
induced apoptosis.  MC3T3 cell apoptosis was significantly reduced by 100 µg/ml holo-
rhLF over the course of 3 days, as evidenced by the increased ratio of live to dead cells in 
the holo-rhLF treated sample relative to control (Figure 31).  Furthermore, holo-rhLF 
treatment (24 hours) increased Akt phosphorylation over control (Figure 32). 
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Figure 31.  Viability of serum starved MC3T3 cells after holo-rhLF treatment. 
Viability assay demonstrates increased live (green) cells relative to dead (red) cells after 
2 days in MC3T3 cells treated with 100 µg/ml holo-rhLF relative to untreated control 
during serum starvation.  
 
 
Figure 32.  Increased phosphorylation of Akt in MC3T3 cells after holo-rhLF treatment. 
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Immunofluorescence showing the phosphorylation of Akt (FITC-labeled secondary 
antibody) in MC3T3 cells treated with 100 µg/ml holo-rhLF treatment relative to 
untreated control after 24 hours.   Nuclei are stained with propidium iodide. 
 
To elucidate the mechanism by which LF promotes cell survival, Wnt-mediated 
signaling transduction pathway array was used (Figure 33). Interestingly, Wnt5a was 
stimulated 3.8—fold upon 24-hour holo-rhLF treatment.   A signaling pathway reported 
to be mediated by Wnt5a’s anti-apoptotic effects is the protein kinase A (PKA)/ cAMP 
response element binding protein (CREB) (Torii et al. 2008).   Next, we used PKA 
inhibitor, H89, and Akt inhibitor, LY294002, to probe these signaling pathways (Figure 
34).   We found that rhLF’s increase phosphorylation of Akt was inhibited by both H89 
an LY294002 – implicating the dependence of both pathways for holo-rhLF’s 
phosphorylation of Akt.   Caspase 3 activity, a marker of cellular apoptosis, was 
decreased upon rhLF treatment and then significantly increased upon H-89 inhibitor 
treatment – confirming the dependence of rhLF/PKA pathway for cell survival (Figure 
35). 
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Figure 33.  Regulation of Wnt signaling pathway in MC3T3 cells by holo-rhLF. 
Wnt Signalling Array was utilized to examine the effect of 100 µg/ml holo-rhLF treatment 
(y-axis) relative to untreated control (x-axis).   Greater than or equal to 2-fold change 
over control was considered to be significantly regulated. 
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Figure 34.  30 µM H89 and 10 µM of LY294002 inhibited holo-rhLF-induced 
phosphorylation of Akt in MC3T3 cells after 24 hours. 
Wnt5a was used as a positive control.  Anti-tubulin blot was used as a loading control.  
 
 
Figure 35.  Caspase-3 activity after 24 hours of holo-rhLF treatment with signaling 
pathway inhibitors, H89 and LY294002. 
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100 ng/ml Wnt-5a and 50 µM Z-FAD-FMK were used as positive controls.  Anti-tubulin 
blot was used as a loading control. 
 
4.3.3.2 Osteogenic effect of holo-rhLF towards MC3T3 cells 
Osteoblast differentiation and mineralization is crucial for a bone regenerative 
biomaterial.  Alkaline phosphatase activity, an early marker of osteoblast differentiation, 
was significantly increased by 100 and 1000 µg/ml holo-rhLF treatment over 14 and 21 
days of MC3T3 culture (Figure 26).    Matrix deposition, a later marker of differentiation, 
was studied through calcium deposition – which also showed at 14 to 21 days of culture 
(Figure 27).  Moreover, 100 and 1000 µg/ml holo-rhLF treatment demonstrated a 
statistically significant increase during the late stage of culture, 14 and 21 days over the 
control. 
4.3.3.2.1 rhLF increases osteogenesis via β catenin signaling pathway. 
The potency of LF’s anabolic actions on the skeleton requires better 
understanding of its molecular mechanisms.  However, the mechanisms and cell 
signaling pathways involved in the transduction of LF’s growth-modulating effects on 
osteoblasts have not yet been comprehensively studied.  We hypothesize osteogenic 
actions induced by rhLF is transduced via β catenin-dependent signaling pathway.  Holo-
rhLF treatment has also been demonstrated to increase phosphorylation of Disheveled 2 
and Gsk3β (Figure 36).  Furthermore, holo-rhLF significantly increased the activation 
(de-phosphorylation) of β catenin relative to untreated control (Figure 37).   This 
accumulation of β catenin was seen in both the nuclear and cytoplasmic fractions (Figure 
38 & 39).  
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Figure 36.  Increased β catenin signaling cascade by holo-rhLF treatment. 
100 µg/ml holo-rhLF increase Disheveled 2, Gsk3β phosphorylation and β catenin 
activation in MC3T3 cells after 24 hour treatment.   Anti-tubulin was used as a gel 
loading control.  100 ng/ml Wnt 3a and 10 mM LiCl were included as positive controls.  
 
Figure 37.   Active βcatenin expression induced in MC3T3 cells by 100 μg/ml holo-rhLF. 
Cells were treated with 100 μg/ml holo-rhLF for 0.25 – 24 hours of treatment in culture.  
Anti-tubulin blot was used as a loading control. 
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Figure 38.  Increased accumulation/activation of β catenin in nucleus and cytoplasm of 
rhLF treated MC3T3 cells after 24 hours treatment. 
10 mM LiCl treatment was used as positive control of activation of β catenin.  Anti-actin 
blot was used as a loading control.  Anti-tubulin was used to test for nuclear/cytoplasmic 
contamination. 
 
Figure 39.  Increased β catenin in MC3T3 cells treated with 100 µg/ml holo-rhLF. 
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10 mM LiCl treatment was used as a positive control for activation of β catenin.  Cells 
were treated for after 24hours.  Propidium iodide was used to stain cell nuclei. 
 
 
Figure 40.  mRNA expression of LRP receptors after holo-rhLF treatment. 
β catenin, LRP1, LRP6 mRNA expression was significantly up-regulated by 100 µg/ml 
holo-rhLF treatment after 24 hours. 
 
Wnt-mediated signaling transduction pathway array demonstrated a significant 
increase in LRP6 and Dvl2 upon 24 hours of rhLF treatment relative to untreated control 
(Figure 33).  Non-canonical Wnt5a was up-regulated, while canonical Wnts, Wnt2 and 3, 
were down-regulated by rhLF treatment.  LRP6 up-regulation in MC3T3 cells was also 
demonstrated through PCR analysis after 24 hours of 100 µg/ml holo-rhLF treatment 
(Figure 40).  Similarly, β catenin and LRP1 (a known putative receptor of LF) were also 
up-regulated by holo-rhLF treatment.  However, LRP5, a co-receptor of the canonical 
Wnt signaling pathway was not found to be significantly up-regulated (Figure 40).   
In our next study, pharmacological inhibitors, DKK1, and H89 were used to 
inhibit the targeted pathways of LRP6 and PKA, respectively (Figure 41).  rhLF’s 
increased phosphorylation of LRP6 and activation of β catenin was inhibited by both 
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DKK1 and H89.   This data suggests the activation of β catenin by rhLF to be dependent 
on PKA/LRP6 signalling pathway. 
 
Figure 41.  Inhibitor studies (30 µM H89 and 100 ng/ml DKK1) to understand the 
osteogenic pathways and β catenin activation. 
Inhibitor experiments were performed for 24 hour stimulation of rhLF.  Wnt5a and BMP2 
were used as positive controls. Anti-tubulin blot was used a loading control. 
 
4.3.4 Discussion 
Our studies demonstrated strong protection against serum starvation-induced 
apoptosis by holo-rhLF treatment in MC3T3 cells after 3 days (Figure 31) and also 
increased phosphorylation of Akt (Figure 32).  Akt was used as a marker of cell survival 
since a common mechanism by which growth factors promote cell survival is PI3K-
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dependent, Akt phosphorylation.  However, the anti-apoptotic properties of bLF have 
been demonstrated to increase LRP1-independent, PI3K/Akt phosphorylation (Grey et al. 
2006).  A previous study has reported that this increased phosphorylation of Akt is not 
required by LF to prevent programmed cell death (Grey et al. 2006).  Thus, the 
mechanism by which LF prevents cellular apoptosis has not been clearly understood.  
PI3K/Akt and PKA signaling transduction pathways are generally strongly 
associated anti-apoptotic pathways.  Interestingly, previous studies have demonstrated 
PI3K/Akt pathway to be activated by Wnt5a treatment (Kawasaki et al. 2007).  
Furthermore, non-canonical Wnt5a has been shown to prevent serum starvation-induced 
osteoblast apoptosis via Src/Erk and PI3K/Akt-dependent mechanism (Almeida et al. 
2005).  LF promotes survival of osteoblasts in vitro, but these actions are independent of 
Erk/MAPK pathway, which subserves its proliferative actions (Grey et al. 2006).   
The Wnt family is comprised of 19 secreted glycoproteins and play essential roles 
in embryonic patterning, cell apoptosis, proliferation and differentiation (Logan, Nusse 
2004, Miller 2002, Moon et al. 2002, Wodarz, Nusse 1998).   In our studies, we utilized a 
Wnt signaling array as a tool to elucidate the regulation of Wnts induced by holo-rhLF 
treatment in MC3T3 cells (Figure 33).   This array was especially selected since the Wnt 
family of secreted growth factors are known to regulate developmental processes, 
including cell survival (Almeida et al. 2005).  The only Wnt molecule that was found to 
be up-regulated upon holo-rhLF treatment in MC3T3 cells was Wnt5a.  A signaling 
pathway reported to be mediated by Wnt5a’s anti-apoptotic effects is the PKA/CREB 
(Torii et al. 2008).  The use of H89 pharmacological inhibitor allowed for confirmation of 
holo-rhLF’s regulation of PKA (Figure 34).  We checked CREB phosphorylation, the 
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downstream signaling molecule of PKA, to confirm inhibition of PKA by H89 inhibitor.  
We included Akt inhibitor, LY294002, in our studies to confirm the previously published 
results by Grey et al. that reported that LF’s anti-apoptotic properties are not dependent 
on Akt phosphorylation (Grey et al. 2006).   Wnt5a was used as a positive control for Akt 
phosphorylation in MC3T3 cells.   Interestingly, Akt inhibitor, LY294002, inhibited both 
holo-rhLF and Wnt5a phosphorylation of Akt.  This data confirms that Wnt5a treatment 
of MC3T3 cells induces Akt phosphorylation – since cells that were co-treated with 
Wnt5a and LY294002 inhibitor did not display increased phosphorylation of Akt.  
Furthermore, PKA inhibitor, H89, also inhibited both holo-rhLF and Wnt5a 
phosphorylation of Akt.  These results confirmed that upon Wnt5a treatment in MC3T3 
cells, PKA activation signals downstream to phosphorylate Akt.  Similarly, upon holo-
rhLF treatment, PKA signals downstream to phosphorylate Akt.  In our next experiment, 
we used caspase 3 activity as an indicator for cellular apoptosis upon inhibition with 
LY294002 and H89 and stimulation with Wnt5a and holo-rhLF (Figure 35).   This 
informative study demonstrated Wnt5a and holo-rhLF to be potent anti-apoptotic 
molecules.  Furthermore, with LY294002 inhibition of Akt, a partial rescue of caspase 3 
activity was induced by Wnt5a and holo-rhLF treatment.   But with H89 inhibition, no 
rescue of caspase activity was induced by Wnt5a and holo-rhLF.  This proved that cell 
survival mechanism of induced by both holo-rhLF and Wnt5a is dependent on PKA 
signaling. 
 The molecular mechanisms underlying the osteogenic properties of holo-
rhLF has been long in question.  Wnt molecules are secreted growth factors are known to 
regulate osteogenic pathways.  Various combinations of Wnts and Fzds transduce two 
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distinct intracellular signaling pathways – “canonical” and “non-canonical” Wnt 
pathways.  The canonical Wnt signaling pathway is centered on the regulation of 
cytoplasmic β catenin levels.  Whereas, non-canonical Wnt pathway is typically 
characterized as β catenin-independent signaling often involving Fzd receptors, but not 
LRPs or TCF/LEF factors. Key Wnt members in the canonical pathway, which include 
Wnt 1, 3a and 8, transduce their signals and play a crucial role in controlling cell 
proliferation and differentiation.  Central to the canonical pathway is the regulation of β 
catenin activity, which depends on its protein cytoplasmic abundance and nuclear 
localization.  The activation of the canonical Wnt pathway is initiated with the activation 
of Disheveled, which leads to the inhibition of Gsk3β and subsequent stabilization of β 
catenin.   Accumulation of β catenin in the cytoplasm prompts its translocation to the 
nucleus, where it interacts with members of the TCF/LEF family of transcription factors 
and induces the transcription of Wnt target genes.  Canonical Wnt signaling controls gene 
expression by allowing β catenin to accumulate when Wnts are present and by reducing 
nuclear β catenin levels when Wnts are absent (Peifer, Polakis 2000, Chan, Struhl 2002, 
Sakanaka, Weiss & Williams 1998).  Interestingly, in our studies, we found that rhLF 
treatment induced significant accumulation of β catenin but down-regulated canonical 
Wnts – Wnt2 and 3.  Other canonical Wnts, which include Wnt1 and 8, were not found to 
be significantly regulated (< 2-fold change) in MC3T3 cells by holo-rhLF.   
Non-canonical Wnt pathways are thought to involve Wnt/Ca2+ (Veeman, Axelrod 
& Moon 2003, Kuhl et al. 2000, Ma, Wang 2006, Slusarski, Corces & Moon 1997) or the 
Wnt/planar cell polarity (PCP) (Veeman, Axelrod & Moon 2003, Adler, Lee 2001) or 
other less well-defined pathways (Logan, Nusse 2004, Miller 2002, Moon et al. 2002, 
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Wodarz, Nusse 1998, Veeman, Axelrod & Moon 2003).  Wnt5a has been considered to 
be a representative non-canonical Wnt in several systems, which include stimulation of 
intracellular Ca2+ release and activation of PKC and CaMKII (Kuhl et al. 2000, Sheldahl 
et al. 1999).  Non-canonical Wnt5a has also been suggested to antagonize canonical Wnt 
activity in mammalian cells (Torres et al. 1996, Olson, Gibo 1998, Ishitani et al. 2003).  
However, direct genetic evidence for this antagonistic interaction is lacking (Topol et al. 
2003).  Furthermore, even though Wnt5a signaling has been shown to support normal 
bone physiology, the biological significance of non-canonical Wnts in osteogenesis is 
essentially unknown.  It has been just recently found that Wnt5a is a substantial 
constituent in BMP2-mediated osteoblast differentiation (Nemoto et al. 2012).  
Osteoblastic differentiation mediated by BMP2 is associated with increased expression 
of Wnt5a and Ror2 in MC3T3 cells. After silencing the gene expression of Wnt5a and 
Ror2 in MC3T3 cells, there was suppression of BMP2-mediated osteoblastic 
differentiation, which suggests that Wnt5a and Ror2 signaling are of substantial 
importance for BMP2-mediated osteoblastic differentiation (Nemoto et al. 2012).  
Our studies demonstrated that LRP6 and Wnt5a were upregulated upon 24 hours 
of rhLF treatment relative to untreated control (Figure 33).  Although Wnt5a and LRP6 
were not previously thought to interact, recent reports have shown that LRP6 can affect 
typical non-canonical Wnt processes.  These interactions have been shown to modulate 
Wnt5a-regulated processes in both Xenopus and mouse (Tahinci et al. 2007, Bryja et al. 
2009).  Furthermore, non-canonical Wnt signaling and β catenin signaling play a role in 
mechanically induced osteogenic cell fate (Arnsdorf, Tummala & Jacobs 2009).  Wnt5a 
treatment has also been shown to increase integrin expression.  Wnt5a enhances 
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osteogenesis through a positive feedback mechanism with integrins through BMP2 
signaling (Olivares-Navarrete et al. 2011).  In this study, scientists demonstrated the 
treatment of HMSCs with Wnt5a increases integrin expression and osteoblast 
differentiation.  Furthermore, these results were confirmed using Wnt5a-knockdown 
HMSCs – where integrin expression on rough surfaces was decreased. 
Biological growth factors, such as parathyroid hormone (PTH), has demonstrated 
PKA/LRP6-dependent signalling to increase bone formation in osteoblasts.  Teriparatide, 
which has the identical sequence of biologically active region of recombinant human 
PTH, is FDA-approved as Forteo® for treatment of osteoporosis or high-risk fracture 
patients (Sibai, Morgan & Einhorn 2011).  Studies have demonstrated the intermittent 
administration of PTH stimulates bone formation, but the precise mechanisms 
responsible for PTH responses in osteoblasts are incompletely understood.  PTH, via the 
PTH/PTH-related protein receptor type 1 (PTH1R), couples to the PKA and the canonical 
Wnt/β catenin signaling pathway play important roles in bone formation. This study 
further utilized H89 inhibitor to confirm the involvement of PKA in PTH signalling, 
antagonized PTH stimulation of β catenin levels (Tobimatsu et al. 2006).  Studies have 
also reported that PKA (Fang et al. 2000) has the ability to stabilize β catenin by 
phosphorylating Gsk3β.  Furthermore, Fang et al. showed that PKA-mediated 
phosphorylation of serine 9 in Gsk3β activity and up-regulation of β catenin (Fang et al. 
2000).   
More recently, a study demonstrated that the binding of PTH to its receptor 
PTH1R induced association of LRP6 with PTH1R.  The formation of the ternary complex 
containing PTH, PTH1R, and LRP6 then promoted rapid phosphorylation of LRP6, 
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which resulted in the recruitment of axin to LRP6, and stabilization of β catenin (Wan et 
al. 2008).  This study demonstrated that activation of PKA is essential for PTH-induced β 
catenin stabilization.  In vivo studies confirmed PTH treatment increases LRP6 
phosphorylation and β catenin accumulation in osteoblasts with a concurrent increase in 
bone formation. These studies correspond with our findings of LF-induced, PKA/LRP6-
dependent β catenin stabilization.  
With the acknowledgment that osteoblast survival influences bone formation and 
skeletal integrity (Manolagas 2000, Weinstein et al. 1998), great likeliness is LF’s anti-
apoptotic activity plays a role in its ability to stimulate bone formation in vivo (Grey et al. 
2006, Cornish et al. 2004).  In our studies, we found LF’s ability to activate β catenin and 
inhibit serum starvation-induced apoptosis to be both dependent on PKA signaling 
transduction pathway (Figure 42).  However, the receptor through which LF is activating 
PKA pathway is still unknown. 
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Figure 42.  Schematic of signaling pathways induced by holo-rhLF in MC3T3 cells. 
 
4.3.5 Conclusions 
The bioactivity of holo-rhLF was investigated in our in vitro cell culture model. 
Holo-rhLF treatment decreased cellular apoptosis in response to serum starvation.  
Furthermore, this bioactive protein up-regulated osteogenic markers, including collagen 1 
and OCN, in MC3T3 cells.  Our results demonstrated the novel discovery that holo-
rhLF’s anti-apoptotic actions and β catenin activation are dependent on PKA signaling 
cascade. 
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5 Preparation and characterization of injectable holo-
rhLF and gelatin gels 
5.1 Development and characterization of bioactive holo-rhLF 
injectable gel via enzymatic crosslinking 
5.1.1 Introduction 
Cell-based therapy has emerged as a promising strategy to repair and/regenerate 
lost, damaged or degenerative tissue using the principles of tissue engineering and 
regenerative medicine.  Pluripotent and multi-potent cells along with tissue-specific cells 
are being investigated to develop novel cell based regenerative therapies.  The therapeutic 
efficacy of local cell based strategies depends on several factors, including the ability to 
retain implanted cells at the defect site and present the cells in a three-dimensional 
manner without adversely affecting its performance (Zhao et al. 2011).  Hydrogels are 
promising candidates due to their unique tissue-mimetic properties and their ability to 
allow gas and nutrient diffusion throughout the matrix, which is crucial for maintaining 
the viability of the encapsulated cells (Nicodemus, Bryant 2008, Annabi et al. 2010). 
Eventhough both performed and injectable hydrogels have been considered for 
biomedical applications, injectable gels are preferred as cell delivery vehicles – as 
discussed previously in Section 2.1.2.2.1.  Injectable scaffolds undergo mild and 
cytocompatible gelation, allow for homogeneous distribution of cells or molecules at the 
injection site, and have the ability to fill irregular defects (Slaughter et al. 2009).  
Moreover, they can be implanted by simple injection (Yu et al. 2008).  Various polymers 
with stimuli sensitive properties and novel cross-linking chemistries are investigated to 
develop injectable hydrogels (Hennink, van Nostrum 2002).  These include thermo-
sensitive and pH-sensitive polymers, which can undergo sol-gel transition at or near 
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physiological conditions (Nair et al. 2007, Jiang et al. 2008),  self-assembling peptides 
(Kopecek, Yang 2009), photo or thiol-mediated polymerization of acrylated polymers 
(Rydholm, Bowman & Anseth 2005) and enzyme-mediated crosslinking of polymers 
with appropriate functional groups (Davis et al. 2010).  Polymers functionalized with 
tyramine, tyrosine or aminophenol side groups can form in situ gels by phenol or aniline 
derivative coupling using H2O2 and HRP as the oxidant and enzyme, respectively 
(Kurisawa et al. 2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007, Lee, Chung & 
Kurisawa 2009).  This biologically compatible system has several advantages as the 
physical properties of the gel may be fine tuned by varying the degree of tyramine 
substitution, polymer and enzyme concentration (Jin et al. 2010, Sakai et al. 2009, Hu et 
al. 2009, Darr, Calabro 2009).  
The objective of this study was to investigate the feasibility of developing 
injectable hydrogels from holo- rhLF gel and characterize the gel properties in terms of 
its gelation time, mechanical properties, water uptake and morphology.  An 
understanding of the physical properties of gels is crucial for determining the range of 
their biomedical applications. Since LF-based biomaterials have been recently developed, 
the understanding of the structure-property relationships in this class of materials is 
limited. Such understanding would provide molecular design principles to tailor material 
properties, allowing the materials to be optimized for clinical applications or tuned 
systematically to address fundamental biological questions.  Depending on various 
parameters, such as the gelation mechanism and polymer concentration, the gels can 
exhibit different mechanical properties.  We hypothesize that varying concentrations of 
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the gel precursors, HRP, modified rhLF and H2O2, will directly affect the gelation rate, 
mechanical strength and morphology of the rhLF gels.  
 
5.1.2 Methods 
5.1.2.1 Synthesis of holo-rhLF tyramine conjugates (modified holo-rhLF) 
Modified holo-rhLF was prepared as described in Appendix of Protocols (Section 
7.9.2.1.1).  
5.1.2.2 Preparation of holo-rhLF gels 
Holo-rhLF gels were prepared by the HRP-mediated oxidative coupling of modified 
holo-rhLF molecules in the presence of H2O2 as described in the Appendix of Protocols 
(Section 7.9.2.1.2.2).  Various concentrations of modified holo-rhLF ranging from 10 
mg/ml to 50 mg/ml were dissolved in 10 U/ml HRP and gelation was initiated by the 
addition of 0.25% aqueous H2O2. 
5.1.2.3 Quantification of tyramine modification 
Holo-rhLF was modified with varying reaction times (0.5 – 24 hours) and tyramine 
concentration was then examined as a function of modification reaction time as described 
in Appendix of Protocols (Section 7.9.2.1.1.1).  A tyramine standard curve was used to 
determine the concentration of a tyramine in the modified holo-rhLF samples. 
5.1.2.4 Gelation time 
Sol to gel time was determined via vial inversion method.  The effect of modified holo-
rhLF (10 – 50 mg/ml), HRP (10 – 50 U/ml) and 0.25% H2O2 (1 - 10 µl) concentration on 
gelation time was investigated.  10mg/ml modified holo-rhLF in 100 µl of 10/ml U HRP 
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+ 1 µl of 0.25% H2O2 represents the standard gelling conditions.   Variables were 
individually varied and tested for effect on gelatin time. 
5.1.2.5 Soluble holo-rhLF protein release from holo-rhLF gel 
10 mg/ml holo-rhLF gel was incubated in PBS at 37oC.  Aliquots were taken from each 
sample every 24 hours for 5 consecutive days and phenolic content was measured via UV 
spectrophotomer at 275 nm.  Details of the protocol were described in Section 7.9.2.3. 
5.1.2.6 Percentage water uptake 
The percentage of water uptake of the injectable gels was determined as described in 
Appendix of Protocols (Section 7.9.2.2.4).  Briefly, 400 µl of holo-rhLF gel were 
prepared in 24-well plastic inserts (n=4). 
5.1.2.7 Morphology 
The morphology of the holo-rhLF gels formed from modified holo-rhLF solutions of 
different concentrations (10, 25, 50 mg/ml) was visualized by scanning electron 
microscope (JEOL 6335 Field Emission Scanning Electron Microscope) to evaluate the 
effect of solution concentrations on gel microstructure – as described in Appendix of 
Protocols (Section 7.9.2.2.3).  Measurements (n=50) of pore size and pore wall width 
were obtained using Image J program. 
5.1.2.8 Rheological analysis 
A rheometer is an ideal instrument that may be used to measure the gel strength.  The 
holo-rhLF gels were subjected to rheological measurements to assess the viscoelastic 
properties at varying component concentrations at 25ºC and 37ºC.   Briefly, the modified 
holo-rhLF/HRP and H2O2 mixture were introduced in a parallel plate rheometer (ARES-
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LS, TA instruments).  Stress sweeps at a constant frequency of 1 Hz were first performed 
to obtain the linear viscoelastic region for collecting subsequent data. Dynamic frequency 
sweeps were then performed in the linear viscoelastic region to determine values of the 
storage (G’) and loss (G”) modulus to compare the mechanical strength of gels with 
different concentrations of holo-rhLF.   
5.1.2.9 Biomaterial degradation in vivo 
Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) (12-16 weeks) were 
used. 10 mg/ml holo-rhLF were injected subcutaneously to form the gels in situ. The 
animals were cared for according to the procedures approved by the Animal Care and 
Use Committee at the University of Connecticut Health Center, and following the 
guidelines established by the U.S. National Institutes of Health.  At 4 and 12 weeks, rats 
were sacrificed and the tissue surrounding the injection sites were excised using blunt 
dissection technique.  Samples were fixed in 10% formalin solution (Surgipath, USA) 
and embedded in paraffin, sectioned and hematoxylin and eosin (H&E) was performed. 
5.1.3 Results 
We investigated tyramine concentrations as a function of chemical modification 
time.  The phenolic content of unmodified holo-rhLF is due to the presence of tyrosine.   
After 24 hours of tyramine modification, the phenolic concentration increased from 0.158 
µg/ml to 0.181 µg/ml.  This increase in phenolic concentration of the modified holo-rhLF 
led to decreased gelation time as in the case of bLF gel (Section 3.1.3.1) (Figure 43).  
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Figure 43.  Inverse effect of tyramine modification time (over 24 hours) on phenolic 
content and gelation time of rhLF.  
The standard gel precursor concentrations, 10 mg/ml modified rhLF dissolved in 100 µl 
of 10 U/ml HRP plus 1 µl of 0.25% H2O2, were used to test gelation time. 
 
 Sol-to-gel time of the holo-rhLF gels was determined via vial inversion method 
(Figure 44).  The flexibility of fast or slow gelation time is possible through the 
manipulation of the concentration of the gel precursors – HRP, modified holo-rhLF and 
H2O2 (Figure 45).  HRP and holo-rhLF polymer concentration had a direct effect on 
gelatin time, whereas, H2O2 concentration did not have this similar trend on gelation 
time.  Lower amounts of H2O2 (0.5-5 µl of 0.25% H2O2) decreased gelation time of holo-
rhLF gel; whereas, higher amounts of H2O2 (10 µl of 0.25% H2O2) actually increased the 
gelation time.  Based on the study, the standard precursor concentrations was determined 
as follows: modified rhLF (10 mg/ml) dissolved in 100 µl of 10 U/ml HRP and 1 µl of 
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0.25% H2O2 in water/PBS mixture– these conditions yielded a gelation time of 
approximately 1 minute. 
 
 
 
Figure 44.  Gelation time of rhLF gel upon addition of dilute H2O2 as determined by the 
vial inversion technique. 
 
 
Figure 45.  Effect of gel precursors (modified rhLF, HRP, H2O2) concentration on 
gelation time. 
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The standard conditions for approximately 1 minute gelation time is 10 mg/ml modified 
rhLF dissolved in 100 µl of 10 U/ml HRP plus 1 µl of 0.25% H2O2.  To study the effect of 
each gel component, one component was varied and the concentrations of other 
components were held at the standard conditions. 
 
 To test whether a substantial amount of polymer was un-crosslinked, we 
measured the amount of protein that was released (un-crosslinked polymer) from the gel 
into PBS buffer over 5 days at 37°C (Figure 46).  After 24 hours, only 4.2 ng/ml of 
protein was released from 10 mg/ml holo-rhLF.  By 5 days, a cumulative amount of 10.1 
ng/ml of modified holo-rhLF protein was released in the PBS buffer.  The study 
demonstrated that enzyme mediated crosslinking of modified rhLF lead to a fully 
crosslinked matrix   
 
 
Figure 46.  Soluble holo-rhLF release from crosslinked 10 mg/ml holo-rhLF gel as a 
function of time. 
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The crosslinked rhLF gel displayed a highly porous microstructure as indicated in 
Figure 47 and Figure 48).  Changes in holo-rhLF polymer, HRP enzyme and H2O2 
oxidant concentrations did not result in a significant change in pore size of the 
crosslinked gel (Figure 48).  The average pore size of holo-rhLF gels was 8.51 ± 2.97 
µm. Figure 45 shows the storage modulus of the gel as a function of rhLF concentration.  
An increase rhLF polymer concentration led to corresponding increase in storage 
modulus, G’ (Figure 49). rhLF gels with polymer concentrations of 10, 25, 50 mg/ml 
resulted in storage moduli of  102.8 ± 8.5, 429.2 ± 31.8, 997.9 ± 204.6 Pa, respectively.  
We also investigated the effect of gelation temperature on the storage modulus of the 
gels.  As shown in Figure 45b, the 50 mg/ml holo-rhLF gels formed at temperatures of 
25°C and 37°C showed storage moduli of 997.9 ± 204.6 Pa and 899.8  ± 93.4 Pa, 
respectively, indicating that temperature of gelation does not have any effect on gel 
mechanical properties. 
Figure 47.  Morphology of 10 mg/ml holo-rhLF gel. 
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Figure 48.  Morphology of holo-rhLF gel at various gel precursor concentrations  
 
 
Figure 49.  A) Effect of holo-rhLF polymer concentration on hydrogel mechanical 
strength as a function of storage moduli, G’.  B) Effect of temperature (25°C vs. 37°C) on 
storage moduli, G’, of 50 mg/ml holo-rhLF gel. 
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Data is expressed in Pascal (Pa).  * indicates p<0.05; # indicates p>0.05 
 
Another physical property investigated was the extent of water uptaken by the 
gels.  Figure 50 shows the extent of water uptake of gels made from different polymer 
concentration.  Although there was a trend towards increasing water uptake as the 
polymer concentration increased, there was no statistically significant differences 
between the weights of the gels at 0 day and after 8 days of incubation in buffer (Figure 
50-52).    Similar trends were observed with gels prepared at different HRP and H2O2 
concentration (Figure 51 &52).  No significant increase in water uptake was observed 
with any of the gels as a function of incubation time in PBS.    
 
Figure 50.  Effect of holo-rhLF concentration on holo-rhLF gel water uptake over 8 days. 
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Figure 51.  Effect of HRP concentration on holo-rhLF gel water uptake over 8 days. 
 
 
Figure 52.  Effect of H2O2 concentration on holo-rhLF gel water uptake over 8 days. 
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Figure 53 shows the H&E-stained subcutaneous tissue surrounding the gel (10 
mg/ml holo-rhLF gel) implantation 4 and 12 weeks past implantation.  At 4 weeks, the 
presence of injectable gel was evident at the site of injection.  Significant cell infiltration 
mainly composed of macrophages and lymphocytes was observed within the gel.  
Interestingly, no sign of fibrous capsule formation was observed. At 12 weeks post 
implantation, the no evidence of gel was observed in the subcutaneous tissue indicating 
the complete degradation of the gel at that time point.    
 
Figure 53.  In vivo degradation of 10 mg/ml holo-rhLF gel in rat subcutaneous tissue 
after 4 and 12 weeks. 
 
Attempts were also made to characterize the ability of rhLF gel to serve as a cell 
delivery vehicle.  Cell delivery vehicle should be able to encapsulate cells under 
physiological condition, support cell adhesion, spreading and proliferation.  Figure 54 
shows the Live/Dead staining of MC3T3 cells encapsulated in holo-rhLF gels.  Three 
different rhLF gel concentration was studied to understand the effect of polymer 
concentration on cell behavior.  As shown in the figure, irrespective of the polymer 
concentration, rhLF gels were able to maintain MC3T3 cell viability.  However, the 
extent of cell spreading and proliferation seems to be negatively affected by increase in 
	   186 
polymer concentration.   Among the samples studied, 10 mg/ml holo-rhLF gel allowed 
for the most extensive cell spreading after 14 days of encapsulation.  
 
 
Figure 54.  Cellular spreading in 10, 25 and 50 mg/ml holo-rhLF gel over 14 days of 
encapsulation using live/dead assay. 
 
5.1.4 Discussion 
In situ formation of injectable biomaterials allows for the biomaterial to fill 
irregular 3D shapes of clinically relevant defects.  The synthesis of our in situ—forming, 
biodegradable holo-rhLF crosslinked gel utilizes modified rhLF.  Standard carbodiimide 
mediated coupling of amino groups of tyramine with the carboxyl groups of holo-rhLF 
was used to develop the modified rhLF (Sakai et al. 2009, Amini, Nair 2012b).  Although 
holo-rhLF contains phenolic amino acids, such as tyrosine, the phenolic content holo-
rhLF is much lower than what is needed to develop an effectively crosslinked matrix via 
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the enzyme-catalyzed coupling.  The reaction of holo-rhLF with tyramine could increase 
the extent of polymer cross-linking by increasing the number of phenolic groups (Figure 
11, Figure 12).  Since there is significant species homology between bLF and hLF (van 
Berkel et al. 2002) (Figure 1), the substitution process of hLF similar to that used for 
developing bLF (section 3.1.3.1).  Holo-rhLF gels were obtained by enzymatic 
crosslinking of the modified holo-rhLF in the presence of HRP, as the catalyst, and H2O2, 
as the oxidant (Figure 13).   Enzymatic crosslinking driven by HRP and H2O2 allows for 
a mild, cell-friendly gelation process.  The advantages of HRP-mediated crosslinking 
include its ability to take place at physiological pH and temperature.  Moreover, the 
gelation time can be modulated to a great extent by varying the reagent concentrations, 
making this a potential route to form injectable cell and protein delivery vehicles (Sakai 
et al. 2009, Hu et al. 2009, Amini, Nair 2012b).   
Gelation time of HRP-mediated enzymatic crosslinking of holo-rhLF yields a 
protein-based hydrogel that may be controlled by the concentration of the reactants.  
Although increased concentration of modified holo-rhLF (polymer) and HRP (catalyst) 
led to decreased gelation time of holo-rhLF gel – this effect was not seen with the 
increase of H2O2 (oxidant).  It has been reported that HRP can be oxidized to an 
inactivated form upon exposure to an excess amount of H2O2 (Arnao et al. 1990, Baynton 
et al. 1994).  Moreover, the use of low amounts of H2O2 is advantageous, since H2O2 may 
give cytotoxicity problems.  Fast gelation time is preferred especially for in situ—
forming gels, since slow gelation in vivo may result in diffusion of gel precursors or 
bioactive molecules to the surrounding areas or failure of gel formation.  The optimal 
gelation time was determined to be in the range of 1 minute. 
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Storage moduli of biomaterials has been shown to have an influence on several 
cellular behaviors, including cell adhesion, spreading, proliferation, morphology and 
differentiation of stem cells (Lo et al. 2000, Pelham, Wang 1997, Cukierman et al. 2001).  
Previous data reports a wide range in substrate stiffness with a soft gel (1 kPa), a stiff gel 
(8 kPa), and a rigid substrate (66 kPa) (Engler et al. 2004).  The degree of stiffness in 
physiological human tissue varies dramatically between tissues: brain is about 0.1-1 kPa; 
striated skeletal muscle is approximately approximately 8-17 kPa and pre-calcified bone 
is 25-40 kPa (Engler et al. 2006, Tse, Engler 2010).  Human bone exhibits unique 
mechanical properties – both elastic and semi-brittle behavior.  There are two types of 
bone, compact or cortical, and cancellous or trabecular (spongy) bone.  Compact and 
trabecular bone have mechanical strengths in the range of 131 - 224 MPa and 5 – 10 
MPa, respectively (Yaszemski et al. 1996, Athanasiou et al. 2000, Currey 1998, Currey 
1970, Currey 1999). However, the storage modulus of holo-rhLF gels (10-50 mg/ml) was 
in the range of 100-1000 Pa.  The low storage modulus of holo-rhLF makes it an 
excellent cell delivery vehicle for non-load bearing applications and for load bearing 
applications with external support.  
Another very important parameter that needs to be evaluated while developing an 
injectable biomaterial is the extent of water uptake of the formed gel once exposed to 
aqueous environment.  Significant water uptake of the gel can adversely affect the 
performance of the injectable gel.  As in the case of mechanical properties, several 
parameters, such as polymer concentration and cross-linking density, can directly affect 
the extent of water uptake.   In our gel studies, holo-rhLF gels demonstrated water uptake 
percentage of about 10% of original gel weight after 8 days of PBS buffer incubation at 
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37°C physiological temperature.  This percentage of water uptake did not seem to 
adversely affect the performance of the encapsulated cells. 
Biomaterial morphology is an important characteristic to investigate when 
designing a cell delivery vehicle.  Hydrogels are porous biomaterials that allow for in 
situ-delivery of encapsulated cells.  Porous interconnectivity also allows for uniform cell 
seeding and necessary diffusion of nutrients and waste.  In our studies, all concentrations 
of holo-rhLF gel that were investigated displayed a porous interconnected structure.  
Osteoblasts require a delivery vehicle that not only maintains cell viability but 
also supports cell attachment and spreading for three-dimensional cellular organization. 
The highly porous structure of holo-rhLF gel allowed for cellular spreading, which was 
inversely regulated with polymer concentration of the gel (Figure 54). Decreased cell 
spreading at high polymer concentration gels may be attributed to the decreased cell 
proliferation at higher concentrations (Huang et al. 2008).   Porous biomaterial hydrogels 
are favorable since they support vascular ingrowth for oxygen transport.  Pore size of 
holo-rhLF gel (10-50 mg/ml) was averaged at approximately 5-10 µm.  However, the 
average size of an osteoblast is approximately 20-25 µm (Puckett, Pareta & Webster 
2008).  Porosity and interconnected pores allow for the diffusion of nutrients and gases 
for enhancing cell viability.  In our cell encapsulation studies, holo-rhLF gel allowed for 
high percentage of live to dead cell ratio.  However, a decrease in cell spreading and 
density was seen in the MC3T3 cells encapsulated in 50 mg/ml holo-rhLF gel (relative to 
10 and 25 mg/ml holo-rhLF gel).  As described below, these results may be explained 
through a variety of different reasonings – decrease cell spreading and density due to 1) 
increased mechanical strength decreasing cell proliferation and spreading or 2) high 
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concentration holo-rhLF adversely affecting the encapsulated cell proliferation and 
spreading. 
Hydrogels, which may act as the ECM that surrounds encapsulated cells, are 
known to contain biochemical information that may regulate cell functions, including 
adhesion, spreading, migration, proliferation, survival, and differentiation (Khatiwala, 
Peyton & Putnam 2006).  A recent study reported an injectable HRP/H2O2 hydrogel 
scaffold system with tunable mechanical properties for controlling the proliferation rate 
and differentiation of human mesenchymal stem cells (Wang et al. 2010). The scientists 
found that the hydrogel stiffness inversely affected the cell proliferation rates – an 
increase in stiffness led to a decrease in cellular proliferation.    
Another possible reason for the decreased cell spreading in holo-rhLF gels of 
higher LF concentrations is that LF being a bioactive protein can adversely affect cellular 
behavior.  In our studies, we only investigated the proliferative effect of 1000 µg/ml holo-
rhLF, which showed an increase in cell proliferation (Figure 19).  However, Huang et al. 
tested concentrations up to 50,000 µg/ml holo-rhLF in HT29 intestinal cells.  In these 
studies, holo-rhLF increase thymidine incorporation in HT29 cells at concentrations of 
10-1,000 µg/ml, however 10,000 and 50,000 µg/ml holo-rhLF treatment led to a 
significant decrease in thymidine incorporation (Huang et al. 2008).  The decrease in 
cellular performance at high concentrations of holo-rhLF treatments in Huang’s study 
may support our findings of decreased cell number and spreading at 50 mg/ml holo-rhLF 
gel.  
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5.1.5 Conclusions 
The study demonstrated the feasibility of developing injectable rhLF gels by the 
enzymatic coupling of tyramine-modified rhLF.  The gelation time of the gels 
significantly depended on the reagent concentrations.  Through the optimization of the 
concentrations of the gel components, a clinically viable gelation time of ~1 minute was 
developed.  However, the gel physical properties, such as morphology and water uptake, 
was not significantly affected by the change in reagent concentrations.  Increase in rhLF 
concentration significantly increased the storage modulus of the gels. Based on the 
storage modulus, the gels were characterized as soft gels.  rhLF-encapsulated MC3T3 
cells in various concentrations of rhLF gel maintained high viability, demonstrating the 
cyto-compatibility of the gels.  However, rhLF gels of higher concentration tended to 
decrease cell spreading and density.  Since even 50 mg/ml rhLF showed a porous 
structure and storage modulus, the decreased cellular activity in rhLF gels with higher LF 
concentrations is presumed to be due to the bioactivity of the gels. 
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5.2 Enzymatically crosslinked injectable gelatin gel as an 
osteoblast delivery vehicle 
5.2.1 Introduction 
The study discussed in section 5.1 demonstrated the feasibility of developing 
rhLF gel and the cytocompatibility of the gel as a potential cell delivery vehicle.  Based 
on the demonstrated bioactivities of rhLF (sections 4.1- 4.3), we hypothesize that rhLF 
gels will retain the unique bioactivities of soluble rhLF protein and could serve as a 
bioactive cell delivery vehicle with anti-apoptotic and osteogenic properties.  To 
demonstrate the bioactivity of rhLF gel towards encapsulated gel, a control gel system 
needs to developed.  The objective of the proposed study is to test if injectable gelatin gel 
may serve as a three dimensional control gel matrix to evaluate the bioactivity of rhLF 
gels.   
Injectable hydrogels based on proteins are highly preferred as they can favorably 
interact with the encapsulated cells via specific peptide epitopes and also undergo cell-
mediated enzymatic degradation (Nguyen, Lee 2010).  Therefore, ECM-derived proteins, 
such as collagen, gelatin, laminin and elastins are potential candidates to develop cell 
delivery vehicles (Stenzel, Miyata & Rubin 1974).  Compared to collagen, gelatin is more 
economical and possesses more integrin binding domains for cell attachment due to its 
less ordered structure.  Furthermore, gelatin is a denatured protein, making it less 
immune-reactive than collagen (Dreesmann, Ahlers & Schlosshauer 2007, Liu et al. 
2009, Spotnitz, Burks 2008).  The good cell-adhesivity of gelatin is particularly useful in 
developing cell delivery vehicles for anchorage dependent cells such as osteoblasts, 
epithelial cells and smooth muscle cells (Kwon, Peng 2002). 
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Several preformed and injectable gelatin formulations have been developed 
(Young et al. 2005, Singh et al. 2010, Lai, Li 2010, Kuwahara et al. 2010, Chen et al. 
2003).  These include chemical cross-linking using the carboxyl or amino groups of 
gelatin with polymers having appropriate reactive groups (Balakrishnan, Jayakrishnan 
2005), and photo cross-linking of acrylated gelatin either alone or in the presence of other 
biocompatible polymers.  Yamamoto et al. used glutaraldehyde to crosslink acidic and 
basic gelatins with iso-electric points of 5.0 and 9.0, respectively (Yamamoto, Takahashi 
& Tabata 2006).  The study demonstrated the ability of chemically crosslinked acidic 
gelatin gels to retain growth factors and function as a sustained delivery vehicle.  The 
spatial and temporal control of the photo-curing process provides unique advantages for 
developing controllable in vitro systems. However, the need to use photo initiators and 
UV light has raised concerns with respect to in vivo applicability (Fukaya et al. 2009, 
Okino et al. 2002, Hoshikawa et al. 2006, Terao et al. 2003).  As discussed before, 
enzyme-catalyzed reactions have recently gained interest due to the ability to use mild, 
cell-friendly natural processes to develop injectable gels.  Several enzymatically-
catalyzed reactions were developed to form gelatin gels.  Transglutaminase cross-linked 
gelatin was developed as a cell delivery vehicle in which covalent N-ε(γ-glutamyl) lysine 
amide bonds are formed between the gelatin molecules in the presence of the enzyme 
(Yung, Bentley & Barbari 2010) (Figure 55).  Cross-linking phenol derivatives of 
polymers in the presence of H2O2 and HRP is another potential route to develop 
injectable gels (Lee, Chung & Kurisawa 2009, Sakai et al. 2009).  Injectable gelatin gels 
using the HRP-H2O2 oxidative coupling reaction has been reported (Sakai et al. 2009, Hu 
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et al. 2009, Park et al. 2011). Recently, gelatin–poly(ethylene glycol)–tyramine (GPT) 
injectable hydrogel was developed to support tissue regeneration (Sakai et al. 2009). 
 
 
Figure 55.  Schematic representation of the enzymatic crosslinking of gelatin-
poly(ethylene glycol) tyramine (GPT) conjugates and the image of the in situ GPT 
hydrogel formation  using a dual syringe. 
The dual syringe contained: (a) 3wt % GPT dissolved in 0.0025 mg/ml HRP in 0.01 M 
HRP and (b) 3wt% GPT dissolved in 0.0125wt % H2O2 in 0.01 M PBS.  Image adapted 
from (Park et al. 2011). 
 
Several parameters such as chemical and biological properties of the polymer, 
pore size, pore structure, stiffness and permeability of the scaffold are known to affect 
cell performance (Kim et al. 2010).  In order to develop the appropriate control for rhLF 
gels, tyramine conjugated gelatin was used for HRP mediated crosslinking similar to 
rhLF gels.   We evaluated the effects of gelatin concentration on the microstructure of the 
injectable gel and the long-term viability and spreading of encapsulated MC3T3 cells.  
The bioactivity of the modified and unmodified gelatin towards MC3T3 was evaluated by 
whether the protein can induce the phosphorylation of ERK and the expression of active 
β catenin and Runx2.  Immunocytochemistry was used to investigate if the gel matrix can 
modulate the osteogenic functions of the encapsulated cells.    
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5.2.2 Methods 
5.2.2.1 Preparation of gelatin gel 
5.2.2.1.1 Synthesis of gelatin tyramine conjugates (modified gelatin) 
Modified gelatins were prepared as described in Appendix of Protocols (Section 
7.9.2.1.1). The extent of tyramine-substitution in modified gelatin was followed by UV-
spectrophotometer at 275 nm and the concentration of the phenolic group in the solutions 
was determined from a standard curve. 
5.2.2.1.2 Preparation of gelatin gels 
Different concentrations of water-soluble modified gelatin (10, 25 and 50 mg/ml) were 
dissolved in HRP solution (10 U/ml) in distilled H2O and gelation was initiated by the 
addition of 0.25% H2O2. 
5.2.2.2 Morphology 
The morphology of the gelatin gels formed from modified gelatin solutions of different 
concentrations (10, 25, 50 mg/ml) was visualized by SEM as described in Appendix of 
Protocols (Section 7.9.2.2.3). 
5.2.2.3 Rheological analysis of gelatin gels 
The gelatin gels were subjected to rheological measurements to assess the viscoelastic 
properties at varying component concentrations at 25ºC as described in Appendix of 
Protocols (Section 7.9.2.2.2).   50 µl of modified gelatin/HRP solution was first 
introduced in a parallel plate rheometer.  Next, 50 µl of modified gelatin/H2O2 solution 
was added during pre-shear step of 50 rad/second for 10 seconds.  Dynamic frequency 
sweeps were then performed in the linear viscoelastic region to determine values of the 
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storage (G’) and loss (G”) modulus to compare the mechanical strength of gels with 
different concentrations of gelatin.  Rheology testing conditions were as follows: angular 
frequency of 1 rad/second; 3% strain; 1000 µm gap width; 100 µl volume load. 
5.2.2.4 Cell encapsulation in gelatin gel 
The water-soluble modified gelatin (10, 25 and 50 mg/ml) was dissolved in 10U/ml 
HRP in distilled water.  Cell suspension on media (500,000 cells) were added and re-
suspended in 100 µl each of the modified gelatin/HRP solutions followed by the addition 
of aqueous H2O2 (1 µl of 0.25% solution).  The encapsulated cells were then cultured in 
basal MEMα medium at 37ºC.  
The water/PBS soluble modified gelatin (10, 25 and 50 mg/ml) was dissolved in 
10U/ml HRP in 50:50 water/PBS mixture.  Cell pellet (500,000 cells) was added and re-
suspended in 100 µl each of the modified gelatin/HRP solutions followed by the addition 
of aqueous H2O2 (1 µl of 0.25% solution).  The encapsulated cells were then cultured in 
basal MEMα medium at 37ºC. 
5.2.2.4.1 Cell viability and spreading 
500,000 cells/ml MC3T3 cell encapsulated in the two different types of gelatin gels were 
incubated at 37°C in basal medium for a time course of 21 days and then imaged every 7 
days using live/dead viability assay as described in Appendix of Protocols (Section 
7.5.2.1). 
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5.2.2.5 Bioactivity of gelatin and modified gelatin 
5.2.2.5.1.1 Western blot analysis 
MC3T3 cells were plated on 10 cm2plates (250,000 cells/plate) and grown to 90% 
confluence in basal media.  Cells were serum starved for 6 hours and treated with gelatin 
or modified gelatin (dissolved in PBS) or with PBS (control) for 15 minutes in serum-free 
media.   For long time-course study, cells were plated at low density (200,000 cells/well) 
on 6-well plate and grown to 90% confluence in basal media and then treated with gelatin 
or modified gelatin or with PBS (control) for 21 days in mineralization media.  Media 
and treatments were changed every 3 days.   Total protein was lysed from cells and 
western blot analysis was performed as described in Appendix of Protocols (Section 
7.2.2.3).	  
5.2.2.5.1.2 Alkaline phosphatase activity 
For alkaline phosphatase studies, MC3T3 cells were plated on 24-well plates at a low 
density (10,000 cells/well) and grown for 1 day in basal media and then treated with 
gelatin or modified gelatin or with PBS (control) for 14 days in mineralization media 
(n=4) and samples were analyzed for alkaline phosphatase activity as described in 
Appendix of Protocols (Section 7.7.2.1). 
5.2.2.5.1.3  Mineralization assay 
For mineralization studies, MC3T3 cells were plated on 24-well plates at a low density 
(10,000 cells/well) and grown for 1 day in basal media and then treated with gelatin or 
modified gelatin or with PBS (control) for 14 days in mineralization media (n=4) and 
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samples were analyzed for calcium deposition using Alizarin Red staining method as 
described in Appendix of Protocols (Section 7.7.2.2). 
5.2.2.6 Bioactivity of gelatin gels 
MC3T3 cells (500,000 cells/ml) were encapsulated in 10 mg/ml gelatin gel dissolved in 
distilled water and were maintained in basal media for 2 days and the 
immunocytochemistry was used to detect the regulation of Erk phosphorylation and 
active β catenin.  Soluble factors, 30 ng/ml insulin and 10 mM LiCl, were added 
separately to the medium of gelatin gel–encapsulated cell samples for 2 hours following 2 
days incubation period.  Immunocytochemistry was performed as described in Appendix 
of Protocols (Section 7.2.2.5). 
5.2.2.7 Statistical data analysis 
All data are presented as mean ± SD (standard deviation) for n = 3, unless stated 
otherwise. Statistical analyses were performed by t-test, and p < 0.05 was considered 
statistically significant. 
5.2.3 Results 
5.2.3.1.1 Synthesis of gelatin-tyramine conjugates 
Figure 56 shows the phenolic content of tyramine modified and unmodified water 
soluble gelatin as a function of reaction time under the described reaction conditions. The 
phenolic content of the modified gelatin was approximately four times higher than of the 
unmodified gelatin.  Moreover, under the reaction conditions used, no significant increase 
in phenolic group was found after 25 minutes of reaction at room temperature.  
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Figure 56.  Extent of phenolic group substitution in gelatin as a function of reaction time 
under the conditions used in the study. 
(n) Gelatin treated with tyramine in the presence of EDC; (☐) Gelatin treated with EDC in 
the absence of tyramine. 
 
5.2.3.1.2 Preparation of gelatin gels 
The concentrations of the reagents (modified gelatin, H2O2 and HRP) play an 
important role in determining the gelation time as well as the properties of the resulting 
gel.  Irrespective of the concentration of the water-soluble modified gelatin (10-50 
mg/ml), H2O2 (0.75-2 µL of 0.25% w/v stock concentration) and HRP (5-10 U/mL) all 
the solutions gelled in less than 10 seconds.  Unlike rhLF gels discussed in section 5.1.3, 
the reagent concentrations did not significantly affect the gelation time.   
5.2.3.1.3 Morphology 
The morphology of flash frozen and lyophilized gels prepared from modified gelatin 
solutions of different concentrations are shown in Figure 57.  The gels formed from 10 
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mg/ml and 25 mg/ml gelatin solutions presented a macro-porous structure with 
interconnected pores.  Even though both 10 and 25 mg/ml presented a porous 
microstructure, the average pore width and pore wall thickness was significantly higher 
in the case of gels formed from 25 mg/ml solution compared to that formed from 
10mg/mL (Figure 58).   On the other hand, the highest concentration solution (50 mg/ml) 
presented a dense, less-porous structure.  In order to investigate the effect of H2O2 
concentration on hydrogel morphology, gels were made from modified gelatin solutions 
of 50 mg/ml in the presence of different concentrations of H2O2.  Irrespective of H2O2 
concentrations, the gels showed a dense less-porous structure at 50 mg/ml concentration.  
It is presumed that at 50 mg/ml concentration, the pore wall thickness increased to the 
extent that the matrix collapsed to form a structure with limited porosity. 
  
 
Figure 57.  SEM images of 10-50 mg/ml gelatin gels. 
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Figure 58.  Average pore width and pore wall thickness of gelatin gels. 
Gels were formed from solutions of 10mg/ml and 25mg/ml gelatin concentrations.   A) 
Average pore width; B) Average pore wall thickness.   * indicates p<0.05 statistical 
significance. 
 
 
5.2.3.1.4 Rheological Analysis 
Storage modulus of gelatin gels (10, 25 and 50 mg/ml) were measured – 220.88 ± 25.70 
Pa, 1579.21 ± 272.49 Pa and 5568.74 ± 543.48 Pa, respectively. 
 
Figure 59.  Rheological testing of 10, 25 and 50 mg/ml gelatin gel. 
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5.2.3.2 Cell-Gelatin Interactions 
5.2.3.2.1 Cell viability and spreading 
 In the present study, the effect of modified gelatin concentration on osteoblast 
viability and spreading in the gels as a function of encapsulation time was investigated.  
The viability and morphology of MC3T3 pre-osteoblast cells encapsulated in two 
different gelatin gels of different polymer concentrations and times in basal media are 
shown in Figure 60 A&B.  The viable cells are indicated by green calcein fluorescent 
labeling and the dead cells by red ethidium homodimer-1 fluorescent labeling.  Cell 
suspension encapsulated in water soluble gelatin gels (Figure 60A) exhibited high 
viability while the extent of cell spreading was dependent on the gelatin concentration.  
The MC3T3 cells encapsulated in 10 mg/ml gels with the lowest storage modulus 
displayed the greatest spreading and number of cells throughout the culture.  The gels 
from 25 mg/ml gelatin also showed good cell spreading with extended filopodia rich 
morphology while cells encapsulated in 50 mg/ml gelatin had a round morphology with 
limited spreading throughout the 21 day culture.  The increase in storage moduli of the 
gels prepared at 10, 25, 50 mg/ml gelatin concentrations was presumed to be one of the 
reasons for the limited spreading and lack of network formation by the cells in 50 mg/ml 
modified gelatin compared to the 10 and 25 mg/ml compositions.  However, cells 
encapsulated in the 50 mg/ml gels started showing some cell spreading by day 21 (arrow, 
Figure 60A).  
 However, since the control gelatin gels were prepared to evalaute the biological 
activity of  LF gel, we developed a modified protocol to develop gelatin gel that can be 
formed from a water/PBS mixture (similar to the LF gel protocol) and cell pellet was 
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encapsulated rather than cell suspension.  Cell pellet were used in lactoferrin gel 
encapsulation studies to remove the contribution of FBS in the media which may exhibit 
some biological activity. The cell pellets encapsulated in gelatin gels prepared from 
water/PBS mixture also showed good cell viability, however, showed a lack of cell 
spreading (Figure 60B). Irrespective of the polymer concentration, none of the gels 
showed the potential of cell spreading over the 21 days culture period studied. Compared 
to the gelatin gel, cell pellet encapsulated in 10mg/mL of lactoferrin gel under similar 
culture condition showed good cell spreading within 24 hours.  
 
A.
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B. 
 
Figure 60.  Photomicrographs of MC3T3 cells encapsulated in gelatin gels of different 
concentrations (10-50 mg/ml) as a function of time. (A) Gels prepared by dissolving 
gelatin in H2O.  (B) Gels prepared by dissolving gelatin in 1:1 H2O:PBS solution.  
Images taken at 20x magnification. 
Cells were stained by a Live/Dead stain: green fluorescence indicating live cells and red 
fluorescence indicating dead cells. 
 
5.2.3.2.2 Bioactivity of gelatin and modified gelatin 
 We probed different functional markers of osteoblasts, such as phosphorylation of 
Erk, activation of β catenin and phosphorylation of Runx2 after exposing the cells to 
media, media containing gelatin or media containing water soluble modified gelatin. The 
western blot analysis using specific phospho-Erk and active β catenin antibodies 
displayed no differences (Figure 61A) in phosphorylation of Erk or accumulation of 
active β-catenin in the cell lysate from cultures exposed to gelatin, modified gelatin or 
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control media.  The non-osteogenic activity of the modified gelatin was further confirmed 
by the expression of Runx2 protein, an osteogenic marker after 21 days in culture in 
mineralization media (Figure 61B).  No significant up-regulation of Runx2 was observed 
in cells exposed to gelatin or modified gelatin compared to cells given mineralization 
media alone.  These studies clearly demonstrated the lack of inherent osteogenic activity 
of modified gelatin.   
 
 
Figure 61.  Bioactivity of gelatin and modified gelatin. 
(A) MC3T3 cells were stimulated with 100µg/mL gelatin (+), modified gelatin (+*) or PBS 
(-) for 15 min in basal media A) or for 21 days in mineralization media B).  Anti-tubulin 
blots were used as loading controls. 
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Figure 62.  Alkaline phosphatase activity of MC3T3 cells treated with gelatin and holo-
rhLF (modified and unmodified). 
Alkaline phosphatase assay was performed on samples maintained in mineralization 
media for 14 days. Statistical significance (p<0.05) is represented as * relative to 
appropriate control.   
 
 
Figure 63.  Calcium deposition of MC3T3 cells treated with gelatin and holo-rhLF 
(modified and unmodified). 
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Alizarin red assay was performed on samples maintained in mineralization media for 14 
days. Statistical significance (p<0.05) is represented as * relative to appropriate control.   
 
5.2.3.2.3   Bioactivity of injectable gelatin gels 
We investigated the effect of three-dimensional encapsulation of MC3T3 cells in 
10 mg/ml gelatin gel in cellular function by following the collagen I deposition as well as 
activating intercellular signaling by following the induction of Erk and β-catenin 
activation using immunocytochemistry.  Propidium iodide (red) was used to label the cell 
nuclei and secondary antibodies were FITC-conjugated (green). Shown in Figure 64 
A&B, no positive antibody staining (green) of active β catenin and Erk phosphorylation 
was observed in the MC3T3 cells encapsulated in water soluble and water/PBS gelatin 
gels. The addition of soluble molecules, 30 ng/mL insulin and 10 mM LiCl, to the media 
of the gelatin gel—encapsulated cells, led to the expression of active β catenin and 
phospho-Erk, after only a 2 day treatment.  These studies confirmed that although the 
enzymatically cross-linked gelatin gel at 10mg/ml supported the adhesion, spreading, 
proliferation and collagen deposition of MC3T3 cells, the three dimensional organization 
of the osteoblast cells in the gel did not induce the phosphorylation of Erk or activation of 
β catenin indicating a lack of inherent osteogenic activity.  However, the increased 
expression of active β catenin and phospho-Erk by the cells cultured in the presence of 
bioactive molecules indicated that the porous structure of this matrix allowed diffusion of 
soluble bioactive molecules to activate intercellular signaling pathways in the 
encapsulated cells.   
 
A. 
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B.  
 
Figure 64.  Phosphorylation of Erk in MC3T3 cells encapsulated in 10 mg/ml gelatin gel. 
MC3T3 cells were encapsulated in 10 mg/ml gelatin gel and maintained in basal media 2 
days.  Activation of β catenin and phosphorylation of ERK were probed using 
immunocytochemistry.  FITC-labeled secondary antibodies (green) and propidium iodide 
(red) were used to detect positive antibody staining and nuclei, respectively. Gelatin gel–
encapsulated MC3T3 cells did not express activation of βcatenin or phospho-Erk after 2 
days of encapsulation (absence of green fluorescence).  Positive expression of 
activation of β-catenin and phospho-ERK occurred after the addition of 10 mM LiCl or 30 
ng/mL insulin, respectively, for 2 hours to the medium following 2 day encapsulation of 
MC3T3 cells in gelatin gel.    
A) Gels were preared by dissolving gelatin in H2O B) Gels were prepared by dissolving 
gelatin in 1:1 H2O:PBS solution Images taken at 20x magnification. 
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5.2.4 Discussion 
Gelatin possesses several desirable features for tissue engineering applications 
such as excellent biocompatibility, biodegradability and low immunogenicity.  Standard 
carbodiimide mediated coupling of amino groups of tyramine with the carboxyl groups of 
gelatin was used to modify gelatin (Sakai et al. 2009).  Natural gelatin contains phenolic 
amino acids, such as tyrosine, depending on its origin and purity. However, the phenolic 
content of natural gelatin has been reported to be much lower than what is needed to 
develop an effectively crosslinked matrix via enzyme-catalyzed coupling. The reaction of 
gelatin with tyramine or hydroxyphenylpropionic acid enhances polymer cross-linking by 
increasing the number of phenolic groups in gelatin (Sakai et al. 2009, Hu et al. 2009).  
Several methods such as colorimetric, spectrophotometric and chromatrographic methods 
can be used to detect the phenolic content of polymers such as gelatin  (Cobbett, 
Kenchington & Ward 1962).   In our studies, we detected phenolic concentration of 
gelatin after tyramine concentration via spectrophotometry.  Phenolic content of the 
modified gelatin increased over 24 hours of reaction time with tyramine. 
Pore size and structure of the scaffold has an affect cell performance when cells 
are seeded on microporous hydrogels.  Betz et al. cultured human mesenchymal stem 
cells on a porous hydrogel (100-250 µm pore size) up-regulated BMP2 expression which 
favored osteogenic differentiation Betz et al. 2010).  The viability and proliferation of 
cells is presumed to be favorably influenced by the microporous structure of the scaffold 
due to increased nutrient and gaseous permeability (Hwang et al. 2010).  The enzymatic 
crosslinking of 10 mg/ml gelatin gel led to microporous structures of approximately 30 
µm pore size, which is sufficent since the average size of an osteoblast is approximately 
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20-25 µm (Puckett, Pareta & Webster 2008).  In our cell encapsulation studies, gelatin gel 
allowed for high percentage of live to dead cell ratio.  However, a decrease in cell 
spreading and density was seen in the MC3T3 cells encapsulated in 50 mg/ml gelatin gel 
(relative to 10 and 25 mg/ml holo-rhLF gel).   These results may be explained through a 
variety of different reasons – decrease cell spreading and density due to 1) increased 
mechanical strength decreasing cell proliferation and spreading or 2) collapsed pore 
structure adversely affecting the encapsulated cell proliferation and spreading.  Although 
gelatin has cell adhesive domains, several three-dimensional hydrogel matrices developed 
from gelatin show poor cell viability and spreading (Hoshikawa et al. 2006, Grinnell et 
al. 2003).  Other parameters, including storage moduli and pore structure, may also be 
playing crucial roles in determining the fate of the encapsulated cells.    
Mechanical testing revealed significant storage modulus increases upon increased 
polymer concentration.  The storage moduli of the gelatin gels were measured to range 
from approximately 200 – 5000 Pa for gelatin polymer concentrations of 10-50 mg/ml.  
As mentioned previously in section 5.1.4, hydrogel stiffness inversely affected the cell 
proliferation rates (Wang et al. 2010).  Perhaps the significant storage moduli of 50 
mg/ml gelatin gel resulted in a decrease proliferation rate of the encapsulated cells. 
Unlike porous 10 mg/ml and 25 mg/ml gelatin gels, SEM analysis of the 50 
mg/ml gelatin gel revealed a collapsed gel structure.  This collapsed structure may not 
present as a conducive environment for cellular spreading and proliferation of the 
encapsulated cells.  However, cells encapsulated in the 50 mg/ml gels started showing 
some cell spreading by day 21 (Figure 60). This may be presumably due to some cell 
	   211 
mediated degradation of the matrix, as gelatin has the same biodegradable epitopoes as 
collagen (Atkinson et al. 1992).   
Since the modified lactoferrin solutions were made in water/PBS mixture, 
modified gelatins were prepared that are highly soluble in water/PBS mixture. Cell 
pellets instead of cell suspension were used for cell encapsulation in LF gels to prevent 
the potential biological activity of serum in the media. The cell pellets encapsulated in LF 
gels maintained high cell viability.  However, the absence of serum completely prevented 
cell spreading in gelatin gels.  The poor cell spreading observed with higher gelatin 
concentrations in the previous study (Figure 60A) as well the present study (Figure 60B) 
can therefore be attributed to the inferior properties of aqueous gelatin solution in the 
absence of serum. Thus, the lack of cell spreading in gelatin gel presents limitation in 
using gelatin gels as proper 3D control systems for LF based gels.  Future studies need to 
focus on developing appropriate intert control gels that can support cell adhesion similar 
to lactoferrin gels to quantitatively evalaute the increase in biological activity of 
lactoferrin gels. 
An ideal cell delivery vehicle should allow for homogeneous mixing of cells 
within the solution before the sol-gel transition and promote favorable cell-matrix 
interactions particularly for anchorage dependent cells, such as osteoblasts (Wang, 
Varshney & Wang 2010).   Gelatin is derived from natural extracellular matrix and 
exhibits a wide range of bioactivity (Alvarez-Perez et al. 2010, Peng et al. 2010).  
Previous studies report favorable effects of gelatin on cell adhesion.  Furthermore, some 
of the recent studies have indicated that an increase in MC3T3 cell proliferation and 
differentiation via the activation of the Erk signaling pathway may be induced by gelatin 
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or chemically/biologically modified gelatin (Lee et al. 2010, Ge et al. 2007).   Recently, 
the ability of gelatin nanostructures to induce Erk activation and the expression of cell 
adherent molecules, focal adhesion kinase, secreted protein acidic and rich in cysteine 
(SPARC) and VEGF in MC3T3 cells was reported (Ge et al. 2007).  Similarly, the 
efficacy of micro-porous hydrogels in up-regulating osteogenic signal expression when 
cells are seeded on the gel was reported (Betz et al. 2010).    
Unlike modified LF, our studies did not indicate any increased bioactivity in 
MC3T3 cells treated with gelatin, tyramine modified gelatin and gelatin gel.  We 
investigated the bioactivity of soluble gelatin and its tyramine-modified form to test 
whether tyramine modification affects gelatin’s bioactivity on MC3T3 cells.  In our 
studies, we probed different functional markers of osteoblasts, including phospho-Erk, β 
catenin, Runx2, ALP activity and mineral deposition.   Our analysis displayed no 
differences in the regulation of the functional markers from MC3T3 cell cultures exposed 
to gelatin, modified gelatin or control media (Figure 61).   Furthermore, holo-rhLF and 
tyramine-modified holo-rhLF samples were included in these studies as positive controls.  
There was no significant difference in bioactivity induced by holo-rhLF and modified 
holo-rhLF.  In summary, this study confirmed positive bioactivity of holo-rhLF and inert 
bioactivity of gelatin.  Moreover, it demonstrated that tyramine modification did not alter 
the bioactivity of gelatin or holo-rhLF.  In our next study, we investigated the bioactivity 
of gelatin gel-encapsulated MC3T3 cells.  No positive expression of our functional 
markers (phospho-Erk and β catenin) were expressed in the gelatin gel-encapsulated 
MC3T3 cells. These studies also demonstrated that exogeneous bioactive factors such as 
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insulin, LiCl and LF may be used to increase bioactivity of inert gels.  These results 
demonstrate the applicability of gelatin gel as an inert osteoblast cell delivery vehicle. 
5.2.5 Conclusions 
Gelatin, an ECM-derived protein, is an excellent candidate for developing cell 
delivery vehicle due to its biocompatibility and biodegradability. The use of aqueous 
gelatin solutions in developing enzymatic gels presented limitations in terms of cell 
spreading.  The absence of inherent osteogenic activity of the modified gelatin and 
gelatin gel indicated the need to include exogenous bioactive molecules to modulate the 
functions of the encapsulated cells.   
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5.3 Evaluation of the bioactivity of holo-rhLF gel as a novel 
cell delivery vehicle 
5.3.1 Introduction 
As a highly specialized and complex organ, the skeleton is composed of extensive 
vasculature, bone cells and mineralized organic matrix.   Bone possesses the intrinsic 
capacity for regeneration and remodeling – a constant formation and resorption of 5-15% 
total bone mass per year under normal physiological conditions (Davies, Hosseini 2000).  
Growth factors, cytokines, hormones, bone matrix proteins and mechanical forces act as 
modulators of essential homeostatic cellular functions, including cell survival, 
proliferation and differentiation, through the induction of specific cell signaling pathway 
cascades.  The lengthy list of essential signaling molecules during bone regeneration 
include IL1, IL6, TNFα, TGFβ, PDGF, BMP, FGF, IGF, MMP, VEGF and angiopoietin 
(Fernandez-Tresguerres-Hernandez-Gil et al. 2006, Devescovi et al. 2008). 
The temporal release of signaling molecules and activation of signaling pathways 
are responsible for the coordinated biological processes involved in bone regeneration – 
which include cell mitogenesis, survival and differentiation.  Precise regulation of Wnt/ 
β-catenin signaling plays a disparate role in the facilitation of pluripotent mesenchymal 
stem cell differentiation into osteoblasts and enhancing bone formation (Silkstone, Hong 
& Alman 2008, Chen et al. 2007).  Erk, a member of the MAPK family, is activated by 
growth factors, such as FGF2, to increase osteoblast proliferation (Chaudhary, Avioli 
2000, Lai, Cheng 2002, Xiao et al. 2000).   Multiple signaling pathways, including ERK, 
have been shown to converge and lead to the activation and phosphorylation of 
osteoblast-specific transcription factor, Runt-related transcription factor 2 (Runx2) 
(Franceschi et al. 2003), which plays a fundamental role in osteoblast differentiation and 
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bone formation (Komori 2002).  Runx2 induces osteoblast and chondrocyte 
differentiation and enhances their migration by coupling with PI3K-Akt signaling (Fujita 
et al. 2004), which has been implicated as a critical pathway for the differentiation and 
cell survival of skeletal component cells including chondrocytes, osteoblasts, myoblasts, 
and adipocytes (Kaliman et al. 1996, Sakaue et al. 1998, Ghosh-Choudhury et al. 2002, 
Hidaka et al. 2001).   
In the case that bone is not able to self heal, bone tissue engineering is needed to 
regenerate the damaged bone (Rose, Oreffo 2002).  Autologous transplantation, the 
current gold standard procedure for bone repair, holds significant drawbacks including 
possible donor site morbidity. Tissue-engineering strategies utilize biocompatible 
scaffolds with specific combinations of cells and bioactive factors (Vaccaro 2002, 
Carson, Bostrom 2007).  Tissue regeneration may be enhanced by the introduction of 
biochemical signals, in the form of growth factors, cytokines and genetics, which directs 
cellular responses.  However, administration of growth factors also present with 
significant shortcomings.  For example, recombinant human BMP2 (rhBMP2) (Infuse®), 
the first approved complete bone graft substitute for spinal fusion, presents drawbacks as 
a regenerative bone factor since the proteins have the propensity to denature, may lead to 
ectopic bone formation, entail high cost, requires high doses to induce adequate bone 
formation, and possesses large variations in response among patients (Hawkins 2010). 
Due to the multitude of growth factors and cell-cell interactions involved in bone 
regeneration, scientists have begun to investigate novel bioengineering systems that have 
the ability to release or bind to multiple growth factors.  For example, dual delivery of 
VEGF and BMP2 from gelatin microparticles for enhanced angiogenesis and 
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osteogenesis in critical-sized defect bone regeneration (Patel et al. 2008).  This 
multifactorial technique has presented itself with strong limitations including lack of 
spatial and temporal control of growth factor release from biomaterial scaffold.  
Thorough testing of the pharmakinetics of the released agents and elucidation of the 
efficacy of the carrier systems must be performed on this type of bioengineering 
approach.  Even so, each in vivo biological system presents its own individuality.  
Therefore, even with complete characterization of the bioengineering system, it still may 
not be fit for different biological systems.  
In summary, the current biomaterials systems present a cytocompatible 
microenvironment to support cell adhesion and growth, they lack specific bioactivities to 
modulate the host/donor cell functions.   Attempts were made to increase their bioactivity 
by incorporating biological molecules such as growth factors, cytokines and chemokines.  
However, those approaches also present various limitations.  These include issues 
regarding inability to retain these bioactive molecules at the defect site due to the 
uncontrolled diffusion of protein from the matrices as well as the inability to present 
multiple bioactive molecules in a spatial and temporal controlled manner which plays a 
very important role in achieving optimal regenerative outcome (as described in section 
2.1.3.2). 
  As discussed previously in section 2.1.3.5, cell-based strategies, on the other 
hand, are raising significant interest lately due to the ease of isolation of autologous 
mesenchymal stem cells and their ability to undergo osteogenic differentiation.  Several 
other potential cell sources with good regenerative ability are also currently been 
investigated.  Despite encouraging results from extensive preclinical studies on cell-based 
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bone tissue engineering, key biological and engineering challenges still need to overcome 
for its successful clinical translation.  Some of the critical challenges include poor cell 
survival and inability to control cellular processes such as proliferation and 
differentiation due to the inability to present appropriate microenvironment with 
bioactive molecules to the transplanted cells (as described in section 4.3). Nevertheless, 
such transient bioactive microenvironments are expected to be necessary for the 
successful regeneration of functional tissue.    Thus, the key for a successful regenerative 
biomaterial for bone regeneration lies in its ability to interact with the surrounding 
environment and activate specific cell signaling pathways to support cell survival and 
functions.  LF’s influential role in bone morphogenesis has been accredited to its wide 
array of effects on bone cells – including proliferative and anti-apoptotic actions of 
osteoblasts and inhibition of osteoclast function (Amini, Nair 2011, Cornish 2004, 
Cornish et al. 2004, Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009).  Based 
on the unique biological activities of LF, we hypothesize that an injectable biomaterial 
developed from rhLF will retains its bioactivities (as described in section 4) and will be 
able to present an artificial microenvironment capable of modulating encapsulated cell 
functions.  The objective of the studies described in this chapter is to evaluate the 
biological activities of injectable holo-rhLF gel compared to the gelatin gel (which has 
shown to have no osteoblast-specific bioactivity towards encapsulated cells as discussed 
in section 5.2 to understand its efficacy as a bioactive cell delivery vehicle.   Cellular 
proliferation analysis methods were investigated in the 2D model using EdU 
incorporation and Ki67 protein expression.   Ki67 protein expression was then used to 
investigate cellular proliferation in MC3T3 encapsulated cells (3D model). 
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Figure 65.  Schematic showing cell encapsulation in holo-rhLF gel. 
Chemical modification of holo-rhLF using standard carbodiimide reaction.  Followed by 
the homogenous mixture of HRP and cells plus H2O2 to yield cell-laden holo-rhLF gel. 
 
5.3.2 Methods 
5.3.2.1 Determination of optimal cell seeding density for cell encapsulation in 
hydrogel 
MC3T3 cells of various cell-seeding densities (2.5 x 106 cells/ml, 1.25 x 106 cells/ml and 
0.5 x 106 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel as described 
in Appendix of protocols (Section 7.9.2.4).  Holo-rhLF gel component concentrations: 
100 µl of 10 mg/ml holo–rhLF gel, 10 U/ml HRP, 0.75 µl of 0.25% H2O2.Cells were then 
maintained in basal media for 1 day and imaged using live/dead assay as described in 
Appendix of protocols (Section 7.5.2.1). 
5.3.2.2 Mitogenic Activity  
5.3.2.2.1 EdU incorporation 
MC3T3 cells were plated on glass-bottom tissue culture plates (50,000 cells/plate) and 
then serum starved for 6 hours.  Cells were either untreated (control) or stimulated with 
holo-rhLF 100 µg/ml for 8 hours.  Click-it EdU Cell Proliferation Assay was performed 
as described in Appendix of Protocols (Section 7.6.2.3). 
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5.3.2.2.2 Protein expression (2D Immunocytochemistry) 
MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2 
days in basal media and then serum starved for 6 hours.  Cells were either untreated 
(control) or stimulated with holo-rhLF 100 μg/ml for 24 hours.  Immunocytochemistry 
was performed as described in Appendix of Protocols (Section 7.2.2.5). 
5.3.2.2.3 Protein expression (3D Immunocytochemistry) 
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel 
as described in Appendix of protocols (Section 7.9.2.4).  Holo-rhLF gel component 
concentrations: 100 µl of 10 mg/ml holo–rhLF gel (10 U/ml HRP, 0.75 µl of 0.25% 
H2O2.  Immunocytochemistry was performed to investigate the phosphorylation of Erk 
and Ki67 expression as described in Appendix of protocols (Section 7.2.2.5). 
5.3.2.2.4 Long term culture of encapsulated cells in the gels 
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel 
as described in Appendix of protocols (Section 7.9.2.4).  Cells were then maintained in 
basal media for 20 days and imaged using live/dead assay as described in Appendix of 
protocols (Section 7.5.2.1). 
5.3.2.3 Anti-apoptotic effect of rhLF gels 
5.3.2.3.1 Serum starvation-induced apoptosis 
500,000 cells/ml in 100 µl of 10 mg/ml holo–rhLF and gelatin gel (10 U/ml HRP, 0.75 µl 
of 0.25% H2O2).  Cells were encapsulated and then grown in basal medium for 24hours.    
Cells were then maintained in serum free media to induce apoptosis and imaged using 
live/dead assay as described in Appendix of protocols (Section 7.5.2.1). 
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5.3.2.3.2 Protein expression 
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF and 
gelatin gels as described in Appendix of protocols (Section 7.9.2.4).  Holo-rhLF gel 
component concentrations: 100 µl of 10 mg/ml holo–rhLF gel (10 U/ml HRP, 0.75 µl of 
0.25% H2O2.  Gelatin gel component concentrations: 100 µl of 10 mg/ml gelatin gel (10 
U/ml HRP, 1 µl of 0.25% H2O2.  Immunocytochemistry was performed as described in 
Appendix of protocols (Section 7.2.2.5). 
5.3.2.3.3 Holo-rhLF/ gelatin composite gels 
The protocol for the following gel biomaterials is described below: 10 mg/ml gelatin gel 
+ 10 mg/ml holo-rhLF; 10 mg/ml gelatin gel + 10 mg/ml tyrosinated holo-rhLF; and 10 
mg/ml holo-rhLF gel + 10 mg/ml tyrosinated holo-rhLF.  Encapsulated cells were 
maintained in basal media for 6 hours and then serum starved for 2 days.  Viability was 
tested using live/dead assay as described in Appendix of protocols (Section 7.5.2.1).  
Phosphorylation of Akt was examined using immunocytochemistry as described in 
Appendix of protocols (Section7.2.2.5). 
10 mg/ml gelatin gel + 10 mg/ml holo-rhLF gel 
• To make 1 ml of 10 mg/ml gelatin/HRP solution:  dissolve 10 mg modified in 1ml 
of 10 U/ml HRP (dissolved in H2O) and then mix well.  
• To make 1 ml of 10 mg/ml holo-rhLF/HRP solution:  dissolve 10 mg tyrosinated 
holo-rhLF in 500 µl of 10 U/ml HRP (dissolved in H2O) and then mix well. Add 
500 µl of 10 U/ml HRP (dissolved in PBS). 
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• Mix 50 µl of gelatin/HRP solution and 50 µl of holo-rhLF/HRP solution.  Add 
500,000 cells/ml and mix well to a 35 mm glass bottom plate.  Next, add 1 µl of 
0.25% H2O2to gel. 
10 mg/ml gelatin gel + 10 mg/ml holo-rhLF (non-tyrosinated) 
• To make 1 ml of 10 mg/ml gelatin/HRP solution:  dissolve 10 mg modified in 1ml 
of 10 U/ml HRP (dissolved in H2O) and then mix well.  
• Next, add 10 mg holo-rhLF to gelatin/HRP solution. 
• Add 500,000 cells/ml to 100 µl gelatin/holo-rhLF/HRP solution and mix well to a 
35 mm glass bottom plate.  Next, add 1 µl of 0.25% H2O2 to gel. 
10 mg/ml holo-rhLF gel + 10 mg/ml holo-rhLF (non-tyrosinated) 
• To make 1 ml of 10 mg/ml holo-rhLF/HRP solution:  dissolve 10 mg tyrosinated 
holo-rhLF in 500 µl of 10 U/ml HRP (dissolved in H2O) and then mix well. Add 
500 µl of 10 U/ml HRP (dissolved in PBS). 
• Next, add 10 mg holo-rhLF to holo-rhLF/HRP solution. 
• Add 500,000 cells/ml to 100 µl holo-rhLF/HRP solution and mix well to a 35 mm 
glass bottom plate.  Next, add 1 µl of 0.25% H2O2 to gel. 
5.3.2.4 Cell differentiation 
5.3.2.4.1 Protein Expression 
500,000 MC3T3 cells/ml were encapsulated in 100 µl of 10 mg/ml holo–rhLF gel (10 
U/ml HRP, 0.75 µl of 0.25% H2O2) and 100 µl of 10 mg/ml gelatin gel (10 U/ml HRP, 
7.5 µl of 0.025% H2O2).  Cell culture was maintained in basal medium for 1 day and then 
changed to mineralization media and cultured for for 21 days.  Immunocytochemistry 
was performed as described in Appendix of protocols (Section 7.2.2.5). 
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5.3.3 Results 
We first tested the optimal cell seeding density for biomaterial encapsulation.  
MC3T3 cells were encapsulated in 10 mg/ml holo-rhLF gels at densities of 2,500,000 
cells/ml 1,250,000 cells/ml and 500,000 cells/ml (Figure 66).  Optimal cell seeding 
density was determined after 24 hours of incubation in basal media using live/dead assay.  
500,000 MC3T3 cells/ml allowed for distinct cell imaging and therefore was determined 
to be the optimal cell seeding density for biomaterial encapsulation for evaluating the 
expression of transcription factors, growth factors and matrix deposition. 
 
 
Figure 66.Various cell seeding densities of MC3T3 cells encapsulated in 10 mg/ml holo-
rhLF gel. 
Imaged after 24 hours of encapsulation using live/dead assay using confocal microscopy 
(5x and 10x magnification). 
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5.3.3.1 Effect of holo-rhLF and holo-rhLF gel encapsulation on MC3T3 cell 
proliferation 
Previous findings have reported rhLF to increase thymidine incorporation in primary rat 
osteoblast cultures (Huang et al. 2008).  Similarly, our studies demonstrated holo-rhLF to 
significantly increase MC3T3 and NHOst cell proliferation at concentrations of 100 and 
1000 µg/ml (Figure 25).  Different proliferation markers, including Ki67, pErk, EdU and 
thymidine incorporation were used to follow the extent of cell proliferation cultured in 
the presence and absence of holo-rhLF.  We found increased Ki67 protein expression and 
EdU incorporation by MC3T3 cells significantly increased after 8 hours of rhLF 
treatment (Figure 67) relative to control.  Since one cycle of MC3T3 cell division 
typically takes 24 hours, we chose to use an earlier time point (8 hours) to visualize cell 
proliferation rate via EdU incorporation.  As seen in top left panel of Figure 67, 100 
µg/ml holo-rhLF treatment increased EdU incorporation.  Furthermore, p42/p44 Erk 
phosphorylation and Ki67 expression increased after 24 hours of 100 µg/ml holo-rhLF 
treatment (bottom left panel of Figure 67, Figure 68).  In these immunocytochemistry 
figures, nuclei (first panel) was stained using propidium iodide (red), protein expression 
(second panel) was visualized using FITC-label secondary antibodies (green) and the 
merged/overlayed images are displayed in the third panel – which demonstrates 
cytoplasmic/nuclear protein localization.   
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Figure 67.  100 µg/ml holo-rhLF increases EdU incorporation and Ki67 protein 
expression in MC3T3 cells after 8 hours treatment. 
Cells were treated for 8 hours in culture.  The images of EdU incorporation (blue; top left 
panel), PI nuclei staining (red; top right panel), Ki67 protein expression (FITC-green, 
bottom left panel) were merged to yield bottom right panel.   
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Figure 68.  Increased phosphorylation of Erk and increased Ki67 protein expression in 
MC3T3 cells treated with 100 µg/ml holo-rhLF. 
Cells were treated for 24hours and protein expression was compared relative to 
untreated control MC3T3 cells.   Propidium iodide was used to stain the cell nuclei.  
Figure 69 shows the pERK and Ki67 expression of cells encapsulated in rhLF 
gels (left panel) and gelatin gels (middle and right panels).  As demonstrated in the 
figure, the proliferative effect of holo-rhLF on MC3T3 cells was retained by the 
crosslinked gel form.  Cell proliferation was counted using live dead assay and Image J 
program after culturing the cells in the holo-rhLF gel for an extended culture period.  
11.2—fold increase of cell number occurred after 20 days of encapsulation in holo-rhLF 
gel (Figure 70). 
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Figure 69.  Phosphorylation of Erk and Ki67 expression in (A) holo-rhLF gel—
encapsulated MC3T3 cells.  (B) Gelatin gels were dissolved in H2O (C) Gelatin gels 
were dissolved in 1:1 H2O:PBS solution  
Cells were encapsulated for 2 days in culture.  Protein expression was compared to that 
of gelatin gel—encapsulated cells.  Propidium iodide was used to stain the cell nuclei. 
 
 
Figure 70.  Cell number and h viability of MC3T3 cells encapsulated in 10mg/mL of holo 
rhLF gels as a function of time.  
Live/dead assay was used to investigate cell viability.  
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5.3.3.2 Anti-apoptotic effect of holo-rhLF gel 
Holo-rhLF gel encapsulated MC3T3 cells demonstrated stimulation of Akt 
phosphorylation after 2 days, which is a common marker in the survival signaling 
cascade (Figure 71).  P-Akt protein expression of MC3T3 cells-encapsulated in holo-
rhLF and gelatin gel was visualized using FITC-labeled secondary antibody (green).   
Cell nuclei were stained with propidium iodide (red).   In the following experiment, we 
encapsulated MC3T3 cells in holo-rhLF and gelatin gels and then exposed them to 
serum-free media to investigate the ability of holo-rhLF gel to protect against serum 
starvation-induced cellular apoptosis.  Significant cell survival was seen using live/dead 
assay in MC3T3 cells encapsulated in holo-rhLF gel after serum starvation for 3 days 
(Figure 72). After 3 days of serum starvation – induced apoptosis, MC3T3 cells 
encapsulated in holo-rhLF gel exhibited a 76% live (green) to dead (red) cells.  
 
  
Figure 71.  Akt phosphorylation in MC3T3 cells encapsulated in (A) 10 mg/ml holo-rhLF 
gel.  (B) Gels were preared by dissolving gelatin  in H2O (C) Gels were prepared by 
dissolving gelatin in 1:1 H2O:PBS solution  
Immunofluorescence testing the phosphorylation of Akt (FITC-labeled secondary 
antibody) in MC3T3 cells treated with 10 mg/ml holo-rhLF treatment relative to untreated 
control after 24 hours.   Nuclei are stained with propidium iodide.  
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Figure 72.  Viability in MC3T3 cells encapsulated in (A) 10 mg/ml holo-rhLF gel during 
serum starvation.  (B) Gels were prepared by dissolving gelatin in H2O (C) Gels were 
prepared by dissolving gelatin in 1:1 H2O:PBS solution  Images taken at 20x 
magnification. 
Live/dead assay was used to investigate cell viability.   
 
Since a certain number of crosslinking sites are required for crosslinking, the 
concentration of bioactive may be higher than what is needed for optimal bioactivity.  
Composite gels of bioactive holo-rhLF and inert gelatin allow manipulation of 
concentration of bioactive holo-rhLF in the gel encapsulating cells.   To test this 
hypothesis, we made a composite gel of 1:1 ratio of 10 mg/ml tyrosinated holo-rhLF and 
10 mg/ml tyrosinated gelatin to yield a 10 mg/ml holo-rhLF/gelatin composite gel which 
contained only half as much bioactive tyrosinated holo-rhLF protein as pure 10 mg/ml 
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holo-rhLF gel.  In other words, we were able to maintaine sufficient crosslinking sites 
(total polymer concentration) while we decreased the amount of bioactive, tyrosinated 
holo-rhLF protein by replacing it with inert, modified gelatin.  Interestingly, 10 mg/ml 
holo-rhLF/gelatin composite gel also supported cell survival as visualized by live/dead 
assay (Figure 73c) and phosphorylation of Akt (Figure 74c) after 2 days of encapsulation.  
However, the addition of holo-rhLF (non-tyrosinated) to gelatin gel did not support cell 
survival (Figure 73b) and phosphorylation of Akt (Figure 74b) after 2 days of 
encapsulation.   This observation supports the notion of tyrosination of holo-rhLF 
increases crosslinking and retention of the bioactive protein surrounding the encapsulated 
cells.  
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Figure 73.  Live/dead assay of serum-starved encapsulated cells in the gels. 
Imaged on day 2 of serum starvation via confocal microscopy (10x magnification).  Dead 
cells (first column) were visualized using ethidium homodimer (red) and live cells 
(second column) were stained using calcein AM (green).  The first and second column 
images were merged to yield the third column to visualize the live/dead ratio.  
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Figure 74.  Phospho-Akt expression of serum-starved encapsulated cells in the gels. 
Imaged on day 2 of serum starvation via confocal microscopy (20x magnification).  Cell 
nuclei (first column) were visualized using propidium iodide (red) and pAkt expression 
(second column) were stained using FITC-labeled antibody (green).  The first and 
second column images were merged to yield the third column to visualize the 
localization of the pAkt protein expression in the encapsulated MC3T3 cells.  (A-C) Gels 
prepared from gelatin dissolved in H2O. (F-G) Gels prepared from gelatin dissolved in 
1:1 H2O:PBS solution  Images taken at 20x magnification. 
	   232 
 
5.3.3.3 Effect of holo-rhLF gel encapsulation on MC3T3 cell osteogenesis 
Holo-rhLF gel biomaterial retained the osteogenic properties of the protein. The 
activation of β catenin was retained by the gel crosslinked form of holo-rhLF.   (Figure 
75).  Collagen 1 and osteocalcin protein expression (Figure 76) were observed in cells 
encapsulated in  holo-rhLF gel and cultured for 21 days  in mineralization media.   
 
 
Figure 75.  Active β catenin expression in MC3T3 cells encapsulated in (A) 10 mg/ml 
holo-rhLF gel and gelatin gel.  (B) Gelatin gels were dissolved in H2O (C) Gelatin gels 
were dissolved in 1:1 H2O:PBS solution Images taken at 20x magnification. 
 
Nuclei are stained with propidium iodide.  Cells were encapsulated for 2 days. 
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Figure 76.  Collagen 1 and OCN expression in MC3T3 cells encapsulated in 10 mg/ml 
holo-rhLF gel and gelatin gel.  A.  Gels prepared from gelatin dissolved in 1:1 H2O: PBS 
solution. B. Gels prepared from gelatin dissolved in H2O.  Images taken at 20x 
magnification.   
 
Nuclei are stained with propidium iodide.  Cells were encapsulated for 21 days. 
 
 
5.3.4 Discussion 
The challenges of this chapter stemmed from the porous structure of the rhLF 
biomaterial gel and also the strong affinity of LF to negatively charged molecules. 
Conventional methods were not selected due to the physical structure and porosity of the 
gels inhibiting accurate measurements of mineralization and proliferation.  Therefore, the 
methodologies for this aim were selected carefully and took these points in to 
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consideration.  Cellular proliferation was measured via Ki67 and pErk protein expression 
instead of thymidine incorporation as used in the 2D studies for soluble rhLF treatment 
on MC3T3 cells.  Protein expression of collagen 1 and OCN, two key specific ostoegenic 
markers, were used to evaluate osteogenic differentiation rather than conventional 
Alizarin Red, which was used for the 2D studies of holo-rhLF on MC3T3 cells.  
Furthermore, cell number for gel encapsulation was optimized to 500,000 cells/ml of gel 
since this cell density allowed for distinct cell imaging for evaluating the expression of 
transcription factors and growth factors. 
Based on the previous gel characterization studies (section 5.1), 10 mg/ml holo-
rhLF gel concentration was in our biological studies of the gel.   This gel concentration 
yielded a clinically-feasible gelation time of approximately 1 minute.   Also, 10 mg/ml 
holo-rhLF gel allowed for excellent cell spreading and viability and also provided 
sufficient mechanical strength to serve as an encapsulating cell delivery vehicle.   
The mitogenic effects of LF have been clearly reported in our previous studies 
(Figure 25) and also previously published studies (Huang et al. 2008).  However, it was 
not clear whether the crosslinked matrix would retain the properties of the soluble 
protein.    Since bioactive proteins may activate cellular processes cell internalization or 
receptor-mediated signal transduction – it is therefore not known if an immobilized 
polymer, which is incapable of being endocytosed, will be bioactive or not.  Grey et al. 
reported that LF internalization by osteoblastic cells is not necessary for activation of 
mitogenic signaling (Grey et al. 2004).   Therefore, we could conclude that the 
crosslinked matrix has the potential to retain the protein’s inherent bioactive activity.  
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Different proliferation markers, including Ki67, pErk, EdU and thymidine 
incorporation were used to follow the extent of cell proliferation cultured in the presence 
and absence of holo-rhLF.   Ki67 protein expression is a marker that is expressed by 
proliferating cells in all phases of active cell cycle (G1, S, G2 and M phase).  pErk is a 
signaling marker that is often seen in proliferating cells.  In addition to following 
mitogenic markers, viable cell number in the gel after long-term culture was followed as 
a function of time by fluorescent live/dead staining.  Our previous data (Figure 25) 
indicated increased cell proliferation in MC3T3 cells treated with holo-rhLF.  Similarly, 
our long-term culture of the MC3T3 encapsulated cells in holo-rhLF gel demonstrated 
that this gel presents a conducive microenvironment to promote cell proliferation.  This 
data shows that rhLF gel is mitogenic towards the encapsulated MC3T3 cells and 
immunocytochemistry is a very good tool to follow the mitogenic activity. 
Our previous data demonstrated that holo-rhLF has potent anti-apoptotic effect on 
MC3T3 cells serum-starved in culture  (Figure 31).   Cornish et al. found pAkt, a 
common signaling molecule activated during cell survival events, to be increased by LF 
treatment.  However, they also reported that this phosphorylation event is not required for 
LF-induced cell survival (Grey et al. 2006).  In our studies, we discovered that this 
biological property of holo-rhLF to be dependent on PKA signaling pathway (section 
4.3.3.1).   Cells encapsulated in holo rhLF gels showed good viability upon serum 
starvation for 3 days.  The cells in gelatin gel however did not show cell survival even at 
24 hours.  This can be attributed to the lack of biological activity of gelatin as well as the 
inability of the gel to support cell spreading. Future studies need to compare the 
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antiapoptotic effect of lactoferrin gels to control gels that allow cell spreading (Figure 
72).  
To address the question of whether it is the crosslinked holo-rhLF matrix that is 
showing bioactivity or some remaining/uncrosslinked holo-rhLF we measured the 
amount of protein that was released (un-crosslinked polymer) from the gel into PBS 
buffer over 5 days at 37°C (Figure 46).  By 5 days, a cumulative amount of 10.1 ng/ml of 
modified holo-rhLF protein was released in the PBS buffer.  However, in Figure 19, we 
demonstrated that a minimum of 100 µg/ml rhLF was required for statistically significant 
thymidine incorporation (Cornish et al. 2004).    Therefore, we concluded the bioactivity 
induced in the MC3T3 cells encapsulated in holo-rhLF was a result of the crosslinked 
matrix not the small amount of un-crosslinked, modified holo-rhLF protein.  To further 
confirm our theory, we designed an experiment where modified and unmodified holo-
rhLF was encapsulated in gelatin gel.  In this experiment, the modified holo-rhLF became 
crosslinked in the gelatin gel – forming a bioactive, holo-rhLF/gelatin crosslinked 
composite matrix.    However, the unmodified holo-rhLF was not crosslinked in the 
gelatin gel and therefore did not induce any bioactivity in the encapsulated MC3T3 cells 
– as measured by pAkt expression and also live/dead assay upon serum starvation.   
After confirming the mitogenic and anti-apoptotic effect of the holo-rhLF gel, 
attempts were made to understand the osteogenic activity of holo-rhLF.   Thus far, no 
previously published data has revealed any molecular mechanisms underlying LF’s 
osteogenic effects.   In our studies, we found LF increases Disheveled/ Gsk3β / β catenin 
signaling cascade.   Furthermore, through inhibitor studies, we discovered LF-induced 
PKA/LRP6 is responsible for β catenin accumulation.  The cells encapsulated in holo 
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rhLF gels showed a positive expression for β catenin as well as express osteogenic 
markers – collagen I and OCN – after 21 days culture in osteogenic media.   
There is a great need for a bioactive, biocompatible cell delivery vehicle.   
Furthermore, in the field of orthopedics there no existing biomaterial that provides 
effective cell delivery, survival, proliferation and increased osteogenesis.  Current 
paradigms in tissue engineering involve the synthesis of novel biomaterials that mimic 
essential aspects of the physiological niche.  Ideally, scaffold design is tailored towards 
reproducing required signals to foster and direct cellular attachment, proliferation and 
specific cellular differentiation.  To accomplish that several factors must be taken in to 
account, including the fabrication and implantation of scaffolding material, the physical 
structures and their biological activity.  To date, no studies report cells differentiating into 
osteogenic linage without any exogenous soluble differentiation factors using hydrogel 
biomaterials in vitro.   As demonstrated in the rpesent study, the enzymatically  
crosslinked LF gel presents a conducive environment to support cell viability, 
proliferation and differentiation and support phosphorylation/dephosphorylation of 
proteins demonstrating a potential avenue for developing cell instructive injectable 
materials.  
 
5.3.5 Conclusions 
The proposed studies were aimed to increase our understanding of the effect of holo-
rhLF in modulating skeletal cells and further establish holo-rhLF crosslinked gel as an 
excellent candidate for a skeletal regenerative biomaterial.  In our studies, the bioactive 
holo-rhLF gel matrix is used as a cell delivery vehicle and further promotes cell survival, 
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proliferation, differentiation and mineralization.  The positive effects of holo-rhLF gel on 
cellular processes supports the notion that holo-rhLF gel is a strong candidate for bone 
tissue engineering.  
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6 Future studies 
6.1 Molecular mechanism underlying LF 
 
Grey et al. confirmed that LRP1 is a mitogenic receptor for LF in osteoblastic cells 
(Grey et al. 2004) and that LF inhibits osteoblast apoptosis via a LRP1-independent 
pathway (Grey et al. 2006).  Several questions still remained unanswered such as what 
pathways are involved inLF’s anti-apoptotic effects in osteoblasts.   Our recent studies 
have demonstrated that LF induces PKA-dependent survival in MC3T3 preosteoblast 
cells.  However, the mechanism and receptor by which LF induces PKA is still unknown.  
Numerous studies have reported LF’s osteogenic effects (Cornish et al. 2004).  Our 
studies confirmed the activation of β catenin as it is the penultimate osteogenic signaling 
molecule.   Further investigation revealed that PKA upregulation and LRP6 
phosphorylation.  Identification of LRP6 as LF’s osteogenic receptor should be 
confirmed through DKK1 inhibitor studies and also knockout model.  LRP6-knockout 
mice develop to term (Kelly, Pinson & Skarnes 2004) and therefore would allow for the 
investigation of its role in LF’s osteogenic induction.  Testing of osteogenic 
differentiation potential of primary osteoblast cells from LRP6 knockout mice by LF 
would confirm the LF’s dependence on LRP6 for osteogenic differentiation. 
6.2 LF composite gels 
For sufficient number of available crosslinking sites, LF gels required 
approximately 10 mg/ml of tyrosinated LF.  However, in order to study concentration-
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dependent effects of LF on the encapsulated cells, lower concentrations of LF should be 
used.  Composite mixture with inert proteins or polymers (ie. gelatin) will allow for the 
study lower concentrations of crosslinked LF gels.   Furthermore, addition of other 
polymers to LF gel may be used to modify the physical properties such mechanical 
strength and gelation time. 
6.3 Holo-rhLF gel bone regeneration study in vivo 
Maintenance of the skeletal system consists of a dynamic interplay between bone-
forming osteoblasts and bone-resorbing osteoclasts.  LPS-induced periodontitis models 
provide an excellent way to study the interactions between immune and bone cells 
(Yamano et al. 2010).  This inflammatory disease ultimately leads to increased 
osteoclastogenesis and destruction of the periodontium (Clowes, Riggs & Khosla 2005, 
Weitzmann, Pacifici 2007).  LF may affect this model multifold: inhibition of 
osteoclastogenesis, increased osteoblast activity and inhibition of periodontopathic 
bacteria growth.   We hypothesize that localized LF gel injections will decrease the 
inflammation and thus inhibit osteoclastogenesis and destruction of the periodontium.   
Inflammatory markers, such as IL1α and TNFα, from the saliva may be used to monitor 
the inflammatory state of the animal model.   Alveolar bone levels may be monitored 
through live x-ray scanner.  Calcein green labeling may be used to monitor new bone 
growth as described previously (Cornish et al. 2004). 
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7 Appendix of Protocols 
7.1 Cell culture 
7.1.1 Materials 
• MC3T3-E1 Clone 4 cells (ATCC CRL-2593) 
• MEMα medium (Gibco; Grand Island, NY) 
• 10% FBS (Gibco; Grand Island, NY) 
• 1% Pencillin/Streptomycin (Gibco; Grand Island, NY) 
• 2.5% Trypsin/EDTA (Gibco; Grand Island, NY) 
• L-ascorbic acid (Fisher Scientific; Pittsburg, PA)  
• β-glycerophosphate (Sigma-Aldrich; St. Louis, MO) 
• Clonetics Normal Human Osteoblasts (NHOst) cells (Lonza; Walkersville, MD) 
• Osteoblast Basal Medium (Lonza; Walkersville, MD) 
• Single Quots (Lonza; Walkersville, MD) 
• ReagentPack Subculture Reagents (Lonza; Walkersville, MD) 
• Differentiation SingleQuots (Lonza; Walkersville, MD) 
• Bovine LF, native hLF and LiCl (Sigma; St. Louis, MO) 
• rhLFs (endotoxin level: <1.5 EU/mg) (InVitria; Fort Collins, CO) 
• Gelatin Type A (MP Biomedicals; Solon, OH) 
• rhWnt3a, rhWnt5a and rhBMP2 (R&D Systems; Minneapolis, MN) 
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7.1.2 Methods 
7.1.2.1 MC3T3 cell culture 
MC3T3-E1 (passages 18-35) were maintained 37oC, 5% CO2 humidified incubator.  
MC3T3 cells were plated on 75cm2 flasks at the recommended density of 5,000 cells/cm2 
with 0.2 ml/cm2 basal media consisted of MEMα medium supplemented with 10% FBS 
and 1% Pencillin/Streptomycin.   At 80% confluency, the MC3T3 cells were subcultured 
using 2.5% Trypsin/EDTA.   Mineralization media consisted of supplemented MEMα 
media additionally supplemented with 10 µg/ml L-ascorbic acid and 3 mM β-
glycerophosphate. 
7.1.2.2 Human osteoblast cell culture   
Clonetics Normal Human Osteoblasts (NHOst) cells (passages 2-4) were maintained 
37oC, 5% CO2 humidified incubator.  NHOst cells were plated on 75 cm2 flasks at the 
recommended density of 5,000 cells/cm2 with 1 ml/ 5 cm2 Osteoblast Basal Medium 
supplemented with Single Quots, which includes FBS, Gentamycin and Ascorbic Acid.  
At 80% confluency, the NHOst cells were subcultured using ReagentPack Subculture 
Reagents, which includes Trypsin/EDTA, Trypsin Neutralizing Solution and HEPES-
BSS.  To differentiate the NHOst cells to mineralizing bone cells, the supplemented 
Osteoblast Basal Medium were further supplemented with Differentiation SingleQuots, 
which includes Hydrocortisone-21-hemisuccinate (200 nM final concentration) and β-
Glycerophosphate (10 mM final concentration).  
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7.2 Protein analysis 
7.2.1 Materials 
• CellLytic M and Protease Inhibitor (Sigma; St. Louis, MO) 
• Western blot analysis reagents (BioRad; Hercules, CA) 
• BCA Protein Assay Reagent (Peirce; Rockford, IL) 
• ReadyPrep Cytoplasmic/Nuclear Protein Extraction kit (Fisher Scientific; 
Pittsburg, PA) 
• Glass bottom culture plates, 35 mm uncoated (MatTek; Ashland, MA) 
• Primary	  Antibodies	   Company,	  Catalog	  number	   Dilution	  
Phospho-­‐Akt	  (Ser473)	   Cell	  Signalling	  4060	   1:1000	  (western)	  
Phospho-­‐p44/42	  MAPK	  (Erk1/2)	   Cell	  Signalling	  4370	   1:1000	  (western)	  
Phospho-­‐p44/42	  MAPK	  (Erk1/2)	   Millipore	  05-­‐481	   1:100	  (immunocytochemistry)	  
anti-­‐phospho-­‐CREB	  (Ser133)	   Millipore-­‐06-­‐519	   1:1000	  (western)	  
	  
LRP1	  (5A6)	   Santa	  Cruz	  sc57351	   1:1000	  (western)	  
Phospho-­‐LRP1	   Upstate	  30628	   	  
LRP5/6	  (1A12)	   Abcam	  ab257250	   1:1000	  (western)	  
LRP5/6	  (1A12)	   Santa	  Cruz	  sc57354	   	  
Phospho-­‐LRP6	   Millipore	  07218	   1:1000	  (western)	  
	  
VEGF	   Santa	  Cruz	  sc65617	   1:1000	  (western)	  
VEGF	   Abcam	  ab1316	   1:100	  (immunocytochemistry)	  
IL6	   Abcam	  ab6672	   1:100	  (immunocytochemistry)	  
	  
Phospho-­‐Dishevelled	  2	   Millipore	  ab5972	   1:1000	  (western)	  
Phospho-­‐Gsk3β	   Millipore	  ab05643	   1:1000	  (western)	  
β	  catenin	   BD	  610153	   1:2000	  
Active	  β	  catenin	   Millipore	  05-­‐665	   1:1000	  (western)	  
	  
Runx2	  (C-­‐19)	   Santa	  Cruz	  sc8566	   1:1000	  (western)	  
Runx2	   Santa	  Cruz	  sc10758	   	  
Runx2	   Abcam	  ab76956	   1:100	  (immunocytochemistry)	  
Osteocalcin	  (FL-­‐95)	   Santa	  Cruz	  sc30045	   1:100	  (immunocytochemistry)	  
Collagen	  1	   Abcam	  ab292	   1:100	  (immunocytochemistry)	  
	  
Tubulin	   Millipore	  05661	   1:1000	  (western)	  
β	  -­‐	  actin	   Abcam	  ab8227	   1:1000	  (western)	  
Ki67	   Abcam	  ab15580	   1:100	  (immunocytochemistry)	  
	  
Anti-­‐Lactoferrin	   Santa	  Cruz	  SC-­‐14434	   1:1000	  (western)	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Secondary	  Antibodies	  
Goat	  Anti-­‐Rabbit	  IgG	  Conjugate	   KPL	  #474-­‐1516	   1:3000	  (western)	  
Goat	  Anti-­‐Mouse	  IgG	  Conjugate	   KPL	  #474-­‐1806	   1:3000	  (western)	  
Goat	  Anti-­‐Rat	  IgG	  Conjugate	   KPL	  #474-­‐1612	   1:3000	  (western)	  
Donkey	  Anti-­‐Goat	  IgG-­‐FITC	   Abcam	  sc-­‐2024	   1:200	  (immunocytochemistry)	  
Goat	  Anti-­‐Rabbit	  IgG-­‐FITC	   Abcam	  ab6717	   1:200	  (immunocytochemistry)	  
Goat	  Anti-­‐Mouse	  IgG-­‐FITC	   Abcam	  ab6785	   1:200	  (immunocytochemistry)	  
Table 6.  Primary and secondary antibodies used for western blot and 
immunocytochemistry studies. 
 
7.2.2 Methods 
7.2.2.1 Extraction 
Media was aspirated from cells and washed briefly with PBS.   500 µl of CellLytic M and 
Protease Inhibitor at a 1000:1 ratio were added to cells and then incubated at 4°C for 30 
minutes.  Cells were removed by mechanical scrapping and spun down at 10,000 rpm for 
5 minutes.   
7.2.2.2 Bicinchoninic Acid (BCA) total protein assay 
Protein concentrations were measured using BCA Protein Assay Kit.  BCA Protein Assay 
Reagent (Bicinchoninic Acid) contains BCA Reagent A (500 mL), BCA Reagent B (25 
ml), Albumin Standard (2 mg/ml).  Working BCA reagent was prepared by mixing 50 
parts of BCA reagent A with 1 part of BCA reagent B.   10 µl of each unknown sample or 
standard (i.e., diluted with 1% Triton X100 solution) was pipette to a 96 well plate.  90 µl 
of the working reagent was then added to each well and plate was mixed 
thoroughly.   The absorbance of the samples were measured at 562 nm after 30 minute 
incubation at 37°C.   BSA standards were calculated according to Table 7. 
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Table 7.  Diluted albumin (BSA) standards. 
 
7.2.2.3 Western blot analysis 
Each sample was prepared with Laemmli Sample Buffer and samples were boiled for 5 
minutes.  25 µg of each sample were run on 4-15% Tris-HCl Ready Gels for western blot 
protein electrophoresis.   Mini-PROTEAN Tetra System, 10x Tris/Glycine/SDS Buffer, 
Precision Plus Protein Dual Color Standard were used and gels were run at a constant 100 
Volts.  Gels were transferred at a constant 100 Volts for 2 hours using 10x Tris/Glycine 
Buffer, Mini Trans-Blot Electrophoresis Transfer Cell, Blot Papers and 0.2 µm 
Nitrocellulose Membrane.  Membranes were blocked for 2 hours at 4°C in 10% 
milk/TBS-T solution (10x Tris-Buffered Saline, 0.1% Tween-20).  Membranes were 
washed with TBS-T solution after each incubation.  Membranes were incubated 
overnight with primary antibodies diluted in 5% milk/TBS-T solution at 4°C.  Next, 
membranes were incubated for 45 minutes with secondary antibody diluted in 5% milk/ 
TBS-T solution at 4°C and then washed three times with TBS-T.  List of primary and 
secondary antibodies used for western blot are contained in Table 6.  Super Signal West 
Pico Chemiluminescent Substrate was used for detection, and CL-XPosure Film was used 
for exposure of the membranes. 
Vial	   Volume	  of	  diluent	  	  (μl)	   Volume	  &	  Source	  of	  BSA	   Final	  BSA	  concentration	  
A	   450	   150	  μl	  of	  stock	   500	  μg	  /ml	  
B	   300	   300	  μl	  of	  A	   250	  μg	  /ml	  
C	   300	   300	  μl	  of	  B	   125	  μg	  /ml	  
D	   360	   240	  μl	  of	  C	   50	  μg	  /ml	  
E	   300	   300	  μl	  of	  D	   25	  μg	  /ml	  
F	   320	   80	  μl	  of	  E	   5	  μg	  /ml	  
G	   400	   0	   blank	  
	   246 
7.2.2.4 Nuclear/ cytoplasmic protein extraction 
ReadyPrep Cytoplasmic/Nuclear Protein Extraction kit enabled the stepwise separation 
and preparation of cytoplasmic and nuclear extracts from cell samples.  Cells were 
harvested with trypsin-EDTA and then centrifuged at 500 × g for 5 minutes.  Cells were 
washed by suspending the cell pellet with PBS. 1-10 × 106 cells were transferred to a 1.5 
mL microcentrifuge tube and pelleted by centrifugation at 500 × g for 2-3 minutes.  A 
pipette was used to carefully remove and discard the supernatant, leaving the cell pellet 
as dry as possible. This protocol was scaled depending on the cell pellet volume and the 
volume ratio of CER I: CER II: NER reagents was maintained at 200:11:100 µL, 
respectively (	  
Packed	  cell	  volume	  (μl)	   CER	  I	  (μl)	   CER	  II	  (μl)	   NER	  (μl)	  
10	   100	   5.5	   50	  
20	   200	   11	   100	  
50	   500	   27.5	   250	  
100	   1000	   55	   500	  
Table 8).   	  
Packed	  cell	  volume	  (μl)	   CER	  I	  (μl)	   CER	  II	  (μl)	   NER	  (μl)	  
10	   100	   5.5	   50	  
20	   200	   11	   100	  
50	   500	   27.5	   250	  
100	   1000	   55	   500	  
Table 8.  Reagent volumes for different packed cell volumes. 
 
Ice-cold CER I was added to the cell pellet.  The tube was vigorously vortexed on the 
highest setting for 15 seconds to fully suspend the cell pellet and then incubated on ice 
for 10 minutes.  Ice-cold CER II was added to the tube and then vortexed for 5 seconds 
on the highest setting, followed by 1 minute incubation on ice. Samples were centrifuged 
for 5 minutes at maximum speed in a microcentrifuge (~16,000 × g). The supernatant 
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(cytoplasmic extract) was then transferred to a clean pre-chilled tube and samples were 
placed stored at -80°C until use. The insoluble (pellet) fraction, which contains nuclei, 
was suspended in ice-cold NER and vortex on the highest setting for 15 seconds.  The 
samples were placed on ice and continued vortexing for 15 seconds every 10 minutes, for 
a total of 40 minutes. The samples were then centrifuged at maximum speed (~16,000 × 
g) in a microcentrifuge for 10 minutes.  The supernatant (nuclear fraction) was then 
immediately transferred to a clean pre-chilled tube and stored at -80°C until use.	  
7.2.2.5 Immunocytochemistry 
Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated.  Washed 
briefly with PBS and then fixed using -10ºC methanol for 5 minutes.  Next, methanol was 
aspirated and allow to air dry.  Samples were washed in three changes of PBS.  Sufficient 
reagent was used to cover the specimen (approximately 200 µl per slide).  Samples were 
incubated in 10% normal blocking serum in PBS for 20 minutes to suppress non-specific 
binding of IgG.  Blocking serum ideally should be derived from the same species in 
which the secondary antibody is raised and then washed with PBS.   Next, the samples 
were incubated with primary antibody overnight in 1% normal blocking serum.  Washed 
with three changes of PBS for 5 minutes each.  Incubated in dark chamber for 45 minutes 
with fluorochrome-conjugated secondary antibody diluted to in PBS with 1% normal 
blocking serum and washed with three changes of PBS.  List of primary and secondary 
antibodies used for immunocytochemistry are contained in Table 6.  Mounted coverslip 
with Vectashield Mounting Medium with Propidium Iodide (nuclear stain) and imaged 
via confocal microscopy. 
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7.3 Gene expression analysis 
7.3.1 Materials 
• Clontech Sprint RT Complete cDNA synthesis kit (Clontech; Mountain View, 
CA)  
• BioRad MyiQ2 Two-Color Real-Time PCR Detection System, 2x iQ real-time 
PCR Supermix (BioRad; Hercules, CA) 
• TaqMan® Gene Expression Assay Probes (Applied Biosystems; Carlsbad, CA)  
• Microseal 96-Well PCR Plates (BioRad; Hercules, CA) 
• Illumina TotalPrep RNA Amplification Kit (Ambion, Carlsbad, CA) 
• Illumina MouseWG-6 v2.0 Expression BeadChip (Ambion, Carlsbad, CA) 
7.3.2 Methods  
7.3.2.1 RNA extraction and purification 
RNeasy Mini RNA Isolation kit was used to isolate and purify the RNA.  Cells were first 
disrupted by adding Buffer RLT and removed by mechanical scrapping.  Lysate was 
homogenize for 30 seconds using a rotor–stator homogenizer. 1 volume of 70% ethanol 
was added to the homogenized lysate, and mixed well by pipetting and then added to an 
RNeasy spin column placed in a 2 ml collection tube and centrifuged for 15 seconds at 
≥8000 x g.  Flow-through was discarded.  700 µl Buffer RW1 was added to the RNeasy 
spin column and then centrifuged for 15 seconds at ≥8000 x g to wash the spin column 
membrane. Flow-through was discarded. 500 µl Buffer RPE was added to the RNeasy 
spin column and samples were centrifuged for 15 seconds at ≥8000 x g to wash the spin 
column membrane.  Flow-through was discarded.  500 µl Buffer RPE was added to the 
RNeasy spin column and centrifuged for 2 min at ≥8000 x g to wash the spin column 
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membrane.  RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 µl 
RNase-free water was added directly to the spin column membrane and centrifuged for 1 
minute at ≥8000 x g to elute the RNA. 
7.3.2.2 Real time PCR analysis 
For cDNA synthesis, 2 µg total RNA was used as a template for Clontech Sprint RT 
Complete cDNA synthesis kit in a total volume of 20 µl. For quantitative real time PCR, 
BioRad MyiQ2 Two-Color Real-Time PCR Detection System, 2x iQ real-time PCR 
Supermix, TaqMan® Gene Expression Assay Probes were loaded in Microseal 96-Well 
PCR Plates.  Each well contained 10 µl of iQ real-time PCR Supermix, 1 ul of TaqMan® 
Gene Expression Assay probe and 9 µl of diluted cDNA.  Threshold cycle values of 
target genes was standardized against GAPDH expression and normalized to the 
expression in the control culture. The –fold change in expression was calculated using the 
ΔΔCt comparative threshold cycle method. 
7.3.2.3 Microarray analysis 
Three biological replicates were tested for each sample (n=3).  Illumina TotalPrep RNA 
Amplification Kit was used for RNA amplification.  RNA Nano Chip on Agilent 2100 
Bioanalyzer was used to detect quality of RNA and labelled cRNA. Samples were 
hybridized to Illumina MouseWG-6 v2.0 Expression BeadChip.  The multi-sample 
format includes 45,200 transcripts and six samples simultaneously on a single BeadChip, 
which dramatically increases throughput while decreasing experimental variability.  The 
MouseWG-6 beadchip exhibits a dynamic range of > 3 logs; detectable fold change < 
1.35 fold and reproducibility CV < 10%.   The ratio of the signal intensity of each 
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experimental sample and the signal intensity of untreated control was represented as the 
fold change relative to control. 
7.3.2.4 Mouse Wnt signaling pathway array 
Quantitative real time PCR was employed to assess the influence of the 100 µg/ml holo-
rhLF (n=3) on Wnt signaling pathway in MC3T3 preosteoblast cells.  Total RNA was 
isolated using the Qiagen RNeasy Mini Kit according to the manufacturer's instructions. 
For cDNA synthesis, 2 µg total RNA was used as a template for Clontech Sprint RT 
Complete cDNA synthesis kit in a total volume of 20 µl.   BioRad MyiQ2 Two-Color 
Real-Time PCR Detection System was utilized to measure expression profiles of 84 
genes related to WNT-mediated signal transduction on cells treated with of holo-rhLF 
relative to untreated control.  The RT² Profiler™ PCR Arrays includes built-in positive 
control elements for the proper normalization of the data, for the detection of genomic 
DNA contamination, for the quality of RNA samples, and for general PCR performance. 
7.4 Cell Imaging 
7.4.1 Materials 
Alexa Fluor 488 phalloidin (Molecular Probes; Grand Island, NY) 
7.4.2 Methods 
7.4.2.1 Cell morphology   
7.4.2.1.1 Actin staining via Alexa Fluor 488 phalloidin 
Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated (MatTek 
P35G-1.0-14-C).   Washed briefly with PBS and then fixed using 4% paraformaldehyde 
for 30 minutes at 37°C.  Next, aspirate and rinse with PBS.  Incubate samples in 0.1% 
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Triton X-100 in PBS for 3 to 5 minutes.  Wash two or more times with PBS.  Samples 
were then stained with Alexa Fluor 488 phalloidin to visualize the actin filaments.  To 
prepare the stock solution of Alexa Fluor 488 phalloidin, the vial was dissolved in 1.5 
mL methanol to yield a final concentration of 200 units/mL, which is equivalent to 
approximately 6.6 µM.  When staining with any of the fluorescent phallotoxins, dilute 5 
µL methanolic stock solution into 200 µL PBS for each coverslip to be stained. To reduce 
nonspecific background staining with these conjugates, add 1% bovine serum albumin 
(BSA) to the staining solution. Place the staining solution on the coverslip for 20 minutes 
at room temperature in dark incubator.  Wash two or more times with PBS.   Image via 
confocal microscopy (excitation/emission: 495nm/518nm). 
7.4.2.1.2 Nuclear staining via propidium iodide 
To stain the nuclei, mount coverslip with Vectashield Mounting Medium with Propidium 
Iodide (nuclear stain) and image via confocal microscopy (excitation/emission: 535 nm/ 
617 nm). 
7.5 Cell survival and viability 
7.5.1 Materials 
• Live/Dead Viability/Cytotoxicity Kit (Molecular Probes; Grand Island, NY) 
• CaspACE assay (Promega; Madison, WI) 
7.5.2 Methods 
7.5.2.1 Live/Dead Viability assay   
Samples were stained using Live/Dead Viability/Cytotoxicity Kit  to test viability of the 
cells.   2 µM calcein AM and 4 µM Ethidium homodimer-1 was added to PBS.  The 
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polyanionic dye calcein was used since it is well retained within live cells, producing an 
intense uniform green fluorescence in live cells (excitation/emission: 495 nm/ 515 nm).  
EthD-1 was included since it enters cells with damaged membranes and undergoes a 40-
fold enhancement of fluorescence upon binding to nucleic acids, thereby producing a 
bright red fluorescence in dead cells (excitation/emission: 495 nm/ 635 nm).   Zeiss LSM 
510 Confocal Microscope was utilized to image the samples.    
7.5.2.2 Colorimetric CaspACE assay  
CaspACE assay was used to measure the activity of caspase-3, a member of the cysteine 
aspartic acid-specific protease family.  Grow cells on 10cm tissue culture plates to 90% 
confluence.  Add serum-free media to MC3T3 cells as a positive (induced apoptosis) 
control.  For inhibited apoptosis samples, add the Z-VAD-FMK inhibitor to the cells 
(final concentration of 50 µM).  Prepare negative controls using untreated cells.  Incubate 
overnight at 37°C in a humidified, 5% CO2 atmosphere.  Cells were harvested by 
centrifugation at 450 x g for 10 minutes at 4°C.  Keep the cell pellet on ice. Wash 1X 
with ice-cold PBS, and resuspend in Cell Lysis Buffer at a concentration of 108 cells/ml.  
Lyse cells by freeze-thaw, then incubate on ice for 15 minutes (repeat freeze thaw cycles 
as needed to ensure complete cell lysis).  Cell lysates were centrifuged at 15,000 x g for 
20 minutes at 4°C, and the supernatant fraction was collected.  Caspase-3 activity was 
measured in cell extracts from at least 1 x106 cells/assay.  Cell extracts were used as an 
enzyme source.  In a flat-bottom, clear polystyrene 96-well plate 20 µl of cell extract (75 
µg total protein) was added to each reaction.  Prepare replicate wells (n=3) containing 
blank (no cell extract), negative control (extract from untreated cells), induced apoptosis 
(extract from induced cells) and inhibited apoptosis (extract from induced, inhibitor-
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treated cells) samples (according to Table 9).  Add 2 µl of DEVD-pNA Substrate (10mM 
stock) to all wells.  Samples were incubated at 37°C overnight and then the absorbance 
was read at 405 nm.  
 
	   Blank	   Negative	  
Control	  
Induced	  
Apoptosis	  
Inhibited	  
Apoptosis	  
Caspase	  Assay	  Buffer	   32	  μl	   32	  μl	   32	  μl	   32	  μl	  
DMSO	   2	  μl	   2	  μl	   2	  μl	   2	  μl	  
DTT,	  100	  mM	   10	  μl	   10	  μl	   10	  μl	   10	  μl	  
Untreated	  cell	  extract	   -­‐	   20	  μl	   -­‐	   -­‐	  
Induced	  apoptosis	  extract	   -­‐	   -­‐	   20	  μl	   -­‐	  
Inhibited	  apoptosis	  extract	   -­‐	   -­‐	   -­‐	   20	  μl	  
Deionized	  water	  to	  final	  
volume	  
98	  μl	   98	  μl	   98	  μl	   98	  μl	  
Table 9.  Caspase assay control sample preparation. 
7.6 Proliferation assays 
7.6.1 Materials 
• Click-it EdU Cell Proliferation Assay Kit (Invitrogen; Carlsbad, CA) 
• MTS assay (Promega; Grand Island, NY) 
7.6.2 Methods 
7.6.2.1 MTS assay 
Cells were plated at a density of 15,000 cells/well in a 48-well plate with basal media.  
After 24 hours, treatments were administered at various concentrations (n=4 biological 
replicates).  The proliferation of MC3T3 cells was determined by MTS assay.  1000 µl of 
culture medium was incubated with 200 µl of Cell Titer 96 AQueous One Reagent for 2 
hours at 37°C and the absorbance was measured at 492 nm.  
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7.6.2.2 Thymidine incorporation 
Cells were plated and then incubated at 37°C for 6 hours to allow proper cell adhesion 
and maintained in serum-free medium overnight.  The cell culture was then performed 
with supplementation of treatments and [3H]thymidine for 24 hour incubation (n=4 
biological replicates). Incorporation of [3H]thymidine radioactivity was counted for 30 
seconds in a liquid scintillation counter and expressed as disintegrations per minute 
(dpm) per microgram of DNA.  Data was then normalized to untreated control sample 
and expressed as fold change over control.   
7.6.2.3 EdU incorporation  
Click-it EdU Cell Proliferation Assay Kit protocol involves 4 main steps:  preparation of 
stock solutions, EdU labeling, EdU detection and counter nuclear staining. 
7.6.2.3.1 Preparation of stock solutions  
10 mM stock solution of EdU (Component A) was prepared by adding 2 mL of DMSO 
(Component C) to EdU (Component A).  Next, a working solution of the Alexa Fluor® 
azide (Component B) was prepared by adding 70 µL of DMSO (Component C) to 
Component B.  A working solution of 1X Click-iT® EdU reaction buffer (Component D) 
was prepared by diluting the 4 ml of Component D to 36 ml of deionized water.  A 10X 
stock solution of the Click-iT® EdU buffer additive (Component F) was made by adding 
2 mL of deionized water to the Component F vial. 
7.6.2.3.2 EdU labeling    
Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated and allow 
cells to adhere for 6 hours in basal media.   2X working solution of EdU (Component A) 
was prepared in serum free basal media from the 10 mM stock solution.  A suggested 
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starting concentration is 10 µM.  An equal volume of the 2X EdU solution was added to 
the volume of serum free basal media containing cells to be treated to obtain a 1X EdU 
solution (final EdU concentration = 10 µM).   Concurrently, we added 0 or 100 µg/ml 
holo-rhLF to the cell cultures.   The time of EdU exposure to the cells allowed for direct 
measurement of cells synthesizing DNA.  After incubation, media was removed and 1 
mL of 3.7% formaldehyde in PBS was added to each sample and incubated for 15 
minutes at room temperature.  Next, the fixative was removed and the cells were washed 
well twice with 1 mL of 3% BSA in PBS.  Next, 1 mL of 0.5% Triton® X-100 in PBS 
was added to each well and incubated at room temperature for 20 minutes.   
7.6.2.3.3 EdU detection  
First, 1X Click-iT® EdU buffer additive was prepared by diluting the 10X solution 1:10 
in deionized water.   Click-iT® reaction cocktail was prepared according to Table 10. 
Click-iT® reaction cocktail was used within 15 minutes of preparation (as 
recommended). 
Reaction	  
components	  
Number	  of	  samples	  
1	   2	   4	   5	   10	   25	   50	  
1x	  Click-­‐iT	  reaction	  
buffer	  
430	  μl	   860	  μl	   1.8	  mL	   2.2	  mL	   4.3	  mL	   10	  mL	   21.4	  mL	  
CuSO4	   20	  μl	   40	  μl	   80	  μl	   100	  μl	   200	  μl	   500	  μl	   1	  mL	  
Alexa	  Fluor	  azide	   1.2	  μl	   2.5	  μl	   5	  μl	   6	  μl	   12.5	  μl	   31	  μl	   62	  μl	  
Reaction	  buffer	  
additive	  
50	  μl	   100	  μl	   200	  μl	   250	  μl	   500	  μl	   1.25	  ml	   2.5	  ml	  
Total	  volume	   500	  μl	   1	  ml	   2	  ml	   2.5	  ml	   5	  ml	   12.5	  ml	   25	  ml	  
Table 10.  Click-iT reaction cocktails. 
 
Permeabilization buffer was removed and the cells were washed twice with 1 mL of 
3% BSA in PBS. Remove the wash solution.  Next, 0.5 mL of Click-iT® reaction 
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cocktail was added to each sample and incubated for 30 minutes at room temperature, 
protected from light.  The reaction cocktail was removed and then the samples were 
washed with 1 mL of 3% BSA in PBS.  
7.6.2.3.4 Counter DNA stain  
Samples were covered with Vectashield Mounting Medium with Propidium Iodide 
(nuclear stain) and image via confocal microscopy (excitation/emission: 535/617nm).  
Alexa Fluor® 647 EdU staining may be image via confocal microscopy 
(excitaton/emission: 650/670 nm). 
7.7 Cell differentiation assays 
7.7.1 Materials 
• Alkaline Phosphatase Substrate Kit (BioRad; Hercules, CA) 
7.7.2 Methods 
7.7.2.1 Alkaline phosphatase assay 
Alkaline phosphatase activity was determined using the Alkaline Phosphatase 
Substrate Kit.  In this assay, the early phenotypic marker ALP, from osteoblasts in 
culture, converts p-nitrophenyl phosphate (p-NPP) into p-nitrophenol (p- NP). The rate of 
p-NP formation is directly proportional to the ALP activity and can be measured 
colorimetrically.  
At the end of each timepoint, the samples were washed twice with PBS to remove 
any unattached cells.  The samples then incubated in 1% Triton X100.  For a volume of 
100 µL of cell lysate, a 400 µL of p-NPP substrate solution and buffer mixture was added 
and incubated at 37 °C for 30 min. The reaction was stopped by adding 500 µL of 0.4 N 
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NaOH. Subsequently, the ALP induced p-NP production can be estimated by measuring 
the absorption at 405 nm the TECAN.  The results of ALP activity was normalized to the 
total protein content (i.e., BCA assay) from each individual sample. 
7.7.2.2 Alizarin red (Calcium staining) 
Calcium deposition was determined using Alizarin Red staining.  
Reagents were first prepared as follows.   
4 M Alizarin Red –1.369 grams of alizarin red powder dye was dissolved in 100 ml of 
DD1 H2O; 1 N NaOH was used to adjust pH to 4.32 
10mM Na2PO4 –0.142 grams was dissolved in 100ml H2O 
10% (w/v) Cetylpyridinium Chloride (CPC) –10 grams was dissolved in 100ml of 
10mM Na2PO4; 1N HCl was used to adjust pH to 7.0 
Mineralized matrix synthesis was analyzed with Alizarin Red staining method for 
calcium deposition.  This technique used a colormetric analysis based on stabilizing the 
red matrix precipitate with Cetylpyridinium Chloride (CPC) to yield a purple solution.  
Briefly, the protocol is as follows: cells were rinsed twice with PBS- to remove any 
unattached cells and then fixed with 70% ethanol for 1 hour at 4°C.  Ethanol was then 
removed and cells were air-dried and then rinse with DDI water.  Cells were then 
incubated with 4 M Alizarin Red for 10 minutes at room temperature.  Samples were 
wash five times with DDI water and then incubated with 10% CPC for 15 minutes at 
room temperature.  Sample absorbance was read at 562 nm. 
7.8 Signalling pathway probing 
7.8.1 Materials 
• H-89 (Cell Signaling; Danvers, MA) 
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• LY294002 (Cell Signaling; Danvers, MA)  
• DKK1 (R&D Systems; Minneapolis, MN) 
7.8.2 Methods 
7.8.2.1 Pharmalogical pathway inhibitors 
Cells were pretreated with pharmalogical inhibitors (10 µM LY294002, 30 µM H-89 or 
100 ng/ml DKK1) for 2 hours and then stimulated with treatment of choice for 24 hours.  
7.8.2.2 Wnt signalling array 
*See above protocol section 7.3.2.4. 
7.9 Biomaterial studies 
7.9.1 Materials 
• 2-(N-morpholino) ethanesulfonic acid (MES) buffer (Sigma-Aldrich; St. Louis, 
MO) 
• N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (Sigma-
Aldrich; St. Louis, MO)  
• N-Hydroxysuccinimide (NHS) (Sigma-Aldrich; St. Louis, MO) 
• Tyramine (Sigma-Aldrich; St. Louis, MO) 
• Standard Regenerated Cellulose Dialysis Tubing MWCO 10,000 (Spectrum Labs; 
Rancho Dominguez, CA) 
• UV-Vis Spectrophotomer (Thermo Scientific Evolution 60) 
• 100U/ml HRP (Sigma-Aldrich; St. Louis, MO) 
• 30% H2O2 (Sigma-Aldrich; St. Louis, MO)  
• PBS (Gibco; Grand Island, NY)  
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• ARES-LS Parallel plate rheometer (TA Instruments; New Castle, DE) 
• JEOL 6335 Field Emission Scanning Electron Microscope (JEOL; Peabody, MA) 
7.9.2 Methods 
7.9.2.1 Formation of protein crosslinked hydrogels 
7.9.2.1.1 Synthesis of protein-tyramine conjugates 
LF–tyramine conjugates were synthesized by a carbodiimide/active-ester coupling 
reaction.  500 mg protein was dissolved in 50 ml of 1 M MES buffer.  To this solution, 
500 mg of EDC, 150 mg NHS and 300 mg tyramine were added.  The mixture was 
allowed to react for 24 hours at room temperature under gentle stirring.  The modified 
polymer was purified by dialysis against excess deionized water using Standard 
Regenerated Cellulose Dialysis Tubing MWCO 10,000.  Following dialyzation to remove 
unreacted tyramine, EDC, NHS, the remaining solution was subsequently frozen at -20°C 
and then lyophilized to give LF-tyramine conjugates.  
 
 
Water soluble gelatin-tyramine conjugates were synthesized by the carbodiimide/active-
ester coupling reaction.  500 mg protein was dissolved in 50 ml of 1 M MES buffer.  To 
this solution, 500 mg of EDC, 150 mg NHS and 300 mg tyramine were added.  The 
mixture was allowed to react for 24 hours at room temperature under gentle stirring.  The 
modified polymer was purified by dialysis against excess deionized water using Standard 
Regenerated Cellulose Dialysis Tubing MWCO 10,000.  Following dialyzation to remove 
	   260 
unreacted tyramine, EDC, NHS, the remaining solution was subsequently frozen at -20°C 
and then lyophilized to give the water soluble gelatin-tyramine conjugates. 
 
Water/PBS soluble gelatin–tyramine conjugates were also synthesized by the 
carbodiimide/active-ester coupling reaction.  875 mg protein was dissolved in 55 ml of 1 
M MES buffer and 20 mL of H2O.  To this solution, 510 mg of EDC, 150 mg NHS and 
510 mg tyramine were added.  The mixture was allowed to react for 24 hours at room 
temperature under gentle stirring.  The modified polymer was purified by dialysis against 
excess deionized water using Standard Regenerated Cellulose Dialysis Tubing MWCO 
10,000.  Following dialyzation to remove unreacted tyramine, EDC, NHS, the remaining 
solution was subsequently frozen at -20°C and then lyophilized to give gelatin-tyramine 
conjugates.  
 
7.9.2.1.1.1 Quantification of tyramine modification 
Protein was modified with varying reaction times and tyramine concentration was then 
examined as a function of reaction time.   Tyramine concentration was measured at 275 
nm using UV-Vis Spectrophotomer.   A tyramine standard curve was used to determine 
the concentration of a tyramine in the modified bLF samples (Figure 77).   Standard 
curve stock was made by diluting 10.5 mg tyramine in 2 ml MES buffer (n = 4 biological 
replicates).   0 - 40 µl of standard curved stock was diluted in increments of 5 µl further 
in 900 µl MES buffer (n=4) and diluted samples were measured by spectrophotomer at 
275 nm.  
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Figure 77.  Tyramine Concentration Standard Curve. 
 
7.9.2.1.2 Preparation of protein crosslinked gels 
Hydrogels were prepared by the HRP-mediated oxidative coupling of protein-tyramine 
conjugated molecules in the presence of dilute H2O2.  Hydrogel samples were prepared in 
vials at 25oC. 100 U/ml HRP and 30% H2O2 were individually dissolved at varying 
concentrations in PBS or DDI H2O.  HRP solution was added at desired concentrations 
with sufficient agitation and time to ensure the rhLF-Tyr solution was fully hydrated.   
7.9.2.1.2.1 Gelatin gel 
7.9.2.1.2.1.1 Gelatin Gel (dissolved in H2O) 
To make gelatin gel, first dissolve tyramine-modified gelatin in 10 U/ml HRP (diluted in 
H2O) and mix well.  To form gel, at diluted H2O2 and mix well.   For example, the 
following is the protocol to make 10 mg/ml gelatin gel.  To make 1 ml of 10 mg/ml 
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gelatin/HRP solution:  dissolve 10 mg modified in 1 ml of 10 U/ml HRP (dissolved in 
H2O) and then mix well. Finally, to make 10 mg/ml gelatin gel: 100 µl of gelatin/HRP 
solution + 1 µl 0.25% H2O2. 
 
7.9.2.1.2.1.2 Gelatin Gel (dissolved in 1:1 PBS:H2O ratio) 
To make gelatin gel, first dissolve tyramine-modified gelatin in 10 U/ml HRP (diluted in 
1:1 PBS:H2O ratio) and mix well.  To form gel, at diluted H2O2 and mix well.   For 
example, the following is the protocol to make 10 mg/ml gelatin gel.  To make 1 ml of 10 
mg/ml gelatin/HRP solution:  dissolve 10 mg modified in 1 ml of 10 U/ml HRP (diluted 
in 1:1 PBS:H2O ratio) and then mix well. Finally, to make 10 mg/ml gelatin gel: 100 µl 
of gelatin/HRP solution + 1 µl 0.25% H2O2. 
 
7.9.2.1.2.2  LF gels 
To make LF gels, first dissolve tyramine-modified LF in half the total volume of 10 U/ml 
HRP (dissolved in H2O) and mix well.  Next, add the second half of the total volume of 
10 U/ml (dissolved in PBS) and mix well.  To form gel, at diluted H2O2 and mix well.   
For example, the following is the protocol to make 10 mg/ml LF gel.  To make 1 ml of 10 
mg/ml LF/HRP solution:  dissolve 10 mg modified LF in 500 µl of 10 U/ml HRP 
(dissolved in H2O) and then mix well. Add 500 µl of 10 U/ml HRP (dissolved in PBS).  
Finally, to make 10 mg/ml LF gel: 100 µl of LF/HRP solution + 1 µl 0.25% H2O2. 
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7.9.2.2 Characterization of hydrogels 
7.9.2.2.1 Gelation time 
Sol to gel time was determined via vial inversion method (Menger, Caran 2000).   10 
mg/ml protein-tyramine conjugate in 100 µl of 10 U/ml HRP + 1 µl of 0.25% H2O2 
represents the standard gelling conditions for LF and gelatin gels.   Variables were 
individually varied and tested for effect on gelatin time.   
7.9.2.2.2 Rheological testing 
A rheometer is an ideal instrument that may be used to measure the gel strength.  The 
holo-rhLF gels were subjected to rheological measurements to assess the viscoelastic 
properties at varying component concentrations at 25ºC.   Briefly, the 150 μl of modified 
holo-rhLF/HRP and 1 μl H2O2 mixture was mixed together in an eppendorf tube and then 
immediately introduced in a parallel plate rheometer and started the rheological testing 
program.  Dynamic frequency sweeps were then performed in the linear viscoelastic 
region to determine values of the storage (G’) and loss (G”) modulus to compare the 
mechanical strength of gels with different concentrations of holo-rhLF.    Rheology 
testing conditions were as follows: angular frequency of 1 rad/sec; 3% strain; 1000 µm 
gap width; 100 µl volume load. 
7.9.2.2.3 Gel morphology   
The morphology of the hydrogels was visualized by scanning electron microscope to 
evaluate the effect of solution concentrations on gel microstructure.  The gels were flash 
frozen by immersing in liquid nitrogen for 1 minute followed by 24 hour lyophilization 
and then observed under the SEM.  Prior to imaging, the samples were mounted on 
	   264 
aluminum stubs and samples were platinum coated for improved conductivity.  The 
samples were viewed at an accelerating voltage of 10kV and 12 µA.  Measurements 
(n=30) of pore size were obtained using Image J program (U.S. National Institutes of 
Health, Bethesda, MD). 
7.9.2.2.4 Percentage of water uptake 
The percentage of water uptake of the injectable gels (n=4 biological replicates) was 
determined as follows.  Briefly, holo-rhLF gels were prepared in plastic inserts, flash 
frozen with liquid nitrogen and then lypholyzed.  The weight of the samples was 
determined (W1) before incubating them in phosphate buffer solution at 37°C.  At each 
time point, the samples were taken out, dabbed dry with a paper towel and their wet mass 
(Wwet) was determined.  The percentage water uptake of the samples was determined as 
[% water uptake = [(Wwet-W1)/W1) ×100].   
7.9.2.2.5 Degradation of holo-rhLF biogels in vivo 
Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) (12-16 weeks) were 
used 10 mg/ml holo-rhLF were injected subcutaneously to form the gels in situ.  The 
animals were cared for according to the procedures approved by the Animal Care and 
Use Committee at the University of Connecticut Health Center, and following the 
guidelines established by the U.S. National Institutes of Health.  At 4 and 12 weeks, rats 
were sacrificed and the tissue surrounding the injection sites were excised using blunt 
dissection technique. Samples were rinsed with PBS solution, washed with deionized 
water, fixed in 10% formalin solution (Surgipath, USA) and embedded in paraffin, 
sectioned and hematoxylin and eosin (H&E) was performed. 
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7.9.2.3 Soluble holo-rhLF protein release from holo-rhLF gel 
100 µl of 10 mg/ml holo-rhLF gel was formed in a 1.5 ml eppendoff tube (n=5).  1 mL 
PBS was added above the holo-rhLF gel and incubated at 37oC.  150 µl aliquots were 
taken from each sample every 24 hours for 5 consecutive days.  Phenolic content was 
measured via UV Spectrophotomer at 275 nm. 
7.9.2.4 Cell encapsulation in hydrogel 
Protein-tyramine conjugate was dissolved in 10 U/ml HRP.  Appropriate number of cells 
were resuspended in protein-tyramine conjugate/HRP solution followed by the addition 
of H2O2.   The encapsulated cells were then maintained in medium at 37ºC.  
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